Detoxified lipopolysaccharide (LPS), natural non-toxic LPS and its uses
By removing the phosphate group at the C1 position of LPS and retaining the polysaccharide portion at the C6' position, a low-toxic LPS molecule was developed, solving the problems of insufficient toxicity and biological activity of existing LPS adjuvants, and achieving better immune stimulation effect and solubility.
Patent Information
- Application Number
- CN202180034889.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-03-13
- Filing Date
- 2021-03-12
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2041-03-12
AI Technical Summary
Existing LPS adjuvants are toxic and pyrogenic in vaccines, difficult to provide optimal immune response, and lack core oligosaccharides and O-antigen domains, affecting biological activity and solubility.
Develop modified LPS molecular species, remove phosphate groups at the C1 position of the lipid A domain, and retain polysaccharide portions, including core oligosaccharides and O-antigen domains, at the C6' position, reduce toxicity and improve biological activity and solubility.
It significantly reduced the toxicity of LPS, improved the binding ability of TLR4 receptors, improved biological activity and solubility, and enhanced the immune stimulation effect.
Smart Images

Figure CN116249720B_ABST
Abstract
Description
Invention Field
[0001] This invention relates to modified lipopolysaccharide (LPS) molecule-rich aggregates, wherein the modified lipopolysaccharide molecules are:
[0002] - Its lipid A domain has no phosphate group at the C1 position of the reduced end; and
[0003] - The non-reducing C6' position of its lipid A domain is replaced by a hydrophilic portion, provided that the hydrophilic portion is not a hydroxyl group.
[0004] The present invention also relates to compositions comprising modified LPS-rich clusters; and to naturally occurring LPS molecule species and / or modified LPS molecule species-rich clusters for the treatment and / or prevention of cancer, inflammatory diseases or infectious diseases, and for stimulating immune responses or vaccinating subjects. Background of the Invention
[0006] The antigens in vaccine compositions are often poorly immunogenic and require additional components to help stimulate protective immunity based on antibody and effector T cell function. These additional components, called adjuvants, provide the necessary assistance to enhance the immunogenicity of vaccine antigens.
[0007] For decades, adjuvants used in vaccines and immunotherapies have been developed empirically, but their mechanisms of action remain poorly understood. This is true of widely used adjuvants such as Freund's (a mixture of paraffin oil and surfactants with heat-inactivated Mycobacterium tuberculosis or Mycobacterium casei, in which an aqueous antigen solution is emulsified), alum adjuvants (typically, the antigen is adsorbed onto a precipitate of aluminum phosphate and aluminum hydroxide), oil-in-water emulsifiers (e.g., Novartis' MF59 or GlaxoSmithKline's AS03, both squalene-based, in which an aqueous antigen solution is emulsified), or saponin-based adjuvants (e.g., so-called "immunostimulatory complexes" or ISCOM, which are cage-like saponin nanoparticles composed of cholesterol, phospholipids, and antigen). However, these empirically designed adjuvants fall far short of providing optimal responses. Furthermore, a significant portion of the population still fails to achieve adequate seroconversion or protective antibody titers, not to mention the decline in vaccine response in healthy adults or patients aged 40 to 50.
[0008] Recent studies have shown that most adjuvants enhance T and B cell responses by triggering components of the innate immune system, rather than acting directly on lymphocytes. Current research focuses on developing natural or synthetic agonists—obtained through chemical synthesis or directed molecular biology—as adjuvants to define well-defined pattern recognition receptors (PRRs). Almost all members of the PRR family are potential targets for adjuvants—including toll-like receptors (TLRs), which have been extensively studied and are of particular interest in this invention. A specific TLR is the toll-like receptor 4 (TLR4, also known as CD284), a transmembrane protein that binds to MD-2 and CD14 co-receptors, forming the receptor for mammalian bacterial lipopolysaccharide (LPS).
[0009] LPS are phosphoglycolipids found in the outer membranes of Gram-negative bacteria, spirochetes (e.g., Leptospira), cyanobacteria, and some Gram-positive bacteria (e.g., Firmicutes). LPS consists of two distinct regions: an inner phospholipid containing a large number—typically 2 to 9—long-chain fatty acids, called "lipid A," which carries most of the biological characteristics of the LPS; and a polysaccharide moiety comprising a central "core oligosaccharide" domain (a branched oligosaccharide with around nine or ten sugars) and an outer "O-antigen" domain (composed of repeating linear or branched carbohydrate polymers, the number, properties, and spatial arrangement of sugar residues being highly variable). Although some bacterial LPS lack an O-antigen domain, and their "polysaccharide" moiety is limited to "oligosaccharides" containing the core oligosaccharide domain (however, in some cases, they are capped with a capped antigen, for example, in the case of Bordetella pertussis, with a distal trisaccharide that is biosynthesized and genetically distinct from the O-antigen), these LPS are sometimes referred to as LOS, or lipooligosaccharides.
[0010] The lipid A domain contains a disaccharide with numerous long-chain fatty acids as hydrophobic anchors to the LPS on the outer membrane (most commonly β-1,6-glucosamine [GlcN] disaccharide, β-1,6-diaminoglucosamine [DAG] disaccharide, or a β-1,6-disaccharide containing one GlcN residue and one DAG residue). Typically, the lipid A disaccharide is substituted with phosphate groups at the C1 and C4' positions and attached to the C2, C3, C2', and C3' positions by branched or straight-chain fatty acid chains—most commonly 10 to 18 carbon atoms, some hydroxylated at the C3 position, the so-called β-hydroxy fatty acids. This 3-OH group, when present, can also be esterified with other fatty acids (e.g., with unhydroxylated, 2-hydroxylated, and sometimes 3-hydroxylated fatty acids, or even with the lipid moiety). These secondary fatty acids are also called acyl-oxy-acyl fatty acids. Therefore, the total number of fatty acids per lipid A molecule can be from 2 to 9. The lipid A domain at the C6' position is further substituted by a polysaccharide moiety (which contains a complete or truncated core oligosaccharide domain, and optionally, an O-antigen domain and / or any other capped antigen), typically with a 3-deoxy-D-mannooct-2-ketogluconic acid (Kdo) molecule, via a glycosidic bond.
[0011] Upon activation, TLR4 induces the expression of intracellular signaling pathways NF-κB and TRIP, the secretion of pro-inflammatory cytokines (e.g., IL-1, TNFα, IFNγ, and IL-12), and co-stimulatory molecules. This response, initiated by small amounts of LPS, ultimately activates the innate immune system, which in turn initiates the adaptive immune system through, for example, mature antigen-presenting cells (e.g., dendritic cells, macrophages, and B cells) or by expanding T and B cell function. It is for these reasons that LPS has long been considered a potent adjuvant.
[0012] However, LPS is not without its drawbacks when used as an adjuvant:
[0013] (1) Most LPS are naturally toxic and pyrogenic because they can trigger a strong immune response in the host, leading to fever and uncontrolled production of pro-inflammatory cytokines, which often results in septic shock. This toxicity has been shown to originate from the lipid A domain, particularly from the phosphate groups at the C1 and C4' positions. Therefore, the EMA, FDA, and other regulatory agencies have strict requirements for eliminating the toxicity of LPS in pharmaceuticals;
[0014] (2) Although the lipid A domain has long been known to be responsible for TLR4 activation, there is evidence that the core oligosaccharide domain and the present O antigen domain also participate in TLR4 activation. Their presence (1) increases the solubility of LPS compared to isolated lipid A, thereby improving its bioavailability, and (2) maintains the native three-dimensional lipid A conformation. Furthermore, the core oligosaccharide domain and the present O antigen domain define the antigenicity of the molecule. They can also bind to sugar-dependent receptors, such as C-type lectin receptors (CLRs). However, these domains are often intentionally or unintentionally removed during the preparation of LPS-based adjuvants.
[0015] Several LPS-based molecules have been developed with less toxicity than "wild-type" LPS. Among them, monophospholipid A (MPL) is the most well-known LPS-based adjuvant. MPL is produced by GlaxoSmithKline and obtained through controlled hydrolysis of LPS from enteric Salmonella Minnesota R595 serotype by removing (1) the core oligosaccharide domain at the C6' position of the lipid A domain, (2) the phosphate group at the C1 position of the lipid A domain, and (3) the acyl chain at the C3 position of the lipid A domain. MPL is currently used in so-called "adjuvant systems" in many vaccines. &Di Pasquale,2017.Hum Vaccin Immunother.13(1):19-33):
[0016] -AS01: A combination of liposome-based MPL and saponin QS-21—in The vaccine is used to combat malaria caused by the parasite Plasmodium falciparum.
[0017] -AS02: An oil-in-water emulsion of MPL and saponin QS-21;
[0018] -AS04: MPL adsorption on alum – specifically targeting hepatitis B virus (HBV). And against human papillomavirus (HPV) In the vaccine;
[0019] -AS15: A combination of liposome-based MPL, saponin QS-21, and CpG7909.
[0020] Other LPS-based immune adjuvants include synthetic lipid A analogs. Some of these molecules exhibit reduced toxicity to "wild-type" lipid A and promote a protective immune response after vaccination. Furthermore, their synthesis yields higher molecular uniformity and batch-to-batch reproducibility compared to chemically obtained MPLs. Examples of such synthetic lipid A analogs include RC-529, E6020, glucopyranosyl lipid A (GLA), ONO-4007, E5564, and CRX-526.
[0021] However, although they are less toxic, these molecules are still not optimal because (1) they lack a core oligosaccharide domain and, where appropriate, also lack an O antigen domain; (2) they do not react adequately with human TLR4, which utilizes the natural heterogeneity and diversity of lipid A in the bacterial world; and (3) they have limited solubility in common organic solvents and poor solubility in aqueous media, even at very low concentrations (<10). -8 They also tend to aggregate under M conditions, which complicates their formulation.
[0022] Therefore, there is still a need for low-toxicity LPS molecules derived from naturally occurring LPS (to provide natural heterogeneity and diversity in lipid A structure) and retaining its core oligosaccharide domain and, where appropriate, the O-antigen domain (to enhance biological activity).
[0023] Here, the inventors provide modified LPS molecules that lack phosphate at the Cl position of the lipid A domain but retain their polysaccharide moieties (core oligosaccharide domain and, where appropriate, O-antigen domain). These modified LPS molecules may also exhibit fatty acid release at secondary positions, such as the C2 and C2' positions, and, in the presence, at the C3 and C3' positions, the release of acyl-oxy-acyl fatty acids.
[0024] The combination of these characteristics significantly reduces the toxicity of different LPS and LOS tested. In some cases, the detoxification effect can be further enhanced by additionally releasing primary ester-linked fatty acids.
[0025] Therefore, in terms of composition and three-dimensional structure, these modified low-toxicity LPS and LOS molecules are closest to the natural LPS molecule species. This not only improves their binding to the TLR4 receptor, but also enhances their performance in terms of both biological activity and solubility compared to MPL and its synthetic analogues. Summary of the Invention
[0026] This invention relates to modified lipopolysaccharide (LPS) molecule-rich aggregates comprising at least 80% modified LPS molecules, as defined in the claims.
[0027] It also relates to compositions comprising modified LPS molecule-rich clusters as defined in the claims.
[0028] It also relates to naturally occurring, non-toxic LPS molecules and / or modified LPS molecule-rich aggregates, or compositions containing thereof, for the treatment and / or prevention of cancer, inflammatory diseases, or infectious diseases in subjects in need, or for stimulating an immune response in subjects in need; or for the purpose of vaccinating subjects in need, as defined in the claims.
[0029] It also relates to kits as defined in the claims.
[0030] definition
[0031] In this invention, the following terms have the following meanings:
[0032] As used herein, the term "lipopolysaccharide" or "LPS" refers to a phosphoglycolipid present in the outer membranes of Gram-negative bacteria, spirochetes (e.g., Leptospira), cyanobacteria, and some Gram-positive bacteria (e.g., Firmicutes). LPS typically consists of two distinct regions: an inner phospholipid containing a large number—typically 2 to 9—long-chain fatty acids, referred to as "lipid A," which carries most of the biological properties of the LPS; and a polysaccharide moiety containing a central "core oligosaccharide" domain (a branched oligosaccharide with approximately nine or ten sugars) and external antigenic domains, such as an "O-antigen" domain (composed of a linear or branched repeating polymer of sugar residues with highly variable number, properties, and spatial arrangement) and / or a "capped antigen" domain. Some bacterial LPS lack an O-antigen domain and the "polysaccharide" moiety is limited to "oligosaccharides" containing the core oligosaccharide domain; therefore, these LPS are sometimes referred to as LOS, or lipopolysaccharides. However, some bacterial LPS, although lacking an O-antigen domain, are capped by a capped antigen. For example, in the case of Bordetella pertussis, the distal trisaccharide differs from the O-antigen in biosynthesis and genetics.
[0033] As used herein, the term "lipid A" refers to the hydrophobic portion of a lipopolysaccharide (LPS) molecule. It is typically a β-1,6-glucosamine (GlcN) disaccharide, a β-1,6-diaminoglucosamine (DAG) disaccharide, or a mixture of β-1,6-glucosamine-diaminoglucosamine-disaccharides, usually phosphorylated at the C1 and C4' positions and acylated with four to seven fatty acids at the C2, C3, C2', and / or C3 positions. The carbon numbers of the disaccharides forming lipid A are well known in the art and are commonly used by those skilled in the art. Briefly, carbon numbers without an apostrophe (') refer to the carbons of the reducing side sugars of the disaccharide forming the lipid A domain. Carbon numbers with an apostrophe (') refer to the carbons of the non-reducing side sugars of the disaccharide forming the lipid A domain. As used herein, the term "lipid A" also includes the precursors and modified structures of the typical disaccharide lipid A forming the hydrophobic portion of the LPS molecule. Such precursors and modified structures may be naturally present in LPS molecules of certain bacterial species or may be obtained through modification, and include, for example, lipid X and other lipid A backbones, including monosaccharide backbones that retain a portion of the sugars forming the reducing side of the lipid A domain and optionally a portion of the sugars forming the non-reducing side of the lipid A domain.
[0034] As used herein, the term "fatty acid" or "fatty acid residue" refers to an aliphatic monocarboxylic acid that typically, but not always, has an even number of carbon atoms. A fatty acid molecule has two distinct regions: a long hydrocarbon chain (hydrophobic and chemically inert) and a carboxylic acid group (extremely hydrophilic and readily forms ester and amide bonds). In the context of LPS, a fatty acid can be a "primary fatty acid" that has been esterified or amidated at the C2, C3, C2', and C3' positions of the lipid A domain. A fatty acid can also be a "secondary fatty acid" (also called a "cross-lactone-bound fatty acid" or "acyl-oxy-acyl fatty acid"), i.e., a fatty acid esterified on another fatty acid, such as on the 3-OH group of a primary fatty acid. Based on the length of the aliphatic chain, fatty acids can be classified as short-chain, medium-chain, long-chain, and very long-chain fatty acids. As used herein, the term "short-chain fatty acid" or "SCFA" refers to a fatty acid with five or fewer carbon atoms in its aliphatic tail, such as one, two, three, four, or five. As used herein, the term "medium-chain fatty acid" or "MCFA" refers to a fatty acid with 6 to 12 carbons in its aliphatic tail, such as 6, 7, 8, 9, 10, 11, or 12 carbons. As used herein, the term "long-chain fatty acid" or "LCFA" refers to a fatty acid with 13 to 21 carbons in its aliphatic tail, such as 13, 14, 15, 16, 17, 18, 19, 20, or 21 carbons. As used herein, the term "very long-chain fatty acid" or "VLCFA" refers to a fatty acid with 22 or more carbons in its aliphatic tail, such as 22, 23, 24, 25, 26, 27, 28, 29, 30, or more than 30 carbons. Fatty acids may additionally or optionally be classified as saturated or unsaturated fatty acids according to their degree of saturation. As used herein, the term "saturated fatty acid" refers to a fatty acid that does not contain any double-C=C bonds in its fatty acid chain. As used herein, the term "unsaturated fatty acid" refers to a fatty acid that contains at least one or more double-C=C bonds in its fatty acid chain. In this case, the double-C=C bonds can be cis or trans.
[0035] As used herein, the term "core oligosaccharide" or "core-OS" refers to the chain of sugar residues found in Gram-negative lipopolysaccharides (LPS). The combination of core-OS domains is highly diverse across bacterial species and strains. The core-OS is typically divided into two regions, called the "inner core" and the "outer core," with the inner core directly attached to the C6' position of the lipid A domain (corresponding to R3 in Formula I) via an (α2→6) ketoglycosidic bond.
[0036] As used herein, the term "inner core" refers to the first three to six sugar residues, which may be linear or branched. Typically, from the proximal to distal end of the C6' position of the lipid A domain (corresponding to R3 in Formula I), the inner core comprises a first 3-deoxy-D-mann-oct-2-ketoose (Kdo) residue or D-glycerol-D-tarro-oct-2-ketoose (Ko), usually substituted by one or two additional sugar residues in a linear or branched manner, including but not limited to 3-deoxy-D-mann-oct-2-ketoose (Kdo), D-glycerol-D-tarro-oct-2-ketoose (Ko), or 4-amino-4-deoxy-L-arabinose (Ara4N) residues, or combinations thereof. The distal ends of these residues, or individual Kdo molecules, may be modified with phosphate or ethanolamine groups. Further hexose residues may be attached to the distal ends of these residues, including but not limited to two to three optionally phosphorylated heptose residues. LPS molecules that contain only the lipid A domain and the inner core region are often referred to as "deep coarse LPS".
[0037] As used herein, the term "3-deoxy-D-manno-oct-2-ketonic acid" or "Kdo" refers to the ketonic acid of 2-octyl ketose, having the following formula (and the carbon numbers are shown in italics):
[0038]
[0039] As used herein, the term "external core" refers to the sugar residues attached to the farthest end of the internal core, typically a straight or branched hexose chain of heptose residues. This hexose chain usually contains one to six or more hexose residues, including but not limited to glucose, mannose, galactose, and combinations thereof. LPS molecules containing both a lipid A domain and a complete core-OS domain (i.e., possessing both an internal and external core region) are often referred to as "rough LPS".
[0040] As used herein, the term "O-antigen" refers to a polysaccharide typically contained in LPS molecules and linked to a core-OS domain. The composition of the O-antigen domain is highly diverse across bacterial species and strains. LPS molecules containing a lipid A domain, an intact core-OS domain (i.e., with both inner and outer core regions), and an O-antigen domain are often referred to as "smooth LPS".
[0041] As used herein, the term "capped antigen" or "capped sugar" refers to the sugar moiety typically found in LPS molecules that is linked to the core-OS domain, replacing or complementing the O-antigen domain. This capped antigen is biosynthetically and genetically distinct from the typical O-antigen domain. The composition of capped antigens is highly diverse among bacterial species and strains.
[0042] As used herein, the terms "toxicity" or "pyrogenicity," when referring to LPS molecule species, refer to the ability of said LPS molecule species to induce an acute or chronic inflammatory response when administered to a subject. Acute or chronic inflammatory responses may be characterized by the production of inflammatory mediators, including but not limited to IL-6, IL-1β, and TNF-α. Depending on the quantity and structural characteristics of the LPS molecule species administered, these acute or chronic inflammatory responses can range from fever and chills to irreversible and fatal septic shock. Methods and approaches for assessing the toxicity and / or pyrogenicity of LPS molecule species are well known in the art. Examples of such methods and approaches include, but are not limited to, in vivo assays, such as, but not limited to, rabbit pyrogen test (RPT), chicken embryo C… 50 Lethal dose, GalN sensitized mouse C 50 Lethal dose, acute toxicity test in normal mice; and in vitro tests, such as, but not limited to, mononuclear cell activation assay (MAT).
[0043] The rabbit pyrogen test (RPT), performed according to the European Pharmacopoeia (Ph.Eur. 5.1.10, this section is incorporated herein by reference), comprises measuring the temperature rise in three rabbits after intravenous injection of a test solution (e.g., a composition containing the LPS to be tested). Temperature is measured before injection of the test solution; then, the test solution is injected, and the body temperature of each rabbit is measured for 3 hours. If the sum of the temperatures of the three rabbits increases by less than 1.15°C, the test solution is considered pyrogen-free; if the sum of the temperatures of the three rabbits increases by more than 2.65°C, the test solution is considered pyrogenic; if the sum of the temperatures of the three rabbits increases by between 1.15°C and 2.65°C, the test should be repeated to confirm the results.
[0044] The monocyte activation assay (MAT) has been described in the European Pharmacopoeia as a pharmacopoeia method for the detection of pyrogens (January 2010 - Ph. Eur. 9. 8, section 2.6.30, which is incorporated herein by reference). The MAT is based on the activation of monocytes by pyrogens, resulting in the production of cytokines that are detected in immunoassays (e.g., ELISA). The MAT can have various variants depending on (1) the source of the monocytes, including whole blood, isolated primary monocytes (e.g., PBMCs), or monocyte cell lines; and (2) ELISA readings, including IL-6, IL-1β, and TNF-α. All of these mimic the human fever response in vitro.
[0045] For more detailed information on the manner and methods of assessing the toxicity and / or pyrogenicity of LPS molecular species, see Chapters 5.1.10 and 2.6.30 of the European Pharmacopoeia, which are incorporated herein by reference.
[0046] Detailed description
[0047] This invention relates to modified LPS molecule species and rich clusters containing such molecule species.
[0048] In one embodiment, the modified LPS molecule species enrichment cluster comprises at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more than 99% of the total number of modified LPS molecule species in the population according to the invention.
[0049] According to the present invention, the modified LPS molecules do not have a phosphate group at the reduced end C1 position of their lipid A domain; and the non-reduced end C6' position of their lipid A domain is partially replaced by a monosaccharide, oligosaccharide or polysaccharide.
[0050] According to the present invention, the modified LPS molecules may have no phosphate group at the reduced end C4' position of their lipid A domain; and the non-reduced end C6' position of their lipid A domain may be partially replaced by monosaccharides, oligosaccharides or polysaccharides.
[0051] According to the present invention, the modified LPS molecules either lack phosphate groups at the reduced C1 position and the non-reduced C4' position of their lipid A domain; and are partially replaced by monosaccharides, oligosaccharides or polysaccharides at the non-reduced C6' position of their lipid A domain.
[0052] In one implementation, the modified LPS molecule species also contain fewer or more fatty acid chains compared to typical (i.e., unmodified) Escherichia coli or Salmonella enteritidis LPS molecules.
[0053] In one implementation, the modified LPS molecule species also contain shorter or longer fatty acid chains compared to typical (i.e., unmodified) Escherichia coli or Salmonella enteritidis LPS molecules.
[0054] In one embodiment, the modified LPS molecule species have the general formula A:
[0055]
[0056] in
[0057] Y is –O– or –NH–;
[0058] R2 is a phosphate group (–OPO3H2) or a hydroxyl group (–OH); optionally substituted;
[0059] R3 is a monosaccharide, oligosaccharide, or polysaccharide, optionally substituted; preferably, R3 is optionally substituted with an O-antigen domain.
[0060] Core oligosaccharides (i.e., internal core, or internal core and external core);
[0061] R6 is a fatty acid residue; it may be substituted.
[0062] R7 is a hydrogen or fatty acid residue; optionally, it may be substituted.
[0063] Z is a hydroxyl group (–OH), which may optionally be substituted, provided that, if substituted, the substitution is not by a phosphate group (–OPO3H2).
[0064] Composed of, or
[0065] Z is in
[0066] X is –O– or –NH–;
[0067] R1 is a hydroxyl group (–OH), optionally substituted, provided that, if substituted, the substitution is not by a phosphate group (–OPO3H2).
[0068] Composed of;
[0069] R4 is a fatty acid residue; optionally substituted; and
[0070] R5 is a hydrogen or fatty acid residue; it may be substituted.
[0071] In one embodiment, the modified LPS molecule species have the general formula A:
[0072]
[0073] in
[0074] Y is –O– or –NH–;
[0075] R2 is a hydroxyl group (–OH), which may optionally be substituted, provided that, if substituted, the substitution is not by a phosphate group (–OPO3H2).
[0076] Composed of;
[0077] R3 is a monosaccharide, oligosaccharide, or polysaccharide, optionally substituted; preferably, R3 is optionally substituted with an O-antigen domain.
[0078] Core oligosaccharides (i.e., internal core, or internal core and external core);
[0079] R6 is a fatty acid residue; it may be substituted.
[0080] R7 is a hydrogen or fatty acid residue; optionally, it may be substituted.
[0081] Z is a hydroxyl group (–OH), which may optionally be substituted, provided that, if substituted, the substitution is not by a phosphate group (–OPO3H2).
[0082] Composed of, or
[0083] Z is in
[0084] X is –O– or –NH–;
[0085] R1 is a hydroxyl group (–OH), which may optionally be substituted, provided that, if substituted, the substitution is not by a phosphate group (–OPO3H2).
[0086] Composed of;
[0087] R4 is a fatty acid residue; optionally substituted; and
[0088] R5 is a hydrogen or fatty acid residue; it may be substituted.
[0089] In one implementation, the modified LPS molecule species have the general formula B:
[0090]
[0091] in
[0092] X and Y are independently –O– or –NH–;
[0093] R1 is a hydroxyl group (–OH), which may optionally be substituted, provided that, if substituted, the substitution is not by a phosphate group (–OPO3H2).
[0094] Composed of;
[0095] R2 is a phosphate group (–OPO3H2) or a hydroxyl group (–OH); optionally, it may be substituted.
[0096] R3 is a monosaccharide, oligosaccharide, or polysaccharide, optionally substituted; preferably, R3 is optionally substituted with an O-antigen domain.
[0097] Core oligosaccharides (i.e., internal core, or internal core and external core);
[0098] R4 and R6 are fatty acid residues that are independent of each other; optionally substituted; and
[0099] R5 and R7 are hydrogen or fatty acid residues, which are independent of each other; they may be substituted.
[0100] In one implementation, the modified LPS molecule species have the general formula B:
[0101]
[0102] in
[0103] X and Y are independently –O– or –NH–;
[0104] R1 is a phosphate group (–OPO3H2) or a hydroxyl group (–OH); optionally substituted;
[0105] R2 is a hydroxyl group (–OH), which may optionally be substituted, provided that, if substituted, the substitution is not by a phosphate group (–OPO3H2).
[0106] Composed of;
[0107] R3 is a monosaccharide, oligosaccharide, or polysaccharide, optionally substituted; preferably, R3 is optionally substituted with an O-antigen domain.
[0108] Core oligosaccharides (i.e., internal core, or internal core and external core);
[0109] R4 and R6 are fatty acid residues that are independent of each other; they may be substituted; and
[0110] R5 and R7 are hydrogen or fatty acid residues, which are independent of each other; they may be substituted.
[0111] In one implementation, the modified LPS molecule species have the general formula B:
[0112]
[0113] in
[0114] X and Y are independently –O– or –NH–;
[0115] R1 and R2 are hydroxyl groups (–OH), which may optionally be substituted, provided that, if substituted, the substitution is not by a phosphate group.
[0116] Composed of (–OPO3H2);
[0117] R3 is a monosaccharide, oligosaccharide, or polysaccharide, optionally substituted; preferably, R3 is optionally substituted with an O-antigen domain.
[0118] Core oligosaccharides (i.e., internal core, or internal core and external core);
[0119] R4 and R6 are fatty acid residues that are independent of each other; optionally substituted; and
[0120] R5 and R7 are hydrogen or fatty acid residues, which are independent of each other; they may be substituted.
[0121] In one embodiment, the modified LPS molecule species have the general formula A:
[0122]
[0123] in
[0124] Y is –O– or –NH–;
[0125] R2 is a phosphate group (–OPO3H2) or a hydroxyl group (–OH); optionally, it may be substituted.
[0126] R3 is a monosaccharide, oligosaccharide, or polysaccharide, optionally substituted; preferably, R3 is optionally substituted with an O-antigen domain.
[0127] Core oligosaccharides (i.e., internal core, or internal core and external core);
[0128] R6 is a fatty acid residue; it may be substituted.
[0129] R7 is a hydrogen or fatty acid residue; optionally, it may be substituted.
[0130] Z stands for hydroxyl group (–OH).
[0131] In one embodiment, X is –O– and Y is –O–. In this embodiment, the disaccharide of the lipid A domain is therefore a β-1,6-glucosamine [GlcN] disaccharide.
[0132] In one embodiment, X is –NH– and Y is –NH–. In this embodiment, the disaccharide of the lipid A domain is therefore β-1,6-diaminoglycine [DAG] disaccharide.
[0133] In one embodiment, X is –O– and Y is –NH–. In another embodiment, X is –NH– and Y is –O–. In these embodiments, the disaccharide of the lipid A domain is therefore a β-1,6-disaccharide containing one GlcN residue and one DAG residue.
[0134] In one implementation, Z is a hydroxyl group (–OH).
[0135] In one embodiment, R2 is a hydroxyl group (–OH). In another embodiment, both Z and R2 are hydroxyl groups (–OH).
[0136] In one embodiment, Z is a hydroxyl group (–OH), optionally substituted, provided that if substituted, the substitution is not composed of a phosphate group (–OPO3H2). In one embodiment, R2 is a hydroxyl group (–OH), optionally substituted. In one embodiment, both Z and R2 are hydroxyl groups (–OH), optionally substituted, provided that if substituted, the substitution is not composed of a phosphate group (–OPO3H2).
[0137] In one embodiment, Z is a phosphate group (–OPO3H2), provided that R2 is not a phosphate group. In another embodiment, R2 is a phosphate group (–OPO3H2), provided that Z is not a phosphate group.
[0138] In one implementation scheme, Z is Where X is defined as above, and R1, R4, and R5 are defined as follows.
[0139] In one embodiment, R1 is a hydroxyl group (–OH). In one embodiment, R2 is a hydroxyl group (–OH). In one embodiment, both R1 and R2 are hydroxyl groups (–OH).
[0140] In one embodiment, R1 is a hydroxyl group (–OH), optionally substituted, provided that if substituted, the substitution is not composed of a phosphate group (–OPO3H2). In one embodiment, R2 is a hydroxyl group (–OH), optionally substituted. In one embodiment, R1 and R2 are hydroxyl groups (–OH), optionally substituted, provided that if substituted, the substitution of R1 is not composed of a phosphate group (–OPO3H2).
[0141] In one embodiment, R1 is a phosphate group (–OPO3H2), provided that R2 is not a phosphate group. In another embodiment, R2 is a phosphate group (–OPO3H2), provided that R1 is not a phosphate group.
[0142] In one embodiment, Z is a hydroxyl group (–OH) substituted with other substituents, provided that the substitution is not composed of a phosphate group (–OPO3H2). In one embodiment, R1 is a hydroxyl group (–OH) substituted with other substituents, provided that the substitution is not composed of a phosphate group (–OPO3H2). In one embodiment, R2 is a hydroxyl group (–OH) substituted with other substituents.
[0143] In one embodiment, Z is a phosphate group substituted with other substituents (–OPO3H2). In one embodiment, R1 is a phosphate group substituted with other substituents (–OPO3H2). In one embodiment, R2 is a phosphate group substituted with other substituents (–OPO3H2).
[0144] These other substituents include, but are not limited to, ethanolamine "EA" (–CH2-CH2-NH2), phosphorylethanolamine "PEA" (–OPO3H-CH2-CH2-NH2), diphosphorylethanolamine "PPEA" (–OPO3H2–PO3H–CH2–CH2–NH2), 4-amino-4-deoxy-L-arabinose (LArap4N) residues, glucosamine residues, galactosamine residues, etc. In addition, these other substituents include, but are not limited to, alkyl, aminoalkyl, aryl, carboxylalkyl, cycloalkyl, ether or polyether groups, haloalkyl, heteroaryl, nitoxyalkyl, etc.
[0145] The term "alkyl" as used herein, either on its own or as part of another substituent, refers to formula C. n H 2n+1 The alkyl group comprises a hydrocarbon group, wherein n is a number greater than or equal to 1. In one embodiment, the alkyl group comprises 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms, more preferably 1 to 4 carbon atoms, and even more preferably 1 to 3 carbon atoms. The alkyl group can be straight-chain or branched. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, etc.
[0146] The term “aminoalkyl” as used herein, either on its own or as part of another substituent, refers to an alkyl-NH2 group, wherein the alkyl group is as defined herein.
[0147] As used herein, the term "aryl" itself, or as part of another substituent, refers to a polyunsaturated aromatic hydrocarbon group having a monocyclic (i.e., phenyl) or multiple fused aromatic rings (e.g., naphthyl) typically comprising 5 to 12 atoms, preferably 6 to 10 atoms. Non-limiting examples of aryl groups include phenyl, naphthyl, etc.
[0148] The term “carboxylalkyl” as used herein, either on its own or as part of another substituent, refers to an alkyl-COOH group, wherein the alkyl group is as defined herein.
[0149] The term "cycloalkyl" as used herein, either on its own or as part of another substituent, refers to a compound having the formula C1. n H 2n-1 The cyclic hydrocarbon group, wherein n is a number greater than or equal to 1, or a plurality of saturated cyclic hydrocarbon rings fused together. In one embodiment, the cycloalkyl group comprises 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms, more preferably 1 to 5 carbon atoms.
[0150] As used herein, the term "ether group" itself, or as part of another substituent, refers to a hydrocarbon group having an oxygen atom bonded to two carbon atoms. Ether groups can be straight-chain or branched. Examples of ether groups include, but are not limited to, dimethyl ether, diethyl ether, dipropyl ether, dibutyl ether, dipentyl ether, dihexyl ether, diheptyl ether, dioctyl ether, etc. When the ether group repeats in a polymeric manner, it is called a "polyether." Examples of polyethers include, but are not limited to, polyethylene glycol ((–CH2CH2O–)). n ), polypropylene glycol ((–CH2CH(CH3)O–) n Polybutanediol ((–CH2CH2CH2CH2O–) n Paraformaldehyde ((–CH2O–) n )wait.
[0151] The term "haloalkyl" itself, or as part of another substituent, refers to an alkyl group as defined herein, in which one or more hydrogen atoms are substituted with a halogen as defined herein. The term "halogen" refers to fluorine, chlorine, bromine, or iodine. Non-limiting examples of haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, etc.
[0152] As used herein, the term "heteroaryl" refers, either on its own or as part of another substituent, to an aryl group as defined herein, in which at least one carbon atom is substituted with a heteroatom. In other words, it refers to an aromatic monocyclic ring of 5 to 12 carbon atoms or a ring system containing two fused rings typically containing 5 to 6 atoms, wherein one or more carbon atoms are substituted with oxygen, nitrogen, and / or sulfur atoms, wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatomium may optionally be quaternized. Non-limiting examples of such heteroaryls include: Azolyl, thiazolyl, imidazole, furanyl, and pyrrolyl groups.
[0153] The term “nitroalkoxy” as used herein, either on its own or as part of another substituent, refers to an alkyl-ONO2 group, wherein the alkyl group is as defined herein.
[0154] In one embodiment, Z is a hydroxyl group (–OH) substituted with a therapeutic agent. In one embodiment, R1 is a hydroxyl group (–OH) substituted with a therapeutic agent. In one embodiment, R2 is a hydroxyl group (–OH) substituted with a therapeutic agent. In this embodiment, any suitable therapeutic agent may be conjugated to the LPS molecule species directly or through a suitable linker.
[0155] Methods and approaches for conjugating therapeutic agents to LPS molecules are well known in the art. Suitable examples of therapeutic agents conjugated to LPS molecules include, but are not limited to, peptides, polypeptides, proteins, polymers, nucleic acid molecules, small molecules, mimics, synthetic drugs, inorganic molecules, organic molecules, radioisotopes, nanoparticles, carriers, etc.
[0156] Optionally or additionally, suitable examples of therapeutic agents conjugated to LPS molecules include, but are not limited to, chemotherapeutic agents, targeted therapies, cytotoxic agents, antibiotics, antiviral agents, cell cycle synchronizers, cell receptor ligands, immunomodulators, pro-apoptotic agents, anti-angiogenic agents, cytokines, growth factors, antibodies or their antigen-binding fragments, antigens, etc.
[0157] It is obvious that some treatments may belong to more than one category.
[0158] In one implementation, the therapeutic agent is a chemotherapeutic agent.
[0159] The term "chemotherapeutic agent" as used in this article refers to any molecule that is effective in inhibiting tumor growth.
[0160] Suitable examples of chemotherapeutic agents include those described in the L01 subgroup of the Anatomical Therapeutics and Chemotherapy Classification System.
[0161] Examples of suitable chemotherapy agents include, but are not limited to:
[0162] i. Alkylating agents, for example:
[0163] ■ Nitrogen mustards, including nitrogen mustard, cyclophosphamide, ifosfamide, trefophosphamide, chlorambucil, melphalan, prednimustine, bendamustine, uracil nitrogen mustard, naphthalene nitrogen mustard, chlorphosphamide, estradiol, dichloromethyldiethylamine, nitrogen mustard oxide hydrochloride, neo-enpichin, benzyl mustard cholesterol, uramustine, etc.
[0164] ■ Nitrosoureas, including carmustine, lomustine, semustine, formustine, nimustine, ramustine, streptozotocin, chlorhexidine, etc.;
[0165] ■ Alkyl sulfonates, including busulfan, mannitol, and trioxygenated sulfonates;
[0166] ■ Aziproidine derivatives, including carboquinone, thiotepa, triimidequinone, triethylene melamine, benzodopa, meturedopa, uredopa, etc.; hydrazides, including procarbazine, etc.
[0167] ■ Triazine derivatives, including dacarbazine, temozolomide, etc.; ethyleneimine derivatives and methylmelamine derivatives, including hexamethylmelamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, trimethylol melamine, etc.
[0168] ■ and others, including dibromomannitol, piperobromo, actinomycin, bleomycin, mitomycin (including mitomycin C, etc.), purcamycin, etc.;
[0169] ii. Polyacetyl derivatives, such as blatasine, blatasine ketone, etc.;
[0170] iii. Benzodiazepines, such as 2-oxoquazepam, 3-hydroxyfenalazepam, bromazepam, carbamazepam, carburezazepam, nitrazepam, cinazepam, cinusazepam, clonazepam, cloniprazepam, chlorpromazine, ciprozepam, diloxazepam, nordiazepam, desmethylflunitrazepam, divalciphagil, diazepam, diclazepam, difludiazepam, duloxazepam, efazolin, ethylcarboflurane, etc. Diazepam, chlorofluoroethyl ester, flubromozepam, fluezepam, fludiazepam, flunitrazepam, flurazepam, flutrazepam, flutozepam, phosphatidylcholine, gedazepam, halazepam, irazepine, kenazepine, ketazolam, lorazepam, chloromethazine, rufradol, mecloazepam, metronidazole, metronidazole, methazepam, motrozepam, N-dealkylflurazepam, nifoxipam, nitrazepam Emazepam, Nitrazepam, Potassium Nitrate, Norazepam, Notiazepam, Oxazepam, Fennalzepam, Pinazepam, Pivozepam, Prarazepam, Proflurazepam, Quazepam, QH-II-66, Reclozepam, RO4491533, Ro5-4864, SH-I-048A, Thiazepam, Hydroxyazepam, Tetrahydrozepam, Tifludone, Mesylatepam, Triflunordazepam, Toloxacin, Udazepam, Alfendazan, Oxyphenidyl, CP-1414 S, Lofentazone, Trifluramazon, Gelisopam, GYKI-52466, GYKI-52895, Nerizopam, Talenpanel, Tolfilsopam, Atenazolam, Alprazolam, Tranquilizing, Clonazolam, Estazolam, Flualprazolam, Flubromobrozolam, Flunitrazolam, Nitrozolam, Pyrazolium, Triazolam, Bromatazolium, Clomazolam, EVT-201, FG-8205, Flumazenil, GL-II-73, Midazenil 123I-Iodixanil, L-655,708, Cloprozotazone, Midazolam, PWZ-029, Remazolam, Ro15-4513, Ro48-6791, Ro48-8684, Ro4938581, Salmasinil, SH-053-R-CH3-2'F, Chlorpyrifos Alzolium, flutazolam, halogen Oxazolam, methazolam, oxazolam, benzalkonium chloride, clotrazepam, bromhexol, cycloclozolam, etizol, etizol, fluclotizolam, irapafan, JQ1, metizolam, olanzapine, tiramzepine, clopidogrel, zaprazepam, razobac, ribazapam, zolrazepam, zometazidine, zometazampine, pregalizopam, clarazopam, anthraxomycin, avizafen, limazafen, etc.
[0171] iv. Antimetabolites, for example:
[0172] ■ Anti-folate, including aminopterin, methotrexate, pemetrexed, pralatrexate, pteroxetine, raltitrexed, folate, trimethoprim, pemetrexed, etc.
[0173] ■Purine analogues, including pentostatin, cladribine, clofarabine, fludarabine, nerabine, thioguanine, mercaptopurine, etc.;
[0174] ■Pyrimidine analogues, including fluorouracil, capecitabine, deoxyfluorouridine, tegafur, tegafur / gemeracil / oteracil, carmoflu, fluorouridine, cytarabine, gemcitabine, azacytidine, decitabine, etc.
[0175] and
[0176] ■Hydroxyurea;
[0177] v. Androgens, such as capetestosterone, drotalbutone propionate, cyclothionol, meandrolone, testosterone, etc.
[0178] vi. Anti-adrenergic drugs, such as aminoglutide, mitotane, and triplostane;
[0179] vii. Folic acid supplements, such as folinic acid, etc.
[0180] viii. Maytansin compounds, such as maytansin and anserine;
[0181] ix. Platinum analogues, such as platinum, carboplatin, cisplatin, bicyclic platinum, nedaplatin, oxaliplatin, saltiplatin, etc.
[0182] x. Antihormonal agents, such as:
[0183] ■ Anti-estrogens, including tamoxifen, raloxifene, aromatase inhibitors 4(5)-imidazolium, 4-hydroxytamoxifen, trivoxifen, raloxifene, LY117018, onanasone, toremifene, etc.
[0184] ■ Antiandrogens, including flutamide, nilumet, bicalutamide, leuprorelin, goserelin, etc.;
[0185] xi. Trichothecenes, such as T-2 toxin, verrucosporin A, baculosporin A, serpentin, etc.;
[0186] xii. Toxoids, such as cabazitaxel, docetaxel, larotaxel, oxalitaxel, paclitaxel, tistathione, etc.
[0187] xiii. Others, such as camptothecin (including its synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its synthetic analogues adorelasin, calzelecanin, and pyrazelasin); cryptophytic acid (including cryptophytic acid 1 and cryptophytic acid 8); dolasstatin; duocarmycin (including its synthetic analogues KW-2189 and CBI-TMI); eleutheroside; sphagnum mossine; sarcodictyin; spongistatin; aconitine; atrazoserine; bleomycin; actinomycin; kanamycin; erythromycin; carcinogen; chromomycin; actinomycin D; donomycin; detoxin; 6-diazo-5-oxo-L-leucine; doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyridoxine) Doxorubicin, deoxydoxorubicin, etc.; epirubicin; isorubicin; idarubicin; mesorubicin; mycophenolic acid; nogamycin; oligomycin; pepromycin; potfiromycin; puromycin; triamcinolone acetonide; rodorubicin; streptomgrin; streptozotocin; tuberculin; ubenmex; fenestrated statin; zorubicin; acetoglucuronolactone; aldehyde phosphorus Amide glycosides; aminolevulinic acid; acridine; amustine; bifenthrin; edatrazine; defofamine; colchicine; diaciconone; elfornithine; eletidine; epothilone; ethoxycycline; gallium nitrate; hydroxyurea; lentinan; chlordamine; mitoxantrone; mitoxantrone; moparinol; diamine nitroacin; methionine mustard; pirarubicin; podophyllotoxin; 2-ethylhydrazine; Razosen; Rhizomycin; Cizonan; Spirogonnanium; Tenuazonic acid; 2,2',2”-Trichlorotriethylamine; Polyurethane; Vinpocetine; Dacarbazine; Mannitol mustard; Dibromomannitol; Dibromoeutherol; Piperobromide; Gacytosine; Cytarabine; 6-Thioguanine; Vincristine; Etoposide; Vincristine; Vinorelbine; Noviben; Mitoxantrone; Teniposide; Donomycin; Capecitabine; Ibandronate; CPT-11; Topoisomerase inhibitor RFS 2000; Topoisomerase I inhibitor SN38; Difluoromethylornithine; Retinoic acid, etc.
[0188] In one implementation, the therapeutic agent is a targeted therapeutic agent.
[0189] As used herein, the term “targeted therapy” refers to any molecule that targets one or more specific target molecules (e.g., protein molecules) involved in processes such as tumorigenesis, tumor progression, tumor metastasis, tumor cell proliferation, and cell repair.
[0190] Suitable examples of targeted therapies include, but are not limited to, tyrosine kinase inhibitors, serine / threonine kinase inhibitors, and monoclonal antibodies.
[0191] Suitable examples of targeted therapies include, but are not limited to, HER1 / EGFR inhibitors (e.g., brigatinib, erlotinib, gefitinib, omalitinib, osimertinib, roxitinib, vandetanib, etc.); HER2 / neu inhibitors (e.g., afatinib, lapatinib, neratinib, etc.); C-kit and PDGFR inhibitors (e.g., axitinib, masitinib, pazopanib, sunitinib, sorafenib, tocelanib, etc.); FLT3 inhibitors (e.g., neratinib, etc.); VEGFR inhibitors (e.g., axitinib, sildenafil, lenvatinib, nintedanib, pazopanib, regorafenib, etc.). Antibiotics such as fentanyl, sermannib, sorafenib, sunitinib, tevozanib, toselabinib, vandetanib, etc.; RET inhibitors (e.g., vandetanib, entrectinib, etc.); c-MET inhibitors (e.g., cabozantinib, etc.); bcr-abl inhibitors (e.g., imatinib, dasatinib, nilotinib, ponatinib, ladotinib, etc.); Src inhibitors (e.g., bosutinib, dasatinib, etc.); Janus kinase inhibitors (e.g., lesistatinib, momirotinib, ruxotetinib, paklatinib, etc.); MAP2K inhibitors (e.g., cobimetinib, selmetinib, trametinib, bimetinib, etc.). EML4-ALK inhibitors (e.g., alectinib, brigatinib, ceritinib, crizotinib, etc.); Bruton inhibitors (e.g., ibrutinib, etc.); mTOR inhibitors (e.g., everolimus, tesimolimus, etc.); hedgehog inhibitors (e.g., sonidegaphedrine, vemodegaphedrine, etc.); CDK inhibitors (e.g., palbociclib, ribociclib, etc.); anti-HER1 / EGFR monoclonal antibodies (e.g., cetuximab, nexituzumab, panitumumab, etc.); anti-HER2 / neu monoclonal antibodies (e.g., ado trastuzumab, emtansine, pertuzumab, etc.). Trastuzumab, trastuzumab, trastuzumab-dkst, etc.); anti-EpCAM monoclonal antibodies (e.g., caputuzumab, ezetizumab, etc.); anti-VEGF monoclonal antibodies (e.g., bevacizumab, bevacizumab-awwb, etc.); anti-CD20 monoclonal antibodies (e.g., teimozumab, atorzumab, olframumab, rituximab, tosimomumab, etc.); anti-CD30 monoclonal antibodies (e.g., bentuximab, etc.); anti-CD33 monoclonal antibodies (e.g., gemtuzumab, etc.); anti-CD52 monoclonal antibodies (e.g., alemtuzumab, etc.); and their antigen-binding fragments.
[0192] In one implementation, the therapeutic agent is a cytotoxic agent.
[0193] As used in this article, the term "cytotoxic agent" refers to any molecule that causes cell death through any mechanism.
[0194] Suitable examples of cytotoxic agents include, but are not limited to, taxanes, anthracyclines, alkylating agents, vinca alkaloids, antimetabolites, platinum-based agents, steroids, and chemotherapeutic agents.
[0195] Suitable examples of taxanes include, but are not limited to, cabazitaxel, docetaxel, larotaxel, oxalitaxel, paclitaxel, and tistathataxel.
[0196] Suitable examples of anthracyclines include, but are not limited to, arubicin, amrubicin, doxorubicin, epirubicin, idarubicin, pirarubicin, vararubicin, and zorubicin.
[0197] Suitable examples of alkylating agents include, but are not limited to, nitrogen mustards (e.g., nitrogen mustard, cyclophosphamide, ifosfamide, trefophosphamide, chlorambucil, melphalan, prednimustine, bendamustine, uracil mustard, etc.), nitrosoureas (e.g., carmustine, lomustine, semustine, formustine, nimustine, ramustine, streptozotocin, etc.), alkyl sulfonates (e.g., busulfan, mannosulfan, troozopran, etc.), aziridines (e.g., carboquinone, thiotepa, triiminoquinone, triethylene melamine, benzodopa, metotipa, urotepa, etc.), hydrazides (e.g., procarbazine, etc.), triazines (e.g., dacarbazine, temozolomide, hexamethylmelamine, dibromomannitol, piperobromethane, actinomycin, bleomycin, mitomycin, and procainamide).
[0198] Suitable examples of vinca alkaloids include, but are not limited to, vincristine, vinflunine, vindesine and vinorelbine.
[0199] Suitable examples of antimetabolites include, but are not limited to, antifolate agents (e.g., aminopterin, methotrexate, pemetrexed, pralatrexate, raltitrexed, pemetrexed, etc.), purine analogs (e.g., pentostatin, cladribine, clofarabine, fludarabine, nerabine, thioguanine, mercaptopurine, etc.), pyrimidine analogs (e.g., fluorouracil, capecitabine, docefluorouracil, tegafur, tegafur / gemeracil / oteracil, carmoflu, fluorouracil, cytarabine, gemcitabine, azacytidine, decitabine, etc.), and hydroxyurea.
[0200] Suitable examples of platinum preparations include, but are not limited to, carboplatin, cisplatin, bicycloplatin, nedaplatin, oxaliplatin, and ceterplatin.
[0201] Suitable examples of steroids include, but are not limited to, estrogen receptor modulators, androgen receptor modulators, and progesterone receptor modulators.
[0202] The above has described suitable examples of chemotherapy agents.
[0203] In one implementation, the treatment agent is an antibiotic.
[0204] Suitable examples of antibiotics include those described in subgroup J01 of the Anatomical Therapeutics and Chemical Classification System.
[0205] Examples of suitable antibiotics include, but are not limited to:
[0206] i. Aminoglycosides, such as amikacin, gentamicin, kanamycin, neomycin, netilmicin, streptomycin, tobramycin, paromomycin, etc.;
[0207] ii. Ansarmycin derivatives, such as gentamicin and atrazine;
[0208] iii. Carbocephalosporins, such as carbocephalosporins;
[0209] iv. Carbapenems, such as ertapenem, doripenem, imipenem, cilastatin, meropenem, etc.;
[0210] v. First-generation cephalosporins, such as cefadroxil, cefazolin, cefotaxime, cefalexin, etc.;
[0211] vi. Second-generation cephalosporins, such as cefaclor, cefotaxime, cefoxitin, cefprozil, cefuroxime, etc.
[0212] vii. Third-generation cephalosporins, such as cefixime, cefdinir, ceftoran, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, cefbufen, cefazolin, ceftriaxone, etc.
[0213] viii. Fourth-generation cephalosporins, such as cefepime;
[0214] ix. Fifth-generation cephalosporins, such as cefepime;
[0215] x. Glycopeptides, such as teicoplanin and vancomycin;
[0216] xi. Macrolides, such as azithromycin, clarithromycin, erythromycin, roxithromycin, acetomycin, telithromycin, spectinomycin, etc.
[0217] xii. Monocyclic lactams, such as axtreonam, etc.;
[0218] xiii. Penicillins, such as amoxicillin, ampicillin, azlocillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, methicillin, nafcillin, oxacillin, penicillin, piperacillin, ticarcillin, etc.
[0219] xiv. Antibiotic peptides, such as bacitracin, colistin, polymyxin B, etc.
[0220] xv. Quinolones, such as ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lemefloxacin, moxifloxacin, norfloxacin, ofloxacin, trovafloxacin, etc.
[0221] xvi. Sulfonamides, such as sulfamidone, sulfamethoxazole, sulfaacetamide, sulfamethoxazole, sulfonamides, sulfasalazine, sulfaisocyanate, etc. azole, trimethoprim, trimethoprim-sulfamethoxazole azoles, etc.;
[0222] xvii. Tetracyclines, such as demeclocycline, doxycycline, minocycline, oxytetracycline, etc.; and
[0223] xviii. Others, such as arsenamin, chloramphenicol, clindamycin, lincomycin, ethambutol, fosfomycin, fusidic acid, furazolidone, isoniazid, linezolid, metronidazole, mupirocin, nitrofurantoin, acanthomamycin, pyrazinamide, quinupristin / dalfopristin, rifampin / rifampin, tinidazole, etc.
[0224] In one implementation, the treatment agent is an antiviral agent.
[0225] Suitable examples of antiviral agents include those described in subgroup J05 of the Anatomical Therapeutics and Chemochemistry classification system.
[0226] Suitable examples of antiviral agents include, but are not limited to, acetylated mannan, acyclovir, acyclovir sodium, amantadine, adefovir, vidarabine, alovudine, avirsuto, amantadine hydrochloride, aranodin, arilide, atenidine mesylate, avridin, cidofovir, cipanthenine, cytarabine hydrochloride, BMS 806, C31G, carrageenan, zinc salts, cellulose sulfate, cyclodextrin, dapoxetine, diravirine mesylate, dicyclovir, dextrin 2-sulfate, didanoxin, and diclofenac sodium. Thalitazone, dulutivir, edaurudoid, envirozime, etravirine, famciclovir, famodin hydrochloride, fecitabine, nonaluridine, phosphatidylcholine, sodium phosphonoethanolamine, FTC, ganciclovir, ganciclovir sodium, GSK 1265744, 9-2-hydroxyethoxy-methylguanine, ipalizumab, idoxuridine, interferon, 5-iodo-2′-deoxyuridine, IQP-0528, ethoxydihydroxybutanone, lamivudine, lobucavir, maraviro, memodin, pirodavir, penciclovir, retegvir, ribavirin, amantadine hydrochloride, rilpivirine (TMC-278), saquinavir mesylate, SCH-C, SCH-D, somantine hydrochloride Solvudine, Vestolon, Stavudine, T20, Teloron Hydrochloride, TMC120, TMC125, Trifluorouridine, Trifluorothymidine, Tenofovir, Tenofovir Alammet, Tenofovir Disoproxil Fumarate, Tenofovir Prodrug, UC-781, UK-427, UK-857, Valacyclovir, Valacyclovir Hydrochloride, Vidarabine, Vidarabine Phosphate, Vidarabine Sodium Phosphate, Virooxime, Zacitabine, Zidovudine, and Netviroxime.
[0227] In one implementation, the therapeutic agent is a cell cycle synchronizer.
[0228] As used in this article, the term "cell cycle synchronizer" refers to any molecule that can unify the cell cycle of a cell population to the same stage after administration.
[0229] Suitable examples of cell cycle synchronizers include, but are not limited to, afenidimycin, butyrolactone I, colchicine, cyclohexylimide, colchicine, dimethyl sulfoxide, 5-fluorodeoxyuridine, Hoechst33342, mimosine, nocodazole, roscovitine, and thymidine.
[0230] In one implementation, the therapeutic agent is a ligand of a cell receptor.
[0231] As used herein, the term "ligand of a cell receptor" refers to any molecule that binds to a cell receptor (e.g., cell surface receptor, intracellular receptor, or co-receptor, including transcription factors), including agonists and antagonists, as well as incomplete agonists, inverse agonists, and allosteric modulators.
[0232] Suitable examples of ligands for cellular receptors include, but are not limited to, receptors for AATYK, acetylcholine, ADDRG, adiponectin, adrenaline α1, adrenaline α2, adrenaline β1, adrenaline β2, adrenaline β3, adrenaline-myelin, AMPA, anaphylatoxin receptors, angiopoietin receptors, angiotensin receptors, anti-Muller's hormone receptors, apralin receptors, desialyl glycoprotein receptors, AXL receptors, benzodiazepine receptors, bile acid receptors, bufotenide receptors, bone morphogenetic protein receptors, bradykinin receptors, brain-specific angiogenesis inhibitors, cadherin receptors, calcitonin receptors, calcitonin receptor-like receptors, calcium-sensitive receptors, cannabinoid receptors, CD97 receptors, chemokine receptors, and cholecystokinin receptors. Complement receptors, corticotropin-releasing hormone receptors, CysLT receptors, cytokine receptors, DDR receptors, dopamine receptors, EBI2 receptors, exogenous heterologous A receptors, mucin-like hormone receptors containing EGF modules, EGF receptors, endothelin receptors, EPH receptors, estrogen receptors, FGF receptors, free fatty acid receptors, coiled receptors, FSH receptors, GABAB receptors, glycoprotein receptors, GHB receptors, growth hormone-releasing hormone receptors, glucagon receptors, glucagon-like peptide receptors, glutamate receptors, glycine receptors, gonadotropin receptors, gonadotropin-releasing hormone receptors, GPRC6A receptors, growth factor receptors, growth hormone receptors, growth hormone-releasing hormone receptors, guanylate cyclase-coupled receptors, HGF receptors, histamine receptors, hydroxycarboxylic acid receptors.Immunoglobulin receptors, insulin receptor, erythrophyll receptor, KiSS1-derived peptide receptor, spider toxin receptor, leptin receptor, leukotriene B4 receptor, lipoprotein receptor-associated protein receptor, LTK receptor, luteinizing hormone / human chorionic gonadotropin receptor, lysophosphatidylcholine receptor, lysophospholipid receptor, mannose receptor, MAS receptor, melanin condensing hormone receptor, melanocortin receptor, melatonin receptor, methuselah-like protein receptor, motilin receptor, Musk receptor, N-acetylglucosamine Receptors, neuromodulatory receptors, neuropeptide B / W receptors, neuropeptide FF receptors, neuropeptide S receptors, neuropeptide Y receptors, neurociliacin receptors, neurotensin receptors, N-formylpeptide receptors, nicotinic acetylcholine receptors, NMDA receptors, nuclear receptors, olfactory receptors, opioid receptors, opsin receptors, orexinoxin receptors, oxoeicosanoic acid receptors, glutaric acid oxidase receptors, oxytocin receptors, parathyroid hormone receptors, PDGF receptors, pituitary adenylate cyclase-activated polypeptide type I receptors, platelet-activating factor receptors, progesterone receptors. Adiponectin and adiponectin Q receptors, kinin receptors, prolactin receptors, prolactin-releasing peptide receptors, prostacyclin receptors, prostaglandin receptors, protease-activating receptors, PTK7 receptors, purinergic adenosine receptors, purinergic P2X receptors, purinergic P2Y receptors, relaxin receptors, RET receptors, retinoic acid-induced orphan G protein-coupled receptors, ROR receptors, ROS receptors, RYK receptors, scavenger receptors, secretin receptors, serine / threonine-specific protein kinase receptors, serotonin receptors, smooth muscle receptors, and somatostatin. Receptors include sphingosine monophosphate receptor (SMP), SREB receptor, interferon gene stimulator (STING) receptor, succinate receptor, tachykinin receptor, thromboxane receptor, thyrotropin receptor, thyrotropin-releasing hormone receptor, Toll-like receptor, microamine-associated receptor, transferrin receptor, Trk receptor, tumor necrosis factor receptor, tyrosine phosphatase receptor, urotensin-II receptor, vasoactive intestinal peptide receptor, vasopressin receptor, VEGF receptor, vomeronasal receptor, and zinc-activated ion channel receptor.
[0233] In one implementation, the therapeutic agent is an immunomodulator.
[0234] Suitable examples of immunomodulators include, but are not limited to, immunostimulants and immunosuppressants.
[0235] Suitable examples of immunostimulants include those described in subgroup L03 of the Anatomical Therapeutics and Chemochemistry classification system.
[0236] Suitable examples of immunostimulants include, but are not limited to, cytokines (e.g., filgrastim, pegfilgrastim, levofloxacin, molarstig, saxaglastine, acetylcysteine, albinterferon, natural interferon α, interferon α2a, pegylated interferon α-2a, interferon α2b, pegylated interferon α-2b, interferon αn1, interferon alfacon-1, interferon α-n3, natural interferon β, interferon β1a, interferon β1b, interferon γ, aldehyde interleukin, olpresperidin, etc.); and immune checkpoint inhibitors (e.g., CTLA4, PD-1, PD-L1, LAG-3, B7-H3, B7). -H4, TIM3, A2AR, GITR, CD47, TNFR2, CD19 and / or IDO inhibitors, including nivolumab, pembrolizumab, cimiprizumab, spartazine, camrelizumab, sintilimab, tislelizumab, toripalimab, AMP-224, AMP-514, pildizumab, MPDL3280A, MDX-1105, MEDI-4736, arelumab, ipilimumab, trimemumab, pildizumab, IMP321, MGA271, BMS-986016, lirelurumab, urrelurumab, PF-05082566. IPH2101, MEDI-6469, CP-870, 893, mogliflozin, varirubin, acitumb, galiliximab, AUNP12, IDO pathway inhibitors (indoximod), NLG-919, INCB024360, etc.; Toll-like receptor agonists (e.g., buprenorphine, carbamazepine, ethanol, fentanyl, GS-9620, imiquimod, letomodil, levonorgestrel, methadone, morphine, (+)-morphine, morphine-3-glucuronide, oxcarbazepine, oxycodone, pethidine, requimod, SD-101, tapentadol, tesomodil, VTX-2337, from cryptoglobulin Acidic polysaccharides from bacteria, MALP-2 from mycoplasma, MALP-404 from mycoplasma, OspA from borophores, porin from Neisseria or Haemophilus, hsp60, hemagglutinin, LcrV from Yersinia pestis, bacterial flagellin, lipopolysaccharide, lipoteichoic acid, lipomannan from mycobacteria, glycosylphosphatidylinositol, lysophosphatidylserine, lipophosphobiose from Leishmania, yeast polysaccharide from yeast, Pam2CGDPKHPKSF, Pam3CSK4, CpG oligodeoxynucleotides, poly(I:C) nucleic acid sequences, poly(A:U) nucleic acid sequences, double-stranded viral RNA, etc.STING receptor agonists (e.g., those described in WO2017100305, 2,5-hexanone-theobromine (vadimezan), CL656, ADU-S100, 3'3'-cGAMP, 2'3'-cGAMP, MLRR-S2 CDG, MLRR-S2 cGAMP, cyclic bis-GMP, DMXAA, DiABZI, etc.); CD1 ligands; growth hormone; immunoanthocyanins; pegylated enzymes; prolactin; tasoneamine; female sex steroids; histamine dihydrochloride; polyICLC; vitamin D; lentinan; praxavila; roquine; mifamotide; glatiramer acetate; thymopentin; thymosin α1; thymononapeptide; polyinosinic acid: polycytidylic acid; pidotimod; BCG vaccine; melanoma vaccine; sipuleucel T, etc.
[0237] Suitable examples of immunosuppressants include those described in subgroup L04 of the Anatomical Therapeutics and Chemochemistry classification system.
[0238] Examples of suitable immunosuppressants include, but are not limited to:
[0239] i. Antimetabolites, for example
[0240] ■ Anti-folate, including aminopterin, methotrexate, pemetrexed, pralatrexate, pteroxetine, raltitrexed, folate, trimethoprim, pemetrexed, etc.
[0241] ■Purine analogues, including pentostatin, cladribine, clofarabine, fludarabine, nerabine, thioguanine, mercaptopurine, etc.;
[0242] ■Pyrimidine analogues, including fluorouracil, capecitabine, docefluorouracil, tegafur, tegafur / gemeracil / oteracil, carmoflu, fluorouracil, cytarabine, gemcitabine, azacytidine, decitabine, etc.; and
[0243] ■Hydroxyurea;
[0244] ii. Macrolides, such as tacrolimus, cyclosporine, pimecrolimus, abelimus, guanifloxacin, etc.;
[0245] iii. Immunomodulatory imine drugs, such as lenalidomide, pomalidomide, thalidomide, apremilast, etc.;
[0246] iv. IL-1 receptor antagonists, such as anakinin, etc.
[0247] v.mTOR inhibitors, such as sirolimus, everolimus, desfolimus, tancilimus, umirolimus, zotacoximil, etc.
[0248] vi. Serum-targeted antibodies, such as eculizumab, adalimumab, afimomab, pecelizumab, golimumab, infliximab, neremomab, mepolimab, omalizumab, falamomab, esimomab, lerezumab, uteroclosmab, secukinumab, etc.
[0249] vii. Cell-targeting antibodies, such as moromuzumab-CD3, oxizumab, teribizumab, vecizumab, crixazab, kelixizumab, zamumab, efazolinumab, errizumab, oxotuzumab, rituximab, octocilizumab, octocilizumab, pacocilizumab, gomiliximab, ruxizumab, tenesimab, toralizumab, acecilizumab, galixizumab, gavimumab, rulizumab, belimumab, blis ibimod, ipilimumab, trimemumab, bertilimumab, ledelimumab, metilimumab, natelimumab, tocilizumab, odorimumab, baliximab, dacrolimus, enoxalimus, azomolimus, atorumab, cililimus, fentolimus, masmolumab, moromumab, pectinumab, resplizumab, rovelimus, cililimus, talilimus, atelimumab, valliximab, velpatimumab, etc.
[0250] viii. Fusion antibodies, such as abatacept, beracide, etanercept, pegsunercept, aflibercept, afasiscept, lilonascept, etc.
[0251] In one implementation, the therapeutic agent is an apoptosis-promoting agent.
[0252] As used herein, the term "apoptotic agent" refers to any molecule that, upon administration, can induce apoptosis or programmed cell death in cells.
[0253] Suitable examples of pro-apoptotic agents include, but are not limited to, histone deacetylase inhibitors (e.g., sodium butyrate, ester peptides, etc.), bortezomib, rotenone, favopiridoline, retinoic acid, fludarabine, kaempferol, mitefoxin, narcissin, obatoclax, omeprazole, and oncolytics.
[0254] In one implementation, the therapeutic agent is an anti-angiogenic agent.
[0255] As used in this article, the term "anti-angiogenic agent" refers to molecules that reduce or prevent angiogenesis, which is responsible for the growth and development of blood vessels.
[0256] Suitable examples of anti-angiogenic agents include, but are not limited to, any inhibitors of vascular endothelial growth factors (VEGF-A, VEGF-B, VEGF-C, or VEGF-D), which are major inducers of angiogenesis under normal and pathological conditions and are essential for embryonic angiogenesis.
[0257] Alternatively, anti-angiogenic agents may also inhibit other angiogenic factors, such as, but not limited to, members of the fibroblast growth factor (FGF) family, such as FGF-1 (acidic), FGF-2 (basic), FGF-4, or FGF-5; or angiopoietin-1, a factor that signals via endothelial cell-specific Tie2 receptor tyrosine kinase; or receptors for any of these angiogenic factors.
[0258] In one implementation, the therapeutic agent is a cytokine.
[0259] Suitable examples of cytokines include, but are not limited to, chemokines, tumor necrosis factors, interleukins, and colony-stimulating factors.
[0260] Suitable examples of chemokines include, but are not limited to, chemokine CC motif ligands (CCL)1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, and CCL26. 26, CCL27, CCL28, chemokine CXC motif ligand (CXCL)1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCL17, fractal chemokines, chemokine C motif ligand (XCL)1 and XCL2.
[0261] Suitable examples of tumor necrosis factors include, but are not limited to, tumor necrosis factor (TNF)α, lymphotoxin, OX40L, CD40LG, Fas ligand, CD70, CD153, 4-1BB ligand, TNF-associated apoptosis-inducing ligand (TRAIL), receptor activator of nuclear factor κ-B ligand (RANKL), proliferation-inducing ligand (APRIL), B cell activator (BAFF), and exoprotein A (EDA).
[0262] Suitable examples of interleukins include, but are not limited to, interleukin-(IL-)1α, IL-1β, IL-1Ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL -22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-3 4. IL-35, IL-36α, IL-36β, IL-36γ, IL-36Ra, IL-37, IL-38, interferon (IFN)α, IFNβ, IFNκ and IFNω.
[0263] Suitable examples of colony-stimulating factors include, but are not limited to, granulocyte-macrophage colony-stimulating factor (GM-CSF) (including granulocyte-macrophage colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF)), erythropoietin, and thrombopoietin.
[0264] In one implementation, the therapeutic agent is a growth factor.
[0265] Suitable examples of growth factors include, but are not limited to, fibroblast growth factor (FGF)1, FGF2, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FGF10, FGF11, FGF12, FGF13, FGF14, FGF16, FGF17, FGF18, FGF19, FGF20, FGF21, FGF23, transforming growth factor (TGF)α, epidermal growth factor (EGF), and heparin-bound EGF-like growth factor (HB-). EGF, transforming growth factor (TGF)β, insulin-like growth factor (IGF)1, IGF2, platelet-derived growth factor (PDGF) subunit A (PDGFA), PDGF subunit B (PDGFB), PDGF subunit C (PDGFC), PDGF subunit D (PDGFD), vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, VEGF-D, placental growth factor (PGF), nerve growth factor (NGF), and hepatocyte growth factor (HGF).
[0266] In one implementation, the therapeutic agent is an antibody or an antigen-binding fragment thereof.
[0267] Suitable examples of antibodies or their antigen-binding fragments include, but are not limited to, monoclonal antibodies, polyclonal antibodies, bispecific antibodies, multispecific antibodies, antibody fragments, and antibody mimics, such as scFv, bivalent-scFv, trivalent-scFv, single-domain antibodies, nanobodies, bispecific T-cell conjugates (BiTE), Fab, F(ab')2, Fab', chemically linked Fab, X-linked Fab, tandem scFv / BiTE, biantibodies, tandem biantibodies, biantibody-Fc fusion, tandem biantibody-Fc fusion, tandem biantibody-CH3 fusion, tetravalent scFv-Fc fusion, bivariate domain immunoglobulin, knob-hole, chain exchange engineered domain, CrossMab, hybridoma-derived bispecific antibodies, single-domain-based antibodies, affibody, affilin, affimer, affitine, antigenin, avimer, DARPin, Kunitz domain peptides, monomers, and nanoCLAMP.
[0268] In one implementation, the therapeutic agent is an antigen.
[0269] As used herein, the term “antigen” refers to any substance that induces a state of susceptibility and / or immune response after any incubation period (typically several days to several weeks in humans) and reacts in a demonstrably in vivo or in vitro with antibodies and / or immune-responding cells of the sensitized subject.
[0270] Suitable examples of antigens include, but are not limited to, pathogen-associated antigens (e.g., antigens of viruses, fungi, or bacteria, or immunogenic molecules derived from them), autoantigens (e.g., cellular antigens, including cells containing normal transplant antigens and / or tumor-associated antigens, RR-Rh antigens, and antigens that are characteristic or specific to a particular cell or tissue or body fluid), allergen-associated antigens (e.g., those associated with environmental allergens), including grass, pollen, mold, dust, insects, dander, venom, etc.; occupational allergens, including latex, dander, polyurethane, epoxy resins, etc.; foods, including shellfish, peanuts, eggs, dairy products, etc.; and drugs, including antibiotics, anesthetics, etc.), neoantigens, and vaccines.
[0271] Examples of antigens include, but are not limited to, 17-IA, 4-1BB, 4Dc, 6-keto-PGF1a, 8-iso-PGF2a, 8-oxo-dG, A1 adenosine receptor, A33, ACE, ACE-2, activating protein, activating protein A, activating protein AB, activating protein B, activating protein C, activating protein RIA, activating protein RIA ALK-2, and activating protein RIB. ALK-4, activator RIIA, activator RIIB, ADAM, ADAM10, ADAM12, ADAM15, ADAM17 / TACE, ADAM8, ADAM9, ADAMTS, ADAMTS4, ADAMTS5, addressin, aFGF, ALCAM, ALK, ALK-1, ALK-7, α-1-antitrypsin, α-V / β-1 antagonist, ANG, Ang, APAF-1, APE, APJ, APP, APRIL, AR, ARC, ART, leptospirin, anti-Id, ASPARTIC, atrial fibrillation Natriuretic peptide, av / b3 integrin, Axl, b2M, B7-1, B7-2, B7-H, B-lymphocyte stimulating factor (BlyS), BACE, BACE-1, Bad, BAFF, BAFF-R, Bag-1, BAK, Bax, BCA-1, BCAM, Bcl, BCMA, BDNF, b-ECGF, bFGF, BID, Bik, BIM, BLC, BL-CAM, BLK, BMP, BMP-2, BMP-2a, BMP-3 osteoblast, BMP-4, BMP-2b, BMP-5, BMP-6, Vgr-1, BMP -7 (OP-1), BMP-8 (BMP-8a, OP-2), BMPR, BMPR-IA (ALK-3), BMPR-IB (ALK-6), BRK-2, RPK-1, BMPR-II (BRK-3), BMP, β-NGF, BOK, taurine, bone-derived neurotrophic factor, BPDE, BPDE-DNA, BTC, complement factor 3 (C3), C3a, C4, C5, C5a, C10, CA125, CAD-8, calcitonin, cAMP, carcinoembryonic antigen (CEA), tumor-associated antigen, cathepsin A, cathepsin B, group Cathepsin C / DPPI, Cathepsin D, Cathepsin E, Cathepsin H, Cathepsin L, Cathepsin O, Cathepsin S, Cathepsin V, Cathepsin X / Z / P, CBL, CCI, CCK2, CCL, CCL1, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCL3, CCL4CCL5, CCL6, CCL7, CCL8, CCL9 / 10, CCR, CCR1, CCR10, CCR10, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CD1, CD2, CD3, CD3E, CD4, CD5, CD 6. CD7, CD8, CD10, CD11a, CD11b, CD11c, CD13, CD14, CD15, CD16, CD18, CD19, CD20, CD21, CD22, CD23, CD25, CD27L, CD28, CD29, CD30, CD30L, C D32, CD33 (p67 protein), CD34, CD38, CD40, CD40L, CD44, CD45, CD46, CD49a, CD52, CD54, CD55, CD56, CD61, CD64, CD66e, CD74, CD80 (B7-1), CD89, CD95, CD123, CD137, CD138, CD140a, CD146, CD147, CD148, CD152, CD164, CEACAM5, CFTR, cGMP, CINC, botulinum toxin, Clostridium perfringens toxin, CKb8-1, CLC, CMV, CMV UL, CNTF, CNTN-1, COX, C-Ret, CRG-2, CT-1, CTACK, CTGF, CTLA-4, CX3CL1, CX3CR1, CXCL, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCR, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, cytokeratin tumor-associated antigen, DAN, DCC, DcR3, DC-SIGN, complement regulator (degeneration factor), d es(1-3)-IGF-I (brain IGF-1), Dhh, digoxigenin, DNAM-1, deoxyribonuclease, Dpp, DPPIV / CD26, Dtk, ECAD, EDA, EDA-A1, EDA-A2, EDAR, EGF, EGFR (ErbB-1), EMA, EMMPRIN, ENA, endothelin receptor, enkephalin, eNOS, Eot, eosinophil chemokine 1, EpCAM, liver glycoside B2 / EphB4, EPO, ERCC, E-selectin, ET-1, factor IIa, factor VII, factor VIIIc, factor IX, fibroblast activating protein (FAP), Fas, FcR1, FEN-1, ferritin, FGF, FGF-19.FGF-2, FGF3, FGF-8, FGFR, FGFR-3, fibrin, FL, FLIP, Flt-3, Flt-4, follicle-stimulating hormone, fractal chemotactic factor, FZD1, FZD2, FZD3, FZD4, FZD5, FZD6, FZD7, FZD8, FZD9, FZD10, G250, Gas6, GCP-2, GCSF, GD2, GD3, GDF, GDF-1, GDF-3 (Vgr-2), GDF-5 (BMP-14, CDMP-1), GDF-6 (BMP-13, CDMP-1) 2) GDF-7 (BMP-12, CDMP-3), GDF-8 (myosinhibitor of glycogen), GDF-9, GDF-15 (MIC-1), GDNF, GDNF, GFAP, GFRa-1, GFR-α1, GFR-α2, GFR-α3, GITR, glucagon, Glut4, glycoprotein IIb / IIIa (GPIIb / IIIa), GM-CSF, gp130, gp72, GRO, growth hormone-releasing hormone, hapten (NP-cap or NIP-cap), HB-EGF, HCC, HCMV gB envelope glycoprotein, HCMV gH envelope glycoprotein, HCMV UL, hematopoietic growth factor (HGF), Hep B gp120, heparanase, Her2, Her2 / neu (ErbB-2), Her3 (ErbB-3), Her4 (ErbB-4), herpes simplex virus (HSV) gB glycoprotein, HSV gD glycoprotein, HGFA, high molecular weight melanoma-associated antigen (HMW-MAA), HIV gp120, HIV IIIB gp120V3 loop, HLA, HLA-DR, HM1.24, HMFG PEM, HRG, Hrk, human myosin, human cytomegalovirus (HCMV), human growth hormone (HGH), HVEM, 1-309, IAP, ICAM, ICAM-1, ICAM-3, ICE, ICOS, IFNg, Ig, IgA receptor, IgE, IGF, IGF-binding protein, IGF-1R, IGFBP, IGF-I, IGF-II, IL, IL-1, IL-1R, IL-2, IL-2R, IL-4, IL-4R, IL -5, IL-5R, IL-6, IL-6R, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-18, IL-18R, IL-23, Interferon (INF)-α, INF-β, INF-γ, Inhibin, iNOS, Insulin A chain, Insulin B chain, Insulin-like growth factor 1, Integrin α2, Integrin α3, Integrin α4, Integrin α4 / β1, Integrin α4 / β7, Integrin α5 (αV), Integrin α5 / β1Integrin α5 / β3, Integrin α6, Integrin β1, Integrin β2, Interferon γ, IP-10, I-TAC, JE, Kallikrein 2, Kallikrein 5, Kallikrein 6, Kallikrein 11, Kallikrein 12, Kallikrein 14, Kallikrein 15, Kallikrein L1, Kallikrein L2, Kallikrein L3, Kallikrein L4, KC, KDR, Keratinocyte Growth Factor (KGF), Laminin 5, LAMP, LAP, LAP (TGF-1), latent TGF-1, latent TGF-1bp1, LBP, LDGF, LECT2, Left-Right Determinant Factor, Lewis-Y Antigen, Lewis-Y Related Antigen, LFA-1, LFA-3, Lfo, LIF, LIGHT, Lipoprotein, LIX, LKN, Lptn, L-Selectin, LT-a, LT-b, LTB4, LTBP-1, Pulmonary Surfactant, Luteinizing Hormone, Lymphotoxin β-Receptor, Mac-1, MAdCAM, MAG, MAP2, MARC, MCAM, MCAM, MCK-2, MCP, M-CSF , MDC, Mer, METALLOPROTEASES, MGDF receptor, MGMT, MHC (HLA-DR), MIF, MIG, MIP, MIP-1-α, MK, MMAC1, MMP, MMP-1, MMP-10, MMP -11, MMP-12, MMP-13, MMP-14, MMP-15, MMP-2, MMP-24, MMP-3, MMP-7, MMP-8, MMP-9, MPIF, Mpo, MSK, MSP, mucin (Muc1), MUC1 8. Müllerian tubule inhibitors, Mug, Musk, NAIP, NAP, NCAD, NC adhesin, NCA90, NCAM, NCAM, enkephalin, neurotrophic factor-3, neurotrophic factor-4 or neurotrophic factor-6, neurturin, nerve growth factor (NGF), NGFR, NGF-β, nNOS, NO, NOS, Npn, NRG-3, NT, NTN, OB, OGG1, OPG, OPN, OSM, OX40L, OX40R, p150, p95, PADPr, methyl Parathyroid hormone, PARC, PARP, PBR, PBSF, PCAD, P-cadherin, PCNA, PDGF, PDK-1, PECAM, PEM, PF4, PGE, PGF, PGI2, PGJ2, PIN, PLA2, placental alkaline phosphatase (PLAP), PlGF, PLP, PP14, proinsulin, relaxinogen-like protein, protein C, PS, PSA, PSCA, prostate-specific membrane antigen (PSMA), PTEN, PTHrp, Ptk, PTN, R51, RANK.RANKL, RANTES, RANTES, relaxin A chain, relaxin B chain, renin, respiratory syncytial virus (RSV) F, RSV Fgp, Ret, rheumatoid factor, RLIP76, RPA2, RSK, S100, SCF / KL, SDF-1, SERINE, serum albumin, sFRP-3, Shh, SIGIRR, SK-1, SLAM, SLPI, SMAC, SMDF, SMOH, SOD, SPARC, Stat, STEAP, STEAP-II, TACE, TACI, TAG-72 (tumor-associated glycoprotein-72), TARC, TCA-3, T-cell receptors (e.g., T-cell receptor α / β), TdT, TECK, TEM1, TEM5, TEM7, TEM8, TERT, testicular PLAP-like alkaline phosphatase, TfR, TGF, TGF-α, TGF-β, TGF-βPan Specific, TGF-βRI(ALK-5), TGF-βRII, TGF-βRIIb, TGF-βRIII, TGF-β1, TGF-β2, TGF-β3, TGF-β4, TGF-β5, thrombin, thymus Ck-1, thyroid hormone Thyroid hormone, Tie, TIMP, TIQ, tissue factor, TMEFF2, Tmpo, TMPRSS2, TNF, TNF-α, TNF-αβ, TNF-β2, TNFc, TNF-RI, TNF-RII, TNFRSF10A (TRAIL R1 Apo-2, DR4), TNFRSF10B (TRAIL R2 DR5, KILLER, TRICK-2A, TRICK-B), TNFRSF10C (TRAIL R3 DcR1, LIT, TRID), TNFRSF10D (TRAIL R4 DcR2, TRUNDD), TNFRSF11A (RANK ODF R, TRANCE R), TNFRSF11B (OPG OCIF, TR1), TNFRSF12 (TWEAK R FN14), TNFRSF13B (TACI), TNFRSF13C (BAFF R), TNFRSF14 (HVEM ATAR, HveA, LIGHT R, TR2), TNFRSF16 (NGFR p75NTR), TNFRSF17 (BCMA), TNFRSF18 (GITR AITR), TNFRSF19 (TROY TAJ, TRADE), TNFRSF19L (RELT), TNFRSF1A (TNF RI CD120a, p55-60), TNFRSF1B (TNF RIICD120b, p75-80), TNFRSF26 (TNFRH3),TNFRSF3 (LTbR TNF RIII, TNFC R), TNFRSF4 (OX40ACT35, TXGP1 R), TNFRSF5 (CD40 p50), TNFRSF6 (Fas Apo-1, APT1, CD95), TNFRSF6B (DcR3M68, TR6), TNFRSF7 (CD27), TNFRSF8 (CD30), TNFRSF9 (4-1BB CD137, ILA), TNFRSF21 (DR6), TNFRSF22 (DcTRAIL R2 TNFRH2), TNFRST23 (DcTRAIL R1 TNFRH1), TNFRSF25 (DR3 Apo-3, LARD, TR-3, TRAMP, WSL-1), TNFSF10 (TRAIL Apo-2 ligand, TL2), TNFSF11 (TRANCE / RANK ligand ODF, OPG ligand), TNFSF12 (TWEAK Apo-3 ligand, DR3 ligand), TNFSF13 (APRIL TALL2), TNFSF13B (BAFF BLYS, TALL1, THANK, TNFSF20), TNFSF14 (LIGHT HVEM ligand, LTg), TNFSF15 (TL1A / VEGI), TNFSF18 (GITR ligand, AITR ligand, TL6), TNFSF1A (TNF-α Conectin, DIF, TNFSF2), TNFSF1B (TNF-βLTa, TNFSF1), TNFSF3 (LTb) TNFC, p33), TNFSF4 (OX40 ligand gp34, TXGP1), TNFSF5 (CD40 ligand CD154, gp39, HIGM1, IMD3, TRAP), TNFSF6 (Fas ligand Apo-1 ligand, APT1 ligand), TNFSF7 (CD27 ligand CD70), TNFSF8 (CD30 ligand CD153), TNFSF9 (4-1BB ligand CD137 ligand), TP-1, t-PA, Tpo, TRIL, TRIL R, TRAIL-R1, TRAIL-R2, TRANCE, transferrin receptor, TRF, Trk, TROP-2, TSG, TSLP, tumor-associated antigen CA125, tumor-associated antigens expressing Lewis-Y related carbohydrates, TWEAK, TXB2, Ung, uPAR, uPAR-1, urokinase, VCAM, VCAM-1, VECAD, VE-cadherin, VE-cadherin-2, VEFGR-1 (flt-1), VEGF, VEGFR, VEGFR-3 (flt-4), VEGI, VIM, viral antigen, VLA, VLA-1, VLA-4VNR integrin, von Willebrand factor, WIF-1, WNT1, WNT2, WNT2B / 13, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, WNT16, XCL1, XCL2, XCR1, XCR1, XEDAR, XIAP, XPD, HMGB1, IgA, Aβ, CD81, CD97, CD98, DDR1, DKK1, EREG, Hsp90, IL-17 / IL-17R, IL-20 / IL-20 R, Oxidized LDL, PCSK9, Kallikrein precursor, RON, TMEM16F, SOD1, Chromogranin A, Chromogranin B, tau, VAP1, High molecular weight kininogen, IL-31, IL-31R, Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.5, Nav1.6, Nav1.7, Nav1.8, Nav1.9, EPCR, C1, C1q, C1r, C1s, C2, C2a, C2b, C3, C3a, C3b, C4, C4a, C4b, C5, C5a, C5b, C6, C7, C8, C9, Factor B, Factor D, Factor H, Complementin, Sclerosingin, Fibrinogen Fibrin, Prothrombin, Thrombin, Tissue Factor, Factor V, Factor Va, Factor VII, Factor VIIa, Factor VIII, Factor VIIIa, Factor IX, Factor IXa, Factor X, Factor Xa, Factor XI, Factor XIa, Factor XII, Factor XIIa, Factor XIII, Factor XIIIa, TFPI, Antithrombin III, EPCR, Thrombomotor Protein, TAPI, tPA, Plasminogen Activator, Plasmin, PAI-1, PAI-2, GPC3, Cohesin-1, Cohesin-2, Cohesin-3, Cohesin-4, LPA, SIP, Acetylcholine Receptor, Adiponectin R1, Adiponectin R2, ADP Ribocyclase-1, α-4 / β-7 integrin, α-5 / β-1 integrin, α-v / β-6 integrin, αvβ1 integrin, angiopoietin ligand-2, Angptl2, anthrax, cadherin, carbonic anhydrase-IX, CD105, CD155, CD158a, CD37, CD49b, CD51, CD70, CD72, blocking protein 18, Clostridium difficile toxin, CS1, delta-like protein ligand 4, DHICA oxidase, Dickkopf-1 ligand, dipeptidyl peptidase IV, EPOR, RSV F protein, factor Ia, FasL, folate receptor α, glucagon receptor, glucagon-like peptide-1 receptor, glutamate arginine carboxypeptidase II, GMCSFRHepatitis C virus E2 glycoprotein, hepatic bactericidal peptide, IL-17 receptor, IL-22 receptor, IL-23 receptor, IL-3 receptor, Kit tyrosine kinase, leucine-rich α-2-glycoprotein 1 (LRG1), soluble sphingolipid receptor, membrane glycoprotein OX2, mesothelin, MET, MICA, MUC-16, myelin-associated glycoprotein, neurociliacin-1, neurociliacin-2, Nogo receptor, PLXNA1, PLXNA2, PLXNA3, PLXNA4A, PLXNA4B, PLXNB1, PLXNB2, PLXNB3, PLXNC1, PLXND1, programmed cell death ligand 1, proteolytic enzyme PC9, P-selectin glycoprotein ligand-1, RAGE, reticuloendothelin 4, RF, RON-8, SEMA3A, SEMA3B SEMA3C, SEMA3D, SEMA3E, SEMA3F, SEMA3G, SEMA4A, SEMA4B, SEMA4C, SEMA4D, SEMA4F, SEMA4G, SEMA5A, SEMA5B, SEMA6A, SEMA6B, SEMA6C, SEMA6D, SEMA7A, Shiga-like toxin II, sphingosine-1-phosphate receptor-1, ST2, staphylococcal lipoteichoic acid, tendinin, TG2, thymic stromal lymphoprotein receptor, TNF superfamily receptor 12A, transmembrane glycoprotein NMB, TREM-1, TREM-2, trophoblast glycoprotein, TSH receptor, TTR, tubulin, ULBP2, and growth factor and growth hormone receptors are molecules that exist in soluble form in the body fluids of organisms rather than being fixed on cells.
[0272] Suitable examples of pathogen-associated antigens include, but are not limited to, those derived from vaccinia virus, fowlpox virus, turkey influenza virus, bovine leukemia virus, feline leukemia virus, avian influenza, avian pneumonia virus, canine parvovirus, equine influenza, FHV, Newcastle disease virus (NDV), avian / Pennsylvanic / 1 / 83 influenza virus, infectious bronchitis virus, dengue virus, measles virus, rubella virus, pseudorabies virus, Epstein-Barr virus, HIV, SIV, EHV, BHV, HCMV, Hantavirus, Clostridium tetani, mumps virus, measles virus, and type 1. Herpes simplex virus, herpes simplex virus type 2, human cytomegalovirus, hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis E virus, respiratory syncytial virus, human papillomavirus, influenza virus, Bordetella, Vibrio hygroscopicus, Salmonella, Neisseria, Treponema pallidum, Chlamydia, Plasmodium, Toxoplasma gondii, Cryptococcus, Streptococcus, Staphylococcus, Haemophilus influenzae, diphtheria, tetanus, Escherichia coli, Candida, Aspergillus, Actinomyces, Burkholderia, Moraxella, Pseudomonas, Vibrio, Entamoeba histolytica, Giardia lamblia, and Trypanosomiasis.
[0273] Suitable examples of autoantigens include, but are not limited to, lupus autoantigen, Smith, Ro, La, Ul-RNP, fibrin, nuclear antigen, histone, glycoprotein gp70, ribosomal protein, pyruvate dehydrogenase, dehydrolipoamide acetyltransferase (PCD-E2), hair follicle antigen, human tropomyosin isoform 5 (hTM5), proinsulin, insulin, IA2, GAD65, type II collagen, human cartilage gp39 (HCgp39), gp130-RAPS, dnaJp1, citrulline proteins and peptides (including citrulline type II collagen, citrulline vimentin, and citrulline fibrinogen), myelin basic protein, protein lipoprotein (PLP), myelin oligodendrocyte glycoprotein (MOG), thyroid stimulating factor receptor (TSH-R), acetylcholine receptor (AchR), prolysin, PLP, glucose-6-phosphate isomerase, thyroglobulin, various tRNA synthetases, protease-3, and myeloperoxidase, including fragments thereof.
[0274] Suitable examples of tumor-associated antigens include, but are not limited to, MART-1 / Melan-A, gplOO, dipeptidyl peptidase IV (DPPIV), adenosine deaminase-binding protein (ADAbp), cyclophilin b, colorectal-associated antigen (CRC)-C017-1A / GA733, carcinoembryonic antigen (CEA) and its immunogenic epitopes CAP-1 and CAP-2, etv6, amll, prostate-specific antigen (PSA) and its immunogenic epitopes PSA-1, PSA-2 and PSA-3, prostate-specific membrane antigen (PSMA), T-cell receptor / CD3-ζ chain, and MAGE tumor. Antigen families (e.g., MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A7, MAGE-A8, MAGE-A9, MAGE-A10, MAGE-A11, MAGE-A12, MAGE-Xp2 (MAGE-B2), MAGE-Xp3 (MAGE-B3), MAGE-Xp4 (MAGE-B4), MAGE-C1, MAGE-C2, MAGE-C3, MAGE-C4, MAGE-C5), GAGE tumor antigen families (e.g., GAGE-1, G...) AGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7, GAGE-8, GAGE-9), BAGE, RAGE, LAGE-1, NAG, GnT-V, MUM-1, CDK4, tyrosinase, p53, MUC family (e.g., MUC1, MUC16), HER2 / neu, p21ras, RCAS1, alpha-fetoprotein, epithelial cadherin, α-catenin, β-catenin and γ-catenin, p120ctn, gpl00.sup.Pmel17, PRAME, NY-ESO-1, cdc27, adenoma Polyposis colonic polyposis protein (APC), cytosine, gap junction protein 37, Ig idiotype, p15, gp75, GM2 and GD2 gangliosides, Smad family cancer antigens brain glycogen phosphorylase, SSX-1, SSX-2 (HOM-MEL-40), SSX-1, SSX-4, SSX-5, SCP-1 and CT-7 and c-erbB-2, and viral antigens such as HPV-16 and HPV-18 E6 and E7 antigens and EBV-encoded nuclear antigen (EBNA)-1, including fragments thereof. Other examples of tumor-associated antigens are described, for example, Li et al., 2004. Cancer Immunol Immunother. 53(3):139-43; Novellino et al., 2005. Cancer Immunol Immunother. 54(3):187-20; the entire contents of which are incorporated herein by reference.
[0275] In one embodiment, R3 is a hydrophilic moiety, provided that the hydrophilic moiety is not a hydroxyl group.
[0276] Examples of hydrophilic moieties include, but are not limited to, methoxy groups, phenols, carboxylic acids and their salts, methyl and ethyl esters of carboxylic acids, amides, amino groups, cyano groups, ammonium salts, and sulfonium salts. Salts, epoxy groups, acrylates, sulfonamides, nitro groups, guanidines, amination products, acrylamides, and pyridyl groups.
[0277] Other examples of hydrophilic portions include, but are not limited to, hydrophilic polymers.
[0278] In one embodiment, R3 is a hydrophilic polymer. Examples of hydrophilic polymers include, but are not limited to, polystyrene sulfonic acid, poly-N-alkylvinylpyridine halides, poly(meth)acrylic acid, poly-N-vinylpyrrolidone, polyhydroxyethyl methacrylate, polyethylene ether, polyethylene glycol, polyethyleneimine, polypropylene oxide, and (poly)peptides.
[0279] Other examples of hydrophilic portions include, but are not limited to, sugars, including monosaccharides, disaccharides, oligosaccharides, and polysaccharides.
[0280] In one embodiment, R3 is a sugar selected from agarose, dextran, starch, cellulose, amylose, and amylopectin.
[0281] In one implementation, R3 is a monosaccharide.
[0282] In one embodiment, R3 is a 3-deoxy-D-manno-oct-2-ketoaconic acid (Kdo) residue or a D-propanetriyl-D-taro-oct-2-ketoaconic acid (Ko).
[0283] In one implementation, R3 is a Kdo residue or a Ko residue that has been substituted by other substituents.
[0284] Other substituents of this kind include, but are not limited to, monosaccharides, oligosaccharides, or polysaccharides, whether linear or branched, preferably containing 1 to 200 sugar residues.
[0285] Alternatively, or as an alternative, other substituents may include, but are not limited to, phosphate groups, diphosphate groups, phosphoryl ethanolamine groups “PEA” (-OPO3H-CH2-CH2-NH2), diphosphate ethanolamine groups “PPEA” (-OPO3H2-PO3H-CH2-CH2-NH2), Kdo residues, Kdo2 residues, Ko residues, aminoarabinose (AraN) residues, galactosamine (GalN) residues, glucosamine (GlcN) residues, etc.
[0286] In one embodiment, R3 is a core oligosaccharide domain (i.e., an inner core, or an inner core and an outer core). In one embodiment, the core oligosaccharide domain typically contains 1 to 12 sugar residues. In one embodiment, the core oligosaccharide domain contains more than 2 sugar residues, such as 3, 4, 5, or more than 5 to 12 sugar residues.
[0287] In one implementation, the core oligosaccharide domain may contain one or more non-sugar structural elements in its main chain.
[0288] In one embodiment, R3 is a core oligosaccharide domain containing one or more sugar residues and / or one or more non-sugar structural elements, which, where applicable, are substituted with other substituents.
[0289] Other substituents include, but are not limited to, phosphate groups, phosphoryl ethanolamine groups “PEA” (-OPO3H-CH2-CH2-NH2), diphosphoryl ethanolamine groups “PPEA” (-OPO3H2-PO3H-CH2-CH2-NH2), acetic acid groups, methyl groups, formyl groups, choline, phosphoric acid choline, amino acids, etc.
[0290] In one embodiment, R3 is a core oligosaccharide domain containing one or more sugar residues and / or one or more non-sugar structural elements, which, when applicable, are replaced by a therapeutic agent. Suitable examples of such therapeutic agents have been described above as suitable reagents for conjugation at the Z, R1, and / or R2 positions of Formulas A and B.
[0291] Alternatively or additionally, other substituents may include, but are not limited to, monosaccharides, oligosaccharides, and polysaccharides, whether linear or branched.
[0292] In one embodiment, R3 is a core oligosaccharide domain that is further replaced by an antigen, either directly or via a linker domain, said antigen being, for example, but not limited to, an O-antigen domain and / or a capped antigen. In one embodiment, the core oligosaccharide domain and / or antigen domain independently or collectively comprise one to 200 sugar residues. In one embodiment, the core oligosaccharide domain and / or antigen domain may include one or more non-sugar structural elements in their backbone.
[0293] In one embodiment, R3 is a core oligosaccharide domain that is further replaced by an antigenic domain, such as, but not limited to, an O-antigen domain and / or a capped antigen, wherein one or more sugar residues are replaced by other substituents.
[0294] Other substituents include, but are not limited to, phosphate groups, phosphoryl ethanolamine groups “PEA” (-OPO3H-CH2-CH2-NH2), diphosphoryl ethanolamine groups “PPEA” (-OPO3H2-PO3H-CH2-CH2-NH2), acetic acid groups, methyl groups, formyl groups, choline or phosphoric acid choline, amino acids, etc.
[0295] In one embodiment, R3 is a core oligosaccharide domain further replaced by an antigenic domain, such as, but not limited to, an O-antigen domain and / or a capped antigen, wherein one or more sugar residues are replaced by a therapeutic agent. Suitable examples of such therapeutic agents have been described above as suitable agents for conjugation at the Z, R1, and / or R2 positions of Formulas A and B.
[0296] In one embodiment, R5 is hydrogen. In this embodiment, X-R5 can therefore be hydroxyl (-OH) or amino (-NH2).
[0297] In one embodiment, R7 is hydrogen. In this embodiment, Y-R7 can therefore be hydroxyl (-OH) or amino (-NH2).
[0298] In one embodiment, X-R5 is a hydroxyl (-OH) or amino (-NH2) group substituted with other substituents. In one embodiment, Y-R7 can therefore be a hydroxyl (-OH) or amino (-NH2) group substituted with other substituents.
[0299] In one embodiment, R4 is a primary fatty acid residue. In one embodiment, R5 is a primary fatty acid residue. In one embodiment, R6 is a primary fatty acid residue. In one embodiment, R7 is a primary fatty acid residue.
[0300] In one embodiment, the primary fatty acid is independently selected from short-chain fatty acids (SCFA), medium-chain fatty acids (MCFA), long-chain fatty acids (LCFA), and very long-chain fatty acids (VLCFA).
[0301] In one implementation, the primary fatty acid residues may be saturated or unsaturated independently.
[0302] In one implementation, the primary fatty acid residues may be either straight-chain or branched.
[0303] In one embodiment, the primary fatty acid residue may independently contain a hydroxyl group (-OH) at the C2 position of the fatty acid chain; that is, the primary fatty acid residue may independently be a 2-hydroxy fatty acid residue.
[0304] In one embodiment, the primary fatty acid residue may independently contain a hydroxyl group (-OH) at the C3 position of the fatty acid chain; that is, the primary fatty acid residue may independently be a 3-hydroxy fatty acid residue.
[0305] In one embodiment in which the primary fatty acid residue contains a hydroxyl group (-OH) at the C3 position of the fatty acid chain, the primary fatty acid residue may be esterified with a secondary fatty acid residue at the C3 position (i.e., a fatty acid residue having ester binding, also known as an acyl-oxy-acyl fatty acid).
[0306] In one embodiment, the secondary fatty acid is independently selected from short-chain fatty acids (SCFA), medium-chain fatty acids (MCFA), long-chain fatty acids (LCFA), and very long-chain fatty acids (VLCFA).
[0307] In one implementation, the secondary fatty acid residues may be saturated or unsaturated independently.
[0308] In one implementation, the secondary fatty acid residues may be either straight-chain or branched.
[0309] In one embodiment, the secondary fatty acid residue may independently contain a hydroxyl group (-OH) at the C2 position of the fatty acid chain; that is, the secondary fatty acid residue may independently be a 2-hydroxy fatty acid residue.
[0310] In one embodiment, the secondary fatty acid residue may independently contain a hydroxyl group (-OH) at the C3 position of the fatty acid chain; that is, the secondary fatty acid residue may independently be a 3-hydroxy fatty acid residue.
[0311] In one embodiment, in which the secondary fatty acid residue contains a hydroxyl group (-OH) at the C3 position of the fatty acid chain, the secondary fatty acid residue may be substituted at that position.
[0312] In one implementation, the types of modified LPS molecules may include:
[0313] i. Fewer or more fatty acid chains compared to typical E. coli or Salmonella enteritidis LPS molecules; and / or
[0314] ii. Shorter or longer fatty acid chains compared to typical E. coli or Salmonella enteritidis LPS molecules;
[0315] Typical Escherichia coli or Salmonella enteritidis LPS molecules contain 6 fatty acid chains, of which 4 primary fatty acid chains are C64-C ... 14 One secondary fatty acid chain has C 14 One secondary fatty acid chain has C 12 .
[0316] In one embodiment, the modified LPS molecule comprises four primary fatty acid residues, wherein the four primary fatty acid residues are esterified with a secondary fatty acid residue at the C3 position. In another embodiment, the modified LPS molecule comprises four primary fatty acid residues, wherein at least three primary fatty acid residues are esterified with a secondary fatty acid residue at the C3 position. In yet another embodiment, the modified LPS molecule comprises four primary fatty acid residues, wherein at least two primary fatty acid residues are esterified with a secondary fatty acid residue at the C3 position. In yet another embodiment, the modified LPS molecule comprises up to four primary fatty acid residues, wherein at most one primary fatty acid residue is esterified with a secondary fatty acid residue at the C3 position. In yet another embodiment, the modified LPS molecule comprises up to three primary fatty acid residues, wherein at most one primary fatty acid residue is esterified with a secondary fatty acid residue at the C3 position. In one embodiment, the modified LPS molecule contains at most two primary fatty acid residues, wherein the at most two primary fatty acid residues are esterified with a secondary fatty acid residue at the C3 position. In another embodiment, the modified LPS molecule contains at most two fatty acid residues, wherein at most one fatty acid is esterified with a secondary fatty acid residue at the C3 position.
[0317] In one embodiment, the modified LPS molecule species comprises primary fatty acid residues containing up to 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4 or fewer carbons; preferably up to 14 carbons.
[0318] Alternatively or concurrently, in one embodiment where the modified LPS molecule comprises four primary fatty acid residues, at least one of the four primary fatty acid residues, such as one, two, three, or four, does not contain 14 carbons. In another embodiment where the modified LPS molecule comprises four primary fatty acid residues, at least one of the four primary fatty acid residues, such as one, two, three, or four, contains 18 carbons, 17 carbons, 16 carbons, 15 carbons, 13 carbons, 12 carbons, 11 carbons, 10 carbons, 9 carbons, 8 carbons, 7 carbons, 6 carbons, 5 carbons, 4 carbons, or fewer than 4 carbons.
[0319] In one embodiment, the modified LPS molecule comprises secondary fatty acid residues containing up to 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, or fewer than 4 carbons; preferably up to 14 carbons.
[0320] Alternatively or concurrently, in one embodiment where the modified LPS molecule comprises two secondary fatty acid residues, at least one of the two secondary fatty acid residues, such as one or both, does not contain 12 carbons. In one embodiment, the modified LPS molecule comprises two secondary fatty acid residues, at least one of the two secondary fatty acid residues, such as one or both, containing 18 carbons, 17 carbons, 16 carbons, 15 carbons, 14 carbons, 13 carbons, 11 carbons, 10 carbons, 9 carbons, 8 carbons, 7 carbons, 6 carbons, 5 carbons, 4 carbons, or fewer than 4 carbons.
[0321] Alternatively or concurrently, in one embodiment where the modified LPS molecule comprises two secondary fatty acid residues, at least one of the two secondary fatty acid residues, such as one or both, does not contain 14 carbons. In one embodiment, the modified LPS molecule comprises secondary fatty acid residues, at least one of the two secondary fatty acid residues, such as one or both, containing 18 carbons, 17 carbons, 16 carbons, 15 carbons, 13 carbons, 12 carbons, 11 carbons, 10 carbons, 9 carbons, 8 carbons, 7 carbons, 6 carbons, 5 carbons, 4 carbons, or fewer than 4 carbons.
[0322] In one embodiment, the modified LPS molecule species can be derived from any Gram-negative bacteria and / or from any Gram-positive bacteria whose membranes contain LPS.
[0323] Examples of Gram-negative bacteria include, but are not limited to, bacteria from the phyla Acidobacteria, Aquagenic Bacteria, Armored Bacteria, Bacteroidetes, Thermophilic Bacteria, Chlamydia, Chlorobacteria, Chlorophytes ...
[0324] In one embodiment, the modified LPS molecules may be derived from Gram-negative bacteria of the phylum Proteobacteria, including but not limited to bacteria of the classes Alpha-Proteobacteria, Beta-Proteobacteria, Gamma-Proteobacteria, Delta-Proteobacteria, Epsilon-Proteobacteria, Zeta-Proteobacteria, Sulphobicidae, Hydrophilicidae, and Oligoflexia.
[0325] Examples of Gram-positive bacteria that contain LPS in their membranes include, but are not limited to, Listeria monocytogenes (from Firmicutes).
[0326] In one embodiment, the modified LPS molecule species are derived from the genus *Bordetella* (from the phylum Proteobacteria), including but not limited to *Bordetella angustifolia*, *Bordetella avium*, *Bordetella bronchiseptica*, *Bordetella bronchiseptica*, *Bordetella flabilis*, *Bordetella simonii*, *Bordetella hominis*, *Bordetella Muralis*, *Bordetella parapertussis*, *Bordetella pertussis*, *Bordetella petrieri*, *Bordetella pseudohynnzii*, *Bordetella sputigena*, *Bordetella tumbae*, and *Bordetella tumulicola*. In one embodiment, the modified LPS molecule species are derived from *Bordetella pertussis*, *Bordetella simonii*, or *Bordetella tumulicola*.
[0327] In one embodiment, the modified LPS molecule species are derived from the genus *Vibrio hygroscopicus* (from the phylum Proteobacteria), including but not limited to *Vibrio hygroscopicus*, *Vibrio linearis*, and *Vibrio fecalis*. In another embodiment, the modified LPS molecule species are derived from *Vibrio linearis* species.
[0328] In one embodiment, the modified LPS molecule species is derived from the genus *Salmonella* (from the phylum *Proteobacteria*), including but not limited to *Salmonella bungei* and *Salmonella enterica* (including, but not limited to, *Salmonella enterica*, *Salmonella salamander*, *Salmonella Arizona*, *Salmonella biphasic*, *Salmonella Howtonen*, and *Salmonella ininia*). In one embodiment, the modified LPS molecule species is derived from *Salmonella enterica*, preferably from a subspecies of *Salmonella enterica*, more preferably from a bacterial serotype of *Salmonella enterica* Minnesota serotype or *Salmonella enterica* typhus serotype.
[0329] In one embodiment, the modified LPS molecule species are derived from the genus *Escherichia* (from the phylum *Proteobacteria*), including but not limited to *Escherichia albopictus*, *Escherichia coli*, *Escherichia felganii*, *Escherichia hupensis*, *Escherichia marmoseta*, and *Escherichia coli*. In another embodiment, the modified LPS molecule species are derived from *Escherichia coli* strains, preferably from *Escherichia coli* K12 or *Escherichia coli* J5 strains.
[0330] In one embodiment, the modified LPS molecule species are derived from the genus *Actinomyces* (from the phylum Proteobacteria), including but not limited to *Actinomyces delphinicola*, *Actinomyces arthritis*, *Actinomyces capsulatum*, *Actinomyces delphinicola*, *Actinomyces equina*, *Actinomyces human*, *Actinomyces indole*, *Actinomyces listeri*, *Actinomyces microsporum*, *Actinomyces murineis*, *Actinomyces pleuropneumoniae*, *Actinomyces porcinus*, *Actinomyces loureii*, *Actinomyces scoliaria*, *Actinomyces seminalis*, *Actinomyces succinate*, *Actinomyces suis*, and *Actinomyces urea*. In one embodiment, the modified LPS molecule species are derived from the *Actinomyces pleuropneumoniae* species.
[0331] In one embodiment, the modified LPS molecule species are derived from the genus Burkholderia (from the phylum Proteobacteria), including but not limited to Burkholderia alpineensis, Burkholderia bifidum, Burkholderia stalkedum, Burkholderia arborescens, Burkholderia neocaridia, Burkholderia cepacia, Burkholderia contaminant, Burkholderia dispersal, Burkholderia dolosa, Burkholderia gladiolus, Burkholderia humptydooensis, Burkholderia lata, Burkholderia cryptica, Burkholderia melitica, Burkholderia metalloidia, Burkholderia polyphaga, Burkholderia oxahnae, Burkholderia phytophyte, Burkholderia pseudomultivorans, Burkholderia puraquae, Burkholderia seminalis, Burkholderia singaporensis, Burkholderia Burkholderia singularis, Burkholderia stableis, Burkholderia stagnalis, Burkholderia territorii, Burkholderia thaiensis, Burkholderia ubonensis, and Burkholderia vinifera. In one embodiment, the modified LPS molecule species are derived from Burkholderia melioides species.
[0332] In one embodiment, the modified LPS molecule species are derived from the genus *Moraxella* (from the phylum Proteobacteria), including but not limited to *Moraxella atatense*, *Moraxella boevrei*, *Moraxella bovis*, *Moraxella canis*, *Moraxella caprae*, *Moraxella catarrhalis*, *Moraxella guinea pig*, *Moraxella rabbit*, *Moraxella equi*, *Moraxella loculata*, *Moraxella lincolnii*, *Moraxella nonliquefied*, *Moraxella oblonga*, *Moraxella oslo*, *Moraxella pluranimalium*, *Moraxella porci*, and *Moraxella glycolytica*. In one embodiment, the modified LPS molecule species are derived from *Moraxella catarrhalis* species.
[0333] In one embodiment, the modified LPS molecule species are derived from the genus *Neisseria* (from the phylum Proteobacteria), including but not limited to *Neisseria animaloris*, *Neisseria bacilli*, *Neisseria canis*, *Neisseria grey*, *Neisseria dendrita*, *Neisseria longum*, *Neisseria flavum*, *Neisseria palea*, *Neisseria gonorrhoeae*, *Neisseria lizardii*, *Neisseria lactis*, *Neisseria rhesus*, *Neisseria meningitidis*, *Neisseria mucinae*, *Neisseria oralis*, *Neisseria pharyngis*, *Neisseria polysaccharide*, *Neisseria shayeganii*, *Neisseria sicca*, *Neisseria microglossum*, *Neisseria wevernii*, *Neisseria vesiculosus*, and *Neisseria vesiculosus*. In one embodiment, the modified LPS molecule species are derived from *Neisseria sicca* species.
[0334] In one embodiment, the modified LPS molecule species are derived from the genus *Pseudomonas* (from the phylum *Proteobacteria*), including but not limited to *Pseudomonas aeruginosa*, *Alcaligenes*, *Pseudomonas tonsillar*, *Pseudomonas anguillarum*, *Pseudomonas malathion*, *Pseudomonas aurantii*, *Pseudomonas aurantii*, *Pseudomonas aurantii*, *Pseudomonas aurantii*, *Pseudomonas aurantii*, *Pseudomonas aurantii*, *Pseudomonas aurantii*, *Pseudomonas aurantii*, *Pseudomonas aurantii*, *Pseudomonas blatchfordae*, *Pseudomonas sphaeroides*, *Pseudomonas brassicae*, *Pseudomonas brucellae*, *Pseudomonas papayaensis*, and *Pseudomonas*. *Pseudomonas cedrina*, *Pseudomonas aeruginosa*, *Pseudomonas chicoris*, *Pseudomonas citronellol*, *Pseudomonas haloanae*, *Pseudomonas ventricosa*, *Pseudomonas ventricosa*, *Pseudomonas ventricosa*, *Pseudomonas flavomarginata*, *Pseudomonas berries*, *Pseudomonas chrysophagus*, *Pseudomonas galbana*, *Pseudomonas scabra*, *Pseudomonas scabra*, *Pseudomonas scabra*, *Pseudomonas scabra*, *Pseudomonas libanensis*, *Pseudomonas lundii*, *Pseudomonas leucosus*, *Pseudomonas monsoonii*, *Pseudomonas marginalis*, *Pseudomonas thaliana*, *Pseudomonas mendoza*, *Pseudomonas melioides*, *Pseudomonas mikimotoi*, *Pseudomonas montmorillonii*, *Pseudomonas mortis*, *Pseudomonas scabra*, *Pseudomonas nitroreductoides*, *Pseudomonas oleifera*, *Pseudomonas* *Pseudomonas orientalis*, *Pseudomonas oryzae*, *Pseudomonas ginseng*, *Pseudomonas paraxanthum*, *Pseudomonas perforans*, *Pseudomonas proteoglycans*, *Pseudomonas serratus*, *Pseudomonas utilis*, *Pseudomonas alkaloids*, *Pseudomonas putida*, *Pseudomonas sevierii*, *Pseudomonas rosenbergii*, *Pseudomonas serratus*, *Pseudomonas schrenckii*, *Pseudomonas xanthophylloides*, *Pseudomonas syringae*, *Pseudomonas putida*, *Pseudomonas sevierii*, *Pseudomonas toris*, *Pseudomonas virginiana*, and *Pseudomonas xanthophylloides*. In one embodiment, the modified LPS molecule species are derived from *Pseudomonas aeruginosa* or *Pseudomonas fluorescens* species.
[0335] In one embodiment, the modified LPS molecule species are derived from the genus Vibrio (from the phylum Proteobacteria), including but not limited to Vibrio adaptica, Vibrio aerogenes, Vibrio summerensis, Vibrio estuarineis, Vibrio agaricus, Vibrio albolivans, Vibrio alginolyticus, Vibrio anguillarum, Vibrio serrata, Vibrio artabrorum, Vibrio atypical, Vibrio farcinoptera, Vibrio brasiliensis, Vibrio bovis, Vibrio calvae, Vibrio calves, Vibrio casei, Vibrio sarcopenea, Vibrio cholerae, Vibrio cincinnati, Vibrio lysozyme, Vibrio oysteri, Vibrio circinata, Vibrio devilii, Vibrio diazotrophicus, Vibrio Vibrio ezurae, Vibrio fluvialis, Vibrio viridissus, Vibrio galbana, Vibrio aerogenes, Vibrio megaterium, Vibrio abaloneensis, Vibrio harveyi, Vibrio hepatica, Vibrio hippocampus, Vibrio esculenta, Vibrio indicum, Vibrio canarolo, Vibrio slow-growing, Vibrio violaceum, Vibrio vulcanii, Vibrio thalassemia, Vibrio mimicus, Vibrio musselii, Vibrio sodium-dependent, Vibrio navara Vibrio, Vibrio infantis, Vibrio tectorum, Vibrio pupae, Vibrio auburnis, Vibrio orientalis, Vibrio parcinii, Vibrio parahaemolyticus, Vibrio scallop-killing, Vibrio prawnis, Vibrio bortneri, Vibrio nigricans, Vibrio rotiferus, Vibrio rubrum, Vibrio spp., Vibrio salmoides, Vibrio flounder, Vibrio spp., Vibrio spp., Vibrio spp., Vibrio spp., Vibrio spp., Vibrio spp., Vibrio spp., Vibrio spp., Vibrio spp., Vibrio spp., Vibrio spp., Vibrio spp., Vibrio spp., Vibrio spp., Vibrio spp., and Vibrio spp. In one embodiment, the modified LPS molecule species are derived from Vibrio fischeri.
[0336] In one embodiment, the modified LPS molecule species has the general formula A, wherein:
[0337] Y is –O–;
[0338] Z is a hydroxyl group (–OH);
[0339] R2 is a phosphate group (–OPO3H2);
[0340] R3 is a monosaccharide, oligosaccharide, or polysaccharide, optionally substituted; preferably R3 is a core oligosaccharide (i.e., inner core, or inner core and outer core) optionally substituted with an antigenic domain, such as, but not limited to, an O-antigen domain and / or a capped antigen.
[0341] R6 is a fatty acid residue; optionally substituted; and
[0342] R7 is a hydrogen or fatty acid residue; it may be substituted.
[0343] In one embodiment, the modified LPS molecule species has the general formula A, wherein:
[0344] Y is –O–;
[0345] Z is a phosphate group (–OPO3H2);
[0346] R2 is a hydroxyl group (–OH);
[0347] R3 is a monosaccharide, oligosaccharide, or polysaccharide, optionally substituted; preferably R3 is a core oligosaccharide (i.e., inner core, or inner core and outer core) optionally substituted with an antigenic domain, such as, but not limited to, an O-antigen domain and / or a capped antigen.
[0348] R6 is a fatty acid residue; optionally substituted; and
[0349] R7 is a hydrogen or fatty acid residue; it may be substituted.
[0350] In one embodiment, the modified LPS molecule species has the general formula A, wherein:
[0351] Y is –O–;
[0352] Z is a hydroxyl group (–OH);
[0353] R2 is a hydroxyl group (–OH);
[0354] R3 is a monosaccharide, oligosaccharide, or polysaccharide, optionally substituted; preferably R3 is a core oligosaccharide (i.e., inner core, or inner core and outer core) optionally substituted with an antigenic domain, such as, but not limited to, an O-antigen domain and / or a capped antigen.
[0355] R6 is a fatty acid residue; optionally substituted; and
[0356] R7 is a hydrogen or fatty acid residue; it may be substituted.
[0357] In one embodiment, the modified LPS molecule species has the general formula B, wherein:
[0358] X and Y are –O–;
[0359] R1 is a hydroxyl group (–OH);
[0360] R2 is a phosphate group (–OPO3H2);
[0361] R3 is a monosaccharide, oligosaccharide, or polysaccharide, optionally substituted; preferably R3 is a core oligosaccharide (i.e., inner core, or inner core and outer core) optionally substituted with an antigenic domain, such as, but not limited to, an O-antigen domain and / or a capped antigen.
[0362] R4 and R6 are fatty acid residues that are independent of each other; optionally substituted; and
[0363] R5 and R7 are hydrogen or fatty acid residues, which are independent of each other; they may be substituted.
[0364] In one embodiment, the modified LPS molecule species has the general formula B, wherein:
[0365] X and Y are –O–;
[0366] R1 is a phosphate group (–OPO3H2);
[0367] R2 is a hydroxyl group (–OH);
[0368] R3 is a monosaccharide, oligosaccharide, or polysaccharide, optionally substituted; preferably R3 is a core oligosaccharide (i.e., inner core, or inner core and outer core) optionally substituted with an antigenic domain, such as, but not limited to, an O-antigen domain and / or a capped antigen.
[0369] R4 and R6 are fatty acid residues that are independent of each other; optionally substituted; and
[0370] R5 and R7 are hydrogen or fatty acid residues, which are independent of each other; they may be substituted.
[0371] In one embodiment, the modified LPS molecule species has the general formula B, wherein:
[0372] X and Y are –O–;
[0373] R1 is a hydroxyl group (–OH);
[0374] R2 is a hydroxyl group (–OH);
[0375] R3 is a monosaccharide, oligosaccharide, or polysaccharide, optionally substituted; preferably R3 is a core oligosaccharide (i.e., inner core, or inner core and outer core) optionally substituted with an antigenic domain, such as, but not limited to, an O-antigen domain and / or a capped antigen.
[0376] R4 and R6 are fatty acid residues that are independent of each other; optionally substituted; and
[0377] R5 and R7 are hydrogen or fatty acid residues, which are independent of each other; they may be substituted.
[0378] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (I)(1)(a), (I)(1)(b), (I)(1)(c), (I)(1)(d), (I)(1)(e), (I)(1)(f), (I)(2)(a), (I)(2)(b), (I)(2)(c), (I)(3)(a), (I)(3)(b), (I)(3)(c), (I)(5)(a), (I)(5)(b), (I)(6)(a), (I)(6)(b), (I)(7)(a), (I)(7)(b), (I)(7)(c), (I)(7)(d) Equation (I)(8)(a), Equation (I)(8)(b), Equation (I)(8)(c), Equation (I)(9)(a), Equation (I)(9)(b), Equation (I)(9)(c), Equation (I)(9)(d), Equation (I)(9)(e), Equation (I)(9)(f), Equation (II)(1)(a), Equation (II)(1)(b), Equation (II)(1)(c), Equation (II)(1)(d), Equation (II)(2)(a), Equation (II)(2)(b), Equation (II)(2)(c), Equation (II)(2)(d), Equation (III)(1)(a), Equation (III)(1)(b), Equation (III)(1)(c), Equation (III)(1)(d), Equation ( IV)(1)(a), Equation (IV)(1)(b), Equation (IV)(1)(c), Equation (V)(1)(a), Equation (V)(1)(b), Equation (V)(1)(c), Equation (V)(1)(d), Equation (V)(1)(e), Equation (V)(1)(f), Equation (V)(1)(g), Equation (V)(1)(h), Equation (V)(1)(i), Equation (VI)(1)(a), Equation (VI)(1)(b), Equation (VI)(1)(c), Equation (VI)(1)(d), Equation (VI)(1)(e), Equation (VI)(1)(f), Equation (VI)(1)(g), Equation (VI)(1)(h), Equation (VI)(1)(i), Equation (VI)(1)( j) Equation (VI)(2)(a), Equation (VI)(2)(b), Equation (VI)(2)(c), Equation (VII)(1)(a), Equation (VII)(1)(b), Equation (VII)(1)(c), Equation (VIII)(1)(a), Equation (VIII)(1)(b), Equation (VIII)(1)(c), Equation (VIII)(1)(d), Equation (IX)(1)(a), Equation (IX)(1)(b), Equation (IX)(1)(c), Equation (IX)(1)(d), Equation (X)(1)(a), Equation (X)(1)(b), Equation (X)(1)(c), Equation (X)(1)(d), Equation (XI)(1)(a), Equation (XI)(1)(b)Formula (XI)(1)(c), Formula (XI)(1)(d), Formula (XII)(1), Formula (XIII)(2)(a), Formula (XIII)(2)(b), Formula (XIII)(3 )(a), formula (XIII)(3)(b), formula (XIII)(4)(a), formula (XIII)(4)(b), formula (XIII)(5)(a), formula (XIII)(5)( b), formula (XIII)(5)(c), formula (XIII)(5)(d), formula (XIII)(6)(a), formula (XIII)(6)(b), formula (XIII)(6)(c) ), formula (XIII)(6)(d), formula (XIII)(6)(e), formula (XIII)(6)(f), formula (XIII)(7)(a), formula (XIII)(7)(b), Equations (XIII)(7)(c), (XIII)(7)(d), (XIII)(7)(e), (XIII)(7)(f), (XIII)(8)(a), (XIII)(8)(b), (XIII)(8)(c), (XIII)(8)(d), (XIII)(8)(e), (XIII)(8)(f), (XIII)(9)(a), (XIII)(9)(b), (XIII)(9)(c), (XIII)(9)(d), (XIII)(9)(e), (XIII)(9)(f), (XIII)(9)(g), (XIII)(9)(h), (XIII)(9)(i), (XIII)(9)(j), and their combinations, such as... Figures 2 to 4 As shown in 6 to 17, 27, 29 to 33 and 36 to 43, where R at position C6' is a monosaccharide, oligosaccharide or polysaccharide moiety containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain and / or a capped antigen; and where X at position C1 is an ethyl moiety.
[0379] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (I)(1)(a), (I)(1)(b), (I)(1)(c), (I)(1)(d), (I)(1)(e), (I)(1)(f), (I)(2)(a), (I)(2)(b), (I)(2)(c), (I)(3)(a), (I)(3)(b), (I)(3)(c), (I)(5)(a), (I)(5)(b), (I)(6)(a), (I)(6)(b), (I)(7)(a), (I)(7)(b), (I)(7)(c), (I)(7)(a) d) Equation (I)(8)(a), Equation (I)(8)(b), Equation (I)(8)(c), Equation (I)(9)(a), Equation (I)(9)(b), Equation (I)(9)(c), Equation (I)(9)(d), Equation (I)(9)(e), Equation (I)(9)(f), Equation (II)(2)(a), Equation (II)(2)(b), Equation (II)(2)(c), Equation (II)(2)(d), Equation (III)(1)(a), Equation (III)(1)(b), Equation (III)(1)(c), Equation (III)(1)(d), Equation (IV)(1)(a), Equation (IV)(1)(b), Equation (IV)(1)(c), Equation (V)(1)(a) ), formula (V)(1)(b), formula (V)(1)(c), formula (V)(1)(d), formula (V)(1)(e), formula (V)(1)(f), formula (V) (1)(g), formula (V)(1)(h), formula (V)(1)(i), formula (VI)(1)(a), formula (VI)(1)(b), formula (VI)(1)( c), formula (VI)(1)(d), formula (VI)(1)(e), formula (VI)(1)(f), formula (VI)(1)(g), formula (VI)(1)(h), formula (VI)(1)(i), formula (VI)(1)(j), formula (VI)(2)(a), formula (VI)(2)(b), formula (VI)(2)(c), formula (VII)(1)(a), Equation (VII)(1)(b), Equation (VII)(1)(c), Equation (VIII)(1)(a), Equation (VIII)(1)(b), Equation (VIII)(1)(c), Equation (VIII)(1)(d), Equation (IX)(1)(a), Equation (IX)(1)(b), Equation (IX)(1)(c), Equation (IX)(1)(d), Equation (X)(1)(a), Equation (X)(1)(b), Equation (X)(1)(c), Equation (X)(1)(d), Equation (XI)(1)(a), Equation (XI)(1)(b), Equation (XI)(1)(c), Equation (XI)(1)(d), Equation (XIII)(2)(a)Formula (XIII)(2)(b), Formula (XIII)(3)(a), Formula (XIII)(3)(b), Formula (XIII)(4)(a), Formula (XIII)(4)(b), Formula (XIII)(5)(a), Formula (XIII)(5)(b), Formula (XIII)(5)(c), Formula (XIII)(5)(d), Formula (XII I)(6)(a), formula (XIII)(6)(b), formula (XIII)(6)(c), formula (XIII)(6)(d), formula (XIII)(6)(e), formula (XIII)(6)(f), formula (XIII)(7)(a), formula (XIII)(7)(b), formula (XIII)(7)(c), formula (XIII)(7) (d), Equation (XIII)(7)(e), Equation (XIII)(7)(f), Equation (XIII)(8)(a), Equation (XIII)(8)(b), Equation (XIII)(8)(c), Equation (XIII)(8)(d), Equation (XIII)(8)(e), Equation (XIII)(8)(f), Equation (XIII)(9)(a), Equation (XIII)(9)(b), Equation (XIII)(9)(c), Equation (XIII)(9)(d), Equation (XIII)(9)(e), Equation (XIII)(9)(f), Equation (XIII)(9)(g), Equation (XIII)(9)(h), Equation (XIII)(9)(i), Equation (XIII)(9)(j), and their combinations, such as... Figures 2 to 4 As shown in Figures 7 to 17, 29 to 33 and 36 to 43, where R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide moiety containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen; and where X at position C1 is an ethyl moiety.
[0380] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (I)(1)(a), (I)(1)(b), (I)(1)(c), (I)(1)(d), (I)(1)(e), (I)(1)(f), (I)(2)(a), (I)(2)(b), (I)(2)(c), (I)(3)(a), (I)(3)(b), (I)(3)(c), (II)(1)(a), (II)(1)(b), (II)(1)(c), (II)(1)(d), (I)(I)(1)(a) I)(2)(a), Equation (II)(2)(b), Equation (II)(2)(c), Equation (II)(2)(d), Equation (III)(1)(a), Equation (III)(1)(b), Equation (III)(1)(c), Equation (III)(1)(d), Equation (IV)(1)(a), Equation (IV)(1)(b), Equation (IV)(1)(c), Equation (V)(1)(a), Equation (V)(1)(b), Equation (V)(1)(c), Equation (V)(1)(d), Equation (V)(1)(e), Equation (V)(1)(f), Equation (V)(1)(g), Equation (V) (1)(h), Equation (V)(1)(i), Equation (VI)(1)(a), Equation (VI)(1)(b), Equation (VI)(1)(c), Equation (VI)(1)(d), Equation (VI)(1)(e), Equation (VI)(1)(f), Equation (VI)(1)(g), Equation (VI)(1)(h), Equation (VI)(1)(i), Equation (VI)(1)(j), Equation (VI)(2)(a), Equation (VI)(2)(b), Equation (VI)(2)(c), Equation (VII)(1)(a), Equation (VII)(1)(b), Equation (VII)(1)(c) Equations (VIII)(1)(a), (VIII)(1)(b), (VIII)(1)(c), (VIII)(1)(d), (IX)(1)(a), (IX)(1)(b), (IX)(1)(c), (IX)(1)(d), (X)(1)(a), (X)(1)(b), (X)(1)(c), (X)(1)(d), (XI)(1)(a), (XI)(1)(b), (XI)(1)(c), (XI)(1)(d), (XII)(1), and their combinations, such as Figures 2 to 4 As shown in Figures 6 to 17 and 27, the R at the C6' position is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigenic domain, such as an O-antigen domain, and / or a capped antigen.
[0381] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (I)(1)(a), (I)(1)(b), (I)(1)(c), (I)(1)(d), (I)(1)(e), (I)(1)(f), (I)(2)(a), (I)(2)(b), (I)(2)(c), (I)(3)(a), (I)(3)(b), (I)(3)(c), (II)(2)(a), (II)(2)(b), (II)(2)(c). Equations (II)(2)(d), (III)(1)(a), (III)(1)(b), (III)(1)(c), (III)(1)(d), (IV)(1)(a), (IV)(1)(b), (IV)(1)(c), (V)(1)(a), (V)(1)(b), (V)(1)(c), (V)(1)(d), (V)(1)(e), (V)(1)(f), (V)(1)(g), (V)(1)(h), (V)(1)(i) Equation (VI)(1)(a), Equation (VI)(1)(b), Equation (VI)(1)(c), Equation (VI)(1)(d), Equation (VI)(1)(e), Equation (VI)(1)(f), Equation (VI)(1)(g), Equation (VI)(1)(h), Equation (VI)(1)(i), Equation (VI)(1)(j), Equation (VI)(2)(a), Equation (VI)(2)(b), Equation (VI)(2)(c), Equation (VII)(1)(a), Equation (VII)(1)(b), Equation (VII)(1)(c), Equation (V) III)(1)(a), Equation (VIII)(1)(b), Equation (VIII)(1)(c), Equation (VIII)(1)(d), Equation (IX)(1)(a), Equation (IX)(1)(b), Equation (IX)(1)(c), Equation (IX)(1)(d), Equation (X)(1)(a), Equation (X)(1)(b), Equation (X)(1)(c), Equation (X)(1)(d), Equation (XI)(1)(a), Equation (XI)(1)(b), Equation (XI)(1)(c), Equation (XI)(1)(d), and combinations thereof, such as Figures 2 to 4 As shown in Figures 7 to 17, where R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigenic domain, such as an O-antigen domain, and / or a capped antigen.
[0382] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (I)(1)(a), (I)(1)(b), (I)(1)(c), (I)(1)(d), (I)(1)(e), (I)(1)(f), (I)(2)(a), (I)(2)(b), (I)(2)(c), (I)(3)(a), (I)(3)(b), (I)(3)(c), (I)(5)(a), (I)(5)(b), (I)(6)(a), (I)(6)(b), (I)(7)(a), (I)(7)(b), (I)(7)(c), (I)(7)(d), (I)(8)(a), (I)(8)(b), (I)(8)(c), (I)(9)(a), (I)(9)(b), (I)(9)(c), (I)(9)(d), (I)(9)(e), (I)(9)(f), and combinations thereof, such as Figures 2 to 4 As shown in Figures 29 to 33, where R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide moiety containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen; and where X at position C1 is an ethyl moiety.
[0383] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (I)(1)(a), (I)(1)(b), (I)(1)(c), (I)(1)(d), (I)(1)(e), (I)(1)(f), (I)(2)(a), (I)(2)(b), (I)(2)(c), (I)(3)(a), (I)(3)(b), (I)(3)(c), and combinations thereof, such as Figures 2 to 4 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0384] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (I)(1)(a), (I)(1)(b), (I)(1)(c), (I)(1)(d), (I)(1)(e), (I)(1)(f), and combinations thereof, such as Figure 2 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0385] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (I)(2)(a), (I)(2)(b), (I)(2)(c), and combinations thereof, such as Figure 3 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0386] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (I)(3)(a), (I)(3)(b), (I)(3)(c), and combinations thereof, such as Figure 4 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0387] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (I)(5)(a), (I)(5)(b), and combinations thereof, such as Figure 29 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0388] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (I)(6)(a), (I)(6)(b), and combinations thereof, such as Figure 30 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide moiety containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen; X at position C1 is an ethyl moiety.
[0389] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (I)(7)(a), (I)(7)(b), (I)(7)(c), (I)(7)(d), and combinations thereof, such as Figure 31 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0390] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (I)(8)(a), (I)(8)(b), (I)(8)(c), and combinations thereof, such as Figure 32 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide moiety containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen; X at position C1 is an ethyl moiety.
[0391] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (I)(9)(a), (I)(9)(b), (I)(9)(c), (I)(9)(d), (I)(9)(e), (I)(9)(f), and combinations thereof, such as Figure 33 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0392] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (II)(1)(a), (II)(1)(b), (II)(1)(c), (II)(1)(d), (II)(2)(a), (II)(2)(b), (II)(2)(c), (II)(2)(d), and combinations thereof, such as Figures 6 to 7 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0393] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (II)(1)(a), (II)(1)(b), (II)(1)(c), (II)(1)(d), and combinations thereof, such as Figure 6 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0394] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (II)(2)(a), (II)(2)(b), (II)(2)(c), (II)(2)(d), and combinations thereof, such as Figure 7 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0395] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (III)(1)(a), (III)(1)(b), (III)(1)(c), (III)(1)(d), and combinations thereof, such as Figure 8 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0396] In one embodiment, the modified LPS molecule is selected from compounds of formula (XII)(1), and combinations thereof, such as Figure 27 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0397] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (IV)(1)(a), (IV)(1)(b), (IV)(1)(c), and combinations thereof, such as Figure 9 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0398] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (V)(1)(a), (V)(1)(b), (V)(1)(c), (V)(1)(d), (V)(1)(e), (V)(1)(f), (V)(1)(g), (V)(1)(h), (V)(1)(i), and combinations thereof, such as Figure 10 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0399] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (VI)(1)(a), (VI)(1)(b), (VI)(1)(c), (VI)(1)(d), (VI)(1)(e), (VI)(1)(f), (VI)(1)(g), (VI)(1)(h), (VI)(1)(i), (VI)(1)(j), (VI)(2)(a), (VI)(2)(b), (VI)(2)(c), and combinations thereof, such as Figures 11 to 12 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0400] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (VI)(1)(a), (VI)(1)(b), (VI)(1)(c), (VI)(1)(d), (VI)(1)(e), (VI)(1)(f), (VI)(1)(g), (VI)(1)(h), (VI)(1)(i), (VI)(1)(j), and combinations thereof, such as Figure 11 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0401] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (VI)(2)(a), (VI)(2)(b), (VI)(2)(c), and combinations thereof, such as Figure 12 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0402] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (VII)(1)(a), (VII)(1)(b), (VII)(1)(c), and combinations thereof, such as Figure 13 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0403] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (VIII)(1)(a), (VIII)(1)(b), (VIII)(1)(c), (VIII)(1)(d), and combinations thereof, such as Figure 14 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0404] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (IX)(1)(a), (IX)(1)(b), (IX)(1)(c), (IX)(1)(d), and combinations thereof, such as Figure 15 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0405] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (X)(1)(a), (X)(1)(b), (X)(1)(c), (X)(1)(d), and combinations thereof, such as Figure 16 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0406] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (XI)(1)(a), (XI)(1)(b), (XI)(1)(c), (XI)(1)(d), and combinations thereof, such as Figure 17 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0407] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (XIII)(2)(a), (XIII)(2)(b), (XIII)(3)(a), (XIII)(3)(b), (XIII)(4)(a), (XIII)(4)(b), (XIII)(5)(a), (XIII)(5)(b), (XIII)(5)(c), (XIII)(5)(d), (XIII)(6)(a), (XIII)(6)(b), (XIII)(6)(c), (XIII)(6)(d), (XIII)(6)(e), (XIII)(6)(f), (XIII)(7)(a), (XIII)(7)(b), (XIII)(7)(b), (XIII)(6)(c), (XIII)(6)(c), (XIII)(6)(d), (XIII)(6)(e), (XIII)(6)(f), (XIII)(7)(a), (XIII)(7)(b), (XIII)(6)(c), (XIII)(7 ... XIII)(7)(c), Equation (XIII)(7)(d), Equation (XIII)(7)(e), Equation (XIII)(7)(f), Equation (XIII)(8)(a), Equation (XIII)(8)(b), Equation (XIII)(8)(c), Equation (XIII)(8)(d), Equation (XIII)(8)(e), Equation (XIII)(8)(f), Equation (XIII)(9)(a), Equation (XIII)(9)(b), Equation (XIII)(9)(c), Equation (XIII)(9)(d), Equation (XIII)(9)(e), Equation (XIII)(9)(f), Equation (XIII)(9)(g), Equation (XIII)(9)(h), Equation (XIII)(9)(i), Equation (XIII)(9)(j), and their combinations, such as Figures 36 to 43 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide moiety containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen; X at position C1 is an ethyl moiety.
[0408] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (XIII)(2)(a), (XIII)(2)(b), and combinations thereof, such as Figure 36As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0409] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (XIII)(3)(a), (XIII)(3)(b), and combinations thereof, such as Figure 37 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0410] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (XIII)(4)(a), (XIII)(4)(b), and combinations thereof, such as Figure 38 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide moiety containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen; X at position C1 is an ethyl moiety.
[0411] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (XIII)(5)(a), (XIII)(5)(b), (XIII)(5)(c), (XIII)(5)(d), and combinations thereof, such as Figure 39 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0412] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (XIII)(6)(a), (XIII)(6)(b), (XIII)(6)(c), (XIII)(6)(d), (XIII)(6)(f), and combinations thereof, such as Figure 40 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0413] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (XIII)(7)(a), (XIII)(7)(b), (XIII)(7)(c), (XIII)(7)(d), (XIII)(7)(e), (XIII)(7)(f), and combinations thereof, such as Figure 41As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0414] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (XIII)(8)(a), (XIII)(8)(b), (XIII)(8)(c), (XIII)(8)(d), (XIII)(8)(e), (XIII)(8)(f), and combinations thereof, such as Figure 42 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide moiety containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen; X at position C1 is an ethyl moiety.
[0415] In one embodiment, the modified LPS molecule is selected from compounds of the following formulas: (XIII)(9)(a), (XIII)(9)(b), (XIII)(9)(c), (XIII)(1)(d), (XIII)(9)(e), (XIII)(9)(f), (XIII)(9)(g), (XIII)(9)(h), (XIII)(9)(i), (XIII)(9)(j), and combinations thereof, such as Figure 43 As shown, R at position C6' is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, such as an O-antigen domain, and / or a capped antigen.
[0416] In one embodiment, the modified LPS molecules are soluble in an aqueous solution. In another embodiment, the modified LPS molecules do not precipitate in the aqueous solution. The term "aqueous solution" includes any water-based solution, such as, but not limited to, water, saline solutions, buffer solutions, etc.
[0417] In one embodiment, the modified LPS molecules are soluble in water and / or phosphate-buffered saline (PBS). In another embodiment, the modified LPS molecules do not precipitate in water and / or PBS.
[0418] The dissolution and / or precipitation of LPS molecules can be readily assessed using techniques well known to those skilled in the art. Such techniques include, but are not limited to, dynamic light scattering (DLS), scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FT-IR), etc.
[0419] In one embodiment, modified LPS molecules form particles in an aqueous solution, preferably supramolecular particles.
[0420] In one embodiment, the particles of the modified LPS molecule species according to the present invention, preferably in water and / or PBS, have a diameter of less than about 500 nm, preferably about 490 nm, about 480 nm, about 470 nm, about 460 nm, about 450 nm, about 440 nm, about 430 nm, about 420 nm, about 410 nm, about 400 nm, about 390 nm, about 380 nm, about 370 nm, about 360 nm, about 350 nm, about 340 nm, about 330 nm, about 320 nm, about 310 nm, about 300 nm, about 290 nm, about 280 nm, or about 270 nm. The average size is approximately 260nm, 250nm, 240nm, 230nm, 220nm, 210nm, 200nm, 190nm, 180nm, 170nm, 160nm, 150nm, 140nm, 130nm, 120nm, 110nm, 100nm, 90nm, 80nm, 70nm, 60nm, 50nm, 40nm, 30nm, and 20nm; it can be evaluated, for example, by DLS; preferably, the DLS scattering angle Θ = 90°, the incident laser wavelength λ = 633nm, and the temperature is 25°C.
[0421] In one embodiment, the particles of the modified LPS molecule species according to the invention have an average size of less than about 30 nm in diameter in an aqueous solution, preferably in water and / or PBS; this can be evaluated, for example, by DLS; preferably, the DLS scattering angle Θ = 90°, the incident laser wavelength λ = 633 nm, and the temperature is 25 °C.
[0422] In one embodiment, the particles of the modified LPS molecule species according to the present invention, preferably in water and / or PBS, have diameters ranging from about 6 nm to about 500 nm, from about 6 nm to about 450 nm, from about 6 nm to about 400 nm, from about 6 nm to about 350 nm, from about 6 nm to about 300 nm, from about 6 nm to about 250 nm, from about 6 nm to about 200 nm, from about 6 nm to about 150 nm, from about 6 nm to about 100 nm, from about 6 nm to about 75 nm, from about 6 nm to about 60 nm, from about 6 nm to about 50 nm, from about 6 nm to about 40 nm, from about 6 nm to about 35 nm, from about 6 nm to about 34 nm, from about 6 nm to about 33 nm, from about 6 nm to about 32 nm, from about 6 nm to about 31 nm, from about 6 nm to about 30 nm, from about 6 nm to about 500 nm, from about 6 nm to about 300 nm, from about 6 nm to about 35 ...50 nm, from about 6 nm to about 300 nm, from about 6 nm to about 350 nm, from about 6 nm to about The average size from about 6 nm to about 29 nm, from about 6 nm to about 28 nm, from about 6 nm to about 27 nm, from about 6 nm to about 26 nm, from about 6 nm to about 25 nm, from about 6 nm to about 24 nm, from about 6 nm to about 23 nm, from about 6 nm to about 22 nm, from about 6 nm to about 21 nm, from about 6 nm to about 20 nm, from about 6 nm to about 19 nm, from about 6 nm to about 18 nm, from about 6 nm to about 17 nm, from about 6 nm to about 16 nm, from about 6 nm to about 15 nm, from about 6 nm to about 14 nm, from about 6 nm to about 13 nm, from about 6 nm to about 12 nm, from about 6 nm to about 11 nm, and from about 6 nm to about 10 nm; can be evaluated by, for example, DLS; preferably, the DLS scattering angle Θ = 90°, the incident laser wavelength λ = 633 nm, and the temperature is 25°C.
[0423] In one embodiment, the particles of the modified LPS molecule species according to the present invention, preferably in water and / or PBS, have diameters ranging from about 9 nm to about 500 nm, from about 9 nm to about 450 nm, from about 9 nm to about 400 nm, from about 9 nm to about 350 nm, from about 9 nm to about 300 nm, from about 9 nm to about 250 nm, from about 9 nm to about 200 nm, from about 9 nm to about 150 nm, from about 9 nm to about 100 nm, from about 9 nm to about 90 nm, from about 8 nm to about 80 nm, from about 9 nm to about 75 nm, from about 9 nm to about 50 nm, from about 9 nm to about 40 nm, from about 9 nm to about 35 nm, from about 9 nm to about 34 nm, from about 9 nm to about 33 nm, from about 9 nm to about 32 nm, from about 9 nm to about 31 nm, and from about 9 nm to about 35 nm. The average size from about 9 nm to about 29 nm, from about 9 nm to about 28 nm, from about 9 nm to about 27 nm, from about 9 nm to about 26 nm, from about 9 nm to about 25 nm, from about 9 nm to about 24 nm, from about 9 nm to about 23 nm, from about 9 nm to about 22 nm, from about 9 nm to about 21 nm, from about 9 nm to about 20 nm, from about 9 nm to about 19 nm, from about 9 nm to about 18 nm, from about 9 nm to about 17 nm, from about 9 nm to about 16 nm, from about 9 nm to about 15 nm, from about 9 nm to about 14 nm, from about 9 nm to about 13 nm, from about 9 nm to about 12 nm, from about 9 nm to about 11 nm, and from about 9 nm to about 10 nm; can be evaluated by, for example, DLS; preferably, the DLS scattering angle Θ = 90°, the incident laser wavelength λ = 633 nm, and the temperature is 25°C.
[0424] In one embodiment, the particles of the modified LPS molecule species according to the present invention, preferably in water and / or PBS, have diameters ranging from about 10 nm to about 500 nm, from about 10 nm to about 450 nm, from about 10 nm to about 400 nm, from about 10 nm to about 350 nm, from about 10 nm to about 300 nm, from about 10 nm to about 250 nm, from about 10 nm to about 200 nm, from about 10 nm to about 150 nm, from about 10 nm to about 100 nm, from about 10 nm to about 75 nm, from about 10 nm to about 50 nm, from about 10 nm to about 40 nm, from about 10 nm to about 35 nm, from about 10 nm to about 34 nm, from about 10 nm to about 33 nm, from about 10 nm to about 32 nm, from about 10 nm to about 31 nm, from about 10 nm to about 30 nm, from about 10 nm to about 500 nm, from about 10 nm to about 3 ... The average size is from 10 nm to about 29 nm, from about 10 nm to about 28 nm, from about 10 nm to about 27 nm, from about 10 nm to about 26 nm, from about 10 nm to about 25 nm, from about 10 nm to about 24 nm, from about 10 nm to about 23 nm, from about 10 nm to about 22 nm, from about 10 nm to about 21 nm, from about 10 nm to about 20 nm, from about 10 nm to about 19 nm, from about 10 nm to about 18 nm, from about 10 nm to about 17 nm, from about 10 nm to about 16 nm, from about 10 nm to about 15 nm, from about 10 nm to about 14 nm, from about 10 nm to about 13 nm, from about 10 nm to about 12 nm, and from about 10 nm to about 11 nm; it can be evaluated by, for example, DLS; preferably, the DLS scattering angle Θ = 90°, the incident laser wavelength λ = 633 nm, and the temperature is 25°C.
[0425] In one embodiment, the particles of the modified LPS molecule species according to the present invention, preferably in water and / or PBS, have diameters ranging from about 14 nm to about 500 nm, from about 14 nm to about 450 nm, from about 14 nm to about 400 nm, from about 14 nm to about 350 nm, from about 14 nm to about 300 nm, from about 14 nm to about 250 nm, from about 14 nm to about 200 nm, from about 14 nm to about 150 nm, from about 14 nm to about 100 nm, from about 14 nm to about 75 nm, from about 14 nm to about 50 nm, from about 14 nm to about 40 nm, from about 14 nm to about 35 nm, from about 14 nm to about 34 nm, from about 14 nm to about 33 nm, from about 14 nm to about 32 nm, from about 14 nm to about 500 nm, from about 14 nm to about 450 nm, from about 14 nm to about 400 nm, from about 14 nm to about 32 nm, from about 14 nm to about 35 nm, from about 14 nm to about 34 nm, from about 14 nm to about 33 nm, from about 14 nm to about 32 nm, from about 14 nm to about 35 ...5 nm, from about 14 nm to about 35 nm, from about 14 nm to about 35 nm, from about 14 nm to about 35 nm, from about 14 nm to about 35 The average size is from 14nm to about 31nm, from about 14nm to about 30nm, from about 14nm to about 29nm, from about 14nm to about 28nm, from about 14nm to about 27nm, from about 14nm to about 26nm, from about 14nm to about 25nm, from about 14nm to about 24nm, from about 14nm to about 23nm, from about 14nm to about 22nm, from about 14nm to about 21nm, from about 14nm to about 20nm, from about 14nm to about 19nm, from about 14nm to about 18nm, from about 14nm to about 17nm, from about 14nm to about 16nm, and from about 14nm to about 15nm; it can be evaluated by, for example, DLS; preferably, the DLS scattering angle Θ = 90°, the incident laser wavelength λ = 633nm, and the temperature is 25°C.
[0426] In one embodiment, the modified LPS molecule species are less toxic and / or pyrogenic than typical Escherichia coli or Salmonella LPS molecules.
[0427] Methods and approaches for assessing the toxicity and / or pyrogenicity of LPS molecular species are well known in the art.
[0428] Examples of such methods and approaches include, but are not limited to, in vivo experiments, such as, but not limited to, rabbit pyrogen test (RPT), chicken embryo C... 50 Lethal dose, GalN sensitized mice C 50 Lethal dose and acute toxicity tests in normal mice; and in vitro tests, such as, but not limited to, mononuclear cell activation assay (MAT).
[0429] The rabbit pyrogen test (RPT) involves measuring the temperature rise in three rabbits after intravenous injection of a test solution (e.g., a composition containing the LPS to be tested). Temperature is measured before injection; then, the test solution is injected, and the body temperature of each rabbit is measured for 3 hours. If the sum of the temperatures of the three rabbits increases by less than 1.15°C, the test solution is considered pyrogen-free; if the sum of the temperatures of the three rabbits increases by more than 2.65°C, the test solution is considered pyrogenic; if the sum of the temperatures of the three rabbits increases by between 1.15°C and 2.65°C, the test should be repeated to confirm the results.
[0430] The monocyte activation assay (MAT) is based on the activation of monocytes by pyrogens, resulting in the production of cytokines that are detected in immunoassays such as ELISA. MAT has different variants depending on (1) the source of the monocytes, including whole blood, isolated primary monocytes (e.g., PBMCs), or monocyte cell lines; and (2) ELISA readings, including IL-6, IL-1β, and TNF-α. All of these mimic the human fever response in vitro.
[0431] For more detailed information on the ways and methods of assessing the toxicity and / or pyrogenicity of LPS molecular species, see Chapters 5.1.10 and 2.6.30 of the European Pharmacopoeia.
[0432] In one embodiment, the endotoxin activity of the modified LPS molecule species is less than 5000 endotoxin equivalents (EEU) / μg, preferably less than 4000 EEU / μg, 3000 EEU / μg, 2000 EEU / μg, 1500 EEU / μg, or 1000 EEU / μg; it can be assessed, for example, by a mononuclear cell activation assay (MAT) based on peripheral blood mononuclear cells (PBMCs) and IL-6 response.
[0433] In one embodiment, the modified LPS molecule species according to the invention are modified by any means and methods known to those skilled in the art, including but not limited to chemical, enzymatic, physical, or genetic modifications.
[0434] In one embodiment, the modified LPS molecule species according to the present invention is a chemically modified LPS molecule species.
[0435] In one implementation, the modified LPS molecule species can be obtained by acidic hydrolysis of naturally occurring LPS molecule species.
[0436] In one embodiment, the modified LPS molecule species can be obtained by acidic hydrolysis of naturally occurring LPS molecule species at a temperature of about 4°C to about 85°C.
[0437] In one embodiment, the modified LPS molecule can be obtained by acidic hydrolysis of naturally occurring LPS molecules in the presence of alcohols such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 2-methyl-1-propanol, 2-methyl-2-propanol, 1-pentanol, 3-methyl-1-butanol, 2,2-dimethyl-1-propanol, cyclopentanol, 1-hexanol, cyclohexanol, 1-heptanol, 1-octanol, 1-nonanol, 1-decanol, 2-propen-1-ol, benzyl alcohol, diphenylethanol, triphenylethanol, etc.
[0438] In one embodiment, the modified LPS molecule can be obtained by acid hydrolysis of naturally occurring LPS molecules at a temperature of about 4°C to about 85°C in the presence of alcohols such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 2-methyl-1-propanol, 2-methyl-2-propanol, 1-pentanol, 3-methyl-1-butanol, 2,2-dimethyl-1-propanol, cyclopentanol, 1-hexanol, cyclohexanol, 1-heptanol, 1-octanol, 1-nonanol, 1-decanol, 2-propen-1-ol, benzyl alcohol, diphenylethanol, triphenylethanol, etc.
[0439] In one embodiment, the modified LPS molecule species can be obtained by acidic hydrolysis followed by alkaline hydrolysis of naturally occurring LPS molecule species.
[0440] In a preferred embodiment, the modified LPS molecule species can be obtained by alkaline hydrolysis followed by acidic hydrolysis of naturally occurring LPS molecule species.
[0441] In one embodiment, the modified LPS molecule species can be obtained by acidic hydrolysis followed by alkaline hydrolysis of naturally occurring LPS molecule species. According to this embodiment, it may be necessary to reduce the disaccharide, particularly glucosamine, of the lipid A domain with sodium borohydride prior to alkaline hydrolysis. For example, reduction can be carried out for 12 hours at pH 8 and 52°C in the presence of 0.5 M NaBH (final concentration).
[0442] The present invention also relates to a method for obtaining modified LPS molecule species according to the present invention.
[0443] The innovative process involves dephosphorylation of lipid A phosphate glycosides, which are removed in situ from the intact LPS molecule without breaking them down into lipid A and polysaccharide moieties.
[0444] Specifically, it involves methods for obtaining modified LPS molecule species, which:
[0445] i. There is no phosphate group at the C1 position of the reduced end of the lipid A domain, and at the non-reduced end of its lipid A domain...
[0446] The C6' position is partially replaced by a monosaccharide, oligosaccharide, or polysaccharide; and / or
[0447] ii. There is no phosphate group at the C4 position of the reduced end of the lipid A domain, and at the non-reduced end of its lipid A domain.
[0448] The C6' position is partially replaced by a monosaccharide, oligosaccharide, or polysaccharide.
[0449] and
[0450] iii. Compared to typical (i.e., unmodified) Escherichia coli or Salmonella enterica LPS molecules, it contains fewer or more fatty acid chains—it contains six fatty acid chains, four of which are primary fatty acid chains and two are secondary fatty acid chains; and / or
[0451] iv. Compared to typical (i.e., unmodified) E. coli or Salmonella enterica LPS molecules, it contains shorter and / or longer fatty acid chains—containing four primary 3-OH-C bonds. 14 Fatty acid chain, one secondary carbon 14 Fatty acid chain and a secondary C 12 Fatty acid chains.
[0452] In one embodiment, the method includes an initial step of extracting naturally occurring LPS molecules.
[0453] In one embodiment, the naturally occurring LPS molecule species are extracted from bacterial cultures. All methods of bacterial growth can be used. Examples of bacterial cultures include, but are not limited to, fermenter-based bacterial cultures, flask cultures, solid culture media (e.g., agar cultures), biofilm cultures grown at solid-liquid or liquid-gas interfaces, and any other methods known in the art. In one embodiment, the naturally occurring LPS molecule species are extracted from bacterial precipitates, culture concentrates, culture supernatants, enriched membrane fractions, and / or outer membrane vesicle (OMV) fractions.
[0454] In one implementation, the naturally occurring LPS molecule species are extracted from naturally occurring biomass samples, such as marine plankton or microbiota.
[0455] LPS extraction can be performed using any solvent, reagent, and procedure compatible with the production of the pharmacological product. Following LPS extraction, an LPS purification step is preferred, as this is necessary to reduce contaminants associated with bacteria and manufacturing processes, such as biomass production, to acceptable levels.
[0456] Methods for extracting naturally occurring LPS molecules are well known in the art. Dozens of methods suitable for LPS extraction are described in the literature, see, for example, the review by Wang et al., 2010 (Purification and characterization of lipopolysaccharides. In Wang & Quinn (Eds.), Endotoxins: structure, function and recognition. 53:27-51. Springer). Other methods are also described in U.S. Patent 8,137,935.
[0457] In one embodiment, LPS is extracted according to the method described in U.S. Patent 8,137,935. According to this method, bacterial precipitate, culture concentrate, culture supernatant, enriched membrane fraction, and / or outer membrane vesicle (OMV) fraction are suspended in a solvent mixture comprising about 10% to about 90% of an alkaline aqueous solution of a straight-chain or branched fatty acid containing 3 to 6 carbon atoms, and a fatty amine containing 0 to 12 carbon atoms. The entire mixture is stirred to produce a suspension of bacterial LPS in the solvent mixture containing bacterial cell debris. The LPS extract is recovered from the suspension as supernatant and / or filtrate, respectively, by centrifugation and / or filtration. Particles in the suspension are separated as precipitates and / or residues, respectively, and discarded. Finally, the solvent is removed from the supernatant and / or filtrate, and naturally occurring LPS molecules are typically lyophilized. Other preservation methods may be used, including but not limited to dried forms and suspensions in suitable solvents.
[0458] In one embodiment, the method includes the step of purifying naturally occurring LPS molecule species, as described, for example, in Tirsoaga et al., 2007 (Appl Environ Microbiol. 73(6): 1803-8), to reduce bacterial and process-related contaminants to acceptable levels and to ensure TLR-grade purity of the final product (TLR4 ligand).
[0459] In one embodiment, the method includes the step of treating naturally occurring LPS molecule species by acid hydrolysis.
[0460] Hydrolysis conditions known in the art for removing lipid A phosphate at the reducing end Cl position of the lipid A domain would fatally result in the cleavage of the ketoglycolic bond at the non-reducing end C6' position of the lipid A domain, located between the lipid A and the glycoside moiety (R3 position of formula A or B).
[0461] In one embodiment, the step of treating naturally occurring LPS molecules by acid hydrolysis is carried out under acidic hydrolysis conditions that allow for the removal of phosphate glycosides without cleaving the ketoglycosidic bond at the non-reduced C6' position of the lipid A domain.
[0462] In one embodiment, the acidic hydrolysis is carried out at a temperature below 85°C, preferably at a temperature from about 4°C to about 85°C. Both inorganic and organic acids can be used, with or without additional reagents such as salts. The acidic hydrolysis can be carried out in aqueous or organic solutions. The hydrolysis duration ranges from several minutes to tens of hours, preferably from 1 to 10 hours, to obtain practical results.
[0463] In one embodiment, the acidic hydrolysis is carried out in the presence of alcohols, such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 2-methyl-1-propanol, 2-methyl-2-propanol, 1-pentanol, 3-methyl-1-butanol, 2,2-dimethyl-1-propanol, cyclopentanol, 1-hexanol, cyclohexanol, 1-heptanol, 1-octanol, 1-nonanol, 1-decanol, 2-propen-1-ol, benzyl alcohol, diphenylethanol, triphenylethanol, etc.
[0464] In one embodiment, the acidic hydrolysis is carried out at a temperature below 85°C, preferably about 4°C to about 85°C, in the presence of alcohols such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 2-methyl-1-propanol, 2-methyl-2-propanol, 1-pentanol, 3-methyl-1-butanol, 2,2-dimethyl-1-propanol, cyclopentanol, 1-hexanol, cyclohexanol, 1-heptanol, 1-octanol, 1-nonanol, 1-decanol, 2-propen-1-ol, benzyl alcohol, diphenylethanol, triphenylethanol, etc.
[0465] In one implementation, acid hydrolysis also partially removes one or more secondary fatty acid residues, thus increasing the degree of LPS detoxification.
[0466] In one embodiment, the method includes an additional step of treating naturally occurring LPS molecules with alkaline hydrolysis to remove one or more esterified fatty acid residues, thereby enhancing the degree of LPS detoxification. For certain initial structures of naturally occurring LPS molecules, such as those where the phosphate group at the non-reducing C4' position of the lipid A domain is replaced by an amino sugar (e.g., glucosamine, galactosamine, muramic acid, etc.), alkaline hydrolysis can at least remove part of the phosphate group at the C4' position.
[0467] In one implementation, the acid hydrolysis and alkaline hydrolysis steps can be performed in any order.
[0468] In one embodiment, the acidic hydrolysis step is performed before the alkaline hydrolysis step. Alternatively, the alkaline hydrolysis step is performed before the acidic hydrolysis step.
[0469] In a preferred embodiment, the alkaline hydrolysis step is performed before the acidic hydrolysis step.
[0470] In one embodiment, the acidic hydrolysis step is performed prior to the alkaline hydrolysis step. According to this embodiment, it may be necessary to reduce the disaccharide, particularly glucosamine, of the lipid A domain with sodium borohydride before the alkaline hydrolysis step. For example, reduction can be carried out for 12 hours at pH 8 and 52°C in the presence of 0.5 M NaBH (final concentration).
[0471] Depending on the intended application, those skilled in the art will readily recognize that the LPS molecule species should be purified to a certain level of purity (e.g., GMP grade for intended human applications, or a lower level of purity for veterinary applications). In particular, for veterinary applications, it is conceivable that the method for obtaining the modified LPS molecule species according to the present invention does not include the step of purifying naturally occurring LPS molecule species; that is, the method may include the step of directly processing naturally occurring LPS molecule species from bacterial precipitates, culture concentrates, culture supernatants, enriched membrane fractions, and / or outer membrane vesicles (OMV) fractionation.
[0472] The present invention also relates to compositions comprising at least one type of LPS molecule.
[0473] In one embodiment, at least one LPS molecule species is a modified LPS molecule species according to the present invention.
[0474] In one embodiment, the composition comprises at least one modified LPS molecule of formula A as described above.
[0475] In one embodiment, the composition comprises a mixture of modified LPS molecule species of Formula A as described above.
[0476] In one embodiment, the composition comprises a rich cluster of modified LPS molecules of Formula A as described above.
[0477] In one embodiment, the composition comprises at least one modified LPS molecule of formula B as described above.
[0478] In one embodiment, the composition comprises a mixture of modified LPS molecule species of Formula B as described above.
[0479] In one embodiment, the composition comprises an enriched population of modified LPS molecules of formula B as described above.
[0480] In one embodiment, the composition comprises a mixture of modified LPS molecules as described above, comprising at least 10%, at least 25%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more than 99% of the total LPS molecules in the population.
[0481] In one embodiment, the composition comprises a mixture selected from the following modified LPS molecule species: formula (I)(1)(a), formula (I)(1)(b), formula (I)(1)(c), formula (I)(1)(d), formula (I)(1)(e), formula (I)(1)(f), formula (I)(2)(a), formula (I)(2)(b), formula (I)(2)(c), formula (I)(3)(a), formula (I)(3)(b), formula (I)(3)(c), formula (I)(5)(a), formula (I)(5)(b), formula (I)(6)(a), formula (I)(6)(b), formula (I)(7)(a), formula (I)(7)(b), formula (I)(7)(c), formula (I)(1)(2)(a), formula (I)(2)(b), formula (I)(2)(c), formula (I)(1)(2)(a), formula (I)(1)(2)(b), formula (I)(1)(2)(c), formula (I)(1)(2)(b ...b)(b), formula (I)(1)(b)(b), formula (I)(1)(b)(b), formula (I)(1)(b)(b), formula (I)(1)(b)(b), formula (I)(1)(b)(b), formula (I (7)(d), Equation (I)(8)(a), Equation (I)(8)(b), Equation (I)(8)(c), Equation (I)(9)(a), Equation (I)(9)(b), Equation (I)(9)(c), Equation (I)(9)(d), Equation (I)(9)(e), Equation (I)(9)(f), Equation (II)(1)(a), Equation (II)(1)(b), Equation (II)(1)(c), Equation (II)(1)(d), Equation (II)(2)(a), Equation (II)(2)(b), Equation (II)(2)(c), Equation (II)(2)(d), Equation (III)(1)(a), Equation (III)(1)(b), Equation (III)(1)(c), Equation (III) (1)(d), Equation (IV)(1)(a), Equation (IV)(1)(b), Equation (IV)(1)(c), Equation (V)(1)(a), Equation (V)(1)(b), Equation (V)(1)(c), Equation (V)(1)(d), Equation (V)(1)(e), Equation (V)(1)(f), Equation (V)(1)(g), Equation (V)(1)(h), Equation (V)(1)(i), Equation (VI)(1)(a), Equation (VI)(1)(b), Equation (VI)(1)(c), Equation (VI)(1)(d), Equation (VI)(1)(e), Equation (VI)(1)(f), Equation (VI)(1)(g), Equation (VI)(1)(h), Equation (VI)(1)(i) Equations (VI)(1)(j), (VI)(2)(a), (VI)(2)(b), (VI)(2)(c), (VII)(1)(a), (VII)(1)(b), (VII)(1)(c), (VIII)(1)(a), (VIII)(1)(b), (VIII)(1)(c), (VIII)(1)(d), (IX)(1)(a), (IX)(1)(b), (IX)(1)(c), (IX)(1)(d), (X)(1)(a), (X)(1)(b), (X)(1)(c), (X)(1)(d), (XI)(1)(a)Formula (XI)(1)(b), Formula (XI)(1)(c), Formula (XI)(1)(d), Formula (XII)(1), Formula (XIII)(2)(a), Formula (XIII)(2)(b) , formula (XIII)(3)(a), formula (XIII)(3)(b), formula (XIII)(4)(a), formula (XIII)(4)(b), formula (XIII)(5)(a), formula (X III)(5)(b), formula (XIII)(5)(c), formula (XIII)(5)(d), formula (XIII)(6)(a), formula (XIII)(6)(b), formula (XIII) (6)(c), formula (XIII)(6)(d), formula (XIII)(6)(e), formula (XIII)(6)(f), formula (XIII)(7)(a), formula (XIII)(7)( b) Formulas (XIII)(7)(c), (XIII)(7)(d), (XIII)(7)(e), (XIII)(7)(f), (XIII)(8)(a), (XIII)(8)(b), (XIII)(8)(c), (XIII)(8)(d), (XIII)(8)(e), (XIII)(8)(f), (XIII)(9)(a), (XIII)(9)(b), (XIII)(9)(c), (XIII)(9)(d), (XIII)(9)(e), (XIII)(9)(f), (XIII)(9)(g), (XIII)(9)(h), (XIII)(9)(i), (XIII)(9)(j), and combinations thereof, and the types of LPS molecules.
[0482] In one embodiment, the composition comprises a mixture selected from the following modified LPS molecule species: formula (I)(1)(a), formula (I)(1)(b), formula (I)(1)(c), formula (I)(1)(d), formula (I)(1)(e), formula (I)(1)(f), formula (I)(2)(a), formula (I)(2)(b), formula (I)(2)(c), formula (I)(3)(a), formula (I)(3)(b), formula (I)(3)(c), formula (I)(5)(a), formula (I)(5)(b), formula (I)(6)(a), formula (I)(6)(b), formula (I)(7)(a), formula (I)(7)(b), formula (I)(7)(c), formula (I)(1)(2)(a), formula (I)(2)(b), formula (I)(2)(c), formula (I)(1)(2)(a), formula (I)(1)(2)(b), formula (I)(1)(2)(c), formula (I)(1)(2)(b ...b)(b), formula (I)(1)(b)(b), formula (I)(1)(b)(b), formula (I)(1)(b)(b), formula (I)(1)(b)(b), formula (I)(1)(b)(b), formula (I (7)(d), Equation (I)(8)(a), Equation (I)(8)(b), Equation (I)(8)(c), Equation (I)(9)(a), Equation (I)(9)(b), Equation (I)(9)(c), Equation (I)(9)(d), Equation (I)(9)(e), Equation (I)(9)(f), Equation (II)(2)(a), Equation (II)(2)(b), Equation (II)(2)(c), Equation (II)(2)(d), Equation (III)(1)(a), Equation (III)(1)(b), Equation (III)(1)(c), Equation (III)(1)(d), Equation (IV)(1)(a), Equation (IV)(1)(b), Equation (IV)(1)(c), Equation (V)(1) )(a), formula (V)(1)(b), formula (V)(1)(c), formula (V)(1)(d), formula (V)(1)(e), formula (V)(1)(f), formula ( V)(1)(g), formula (V)(1)(h), formula (V)(1)(i), formula (VI)(1)(a), formula (VI)(1)(b), formula (VI)(1 )(c), formula (VI)(1)(d), formula (VI)(1)(e), formula (VI)(1)(f), formula (VI)(1)(g), formula (VI)(1)(h), formula (VI)(1)(i), formula (VI)(1)(j), formula (VI)(2)(a), formula (VI)(2)(b), formula (VI)(2)(c), Equations (VII)(1)(a), (VII)(1)(b), (VII)(1)(c), (VIII)(1)(a), (VIII)(1)(b), (VIII)(1)(c), (VIII)(1)(d), (IX)(1)(a), (IX)(1)(b), (IX)(1)(c), (IX)(1)(d), (X)(1)(a), (X)(1)(b), (X)(1)(c), (X)(1)(d), (XI)(1)(a), (XI)(1)(b), (XI)(1)(c), (XI)(1)(d), (XIII)(2)(a)Formula (XIII)(2)(b), Formula (XIII)(3)(a), Formula (XIII)(3)(b), Formula (XIII)(4)(a), Formula (XIII)(4)(b), Formula (XIII)(5)(a), Formula (XIII)(5)(b), Formula (XIII)(5)(c), Formula (XIII)(5)(d), Formula (XIII )(6)(a), formula (XIII)(6)(b), formula (XIII)(6)(c), formula (XIII)(6)(d), formula (XIII)(6)(e), formula (XIII)(6)(f), formula (XIII)(7)(a), formula (XIII)(7)(b), formula (XIII)(7)(c), formula (XIII)(7)(d) Formulas (XIII)(7)(e), (XIII)(7)(f), (XIII)(8)(a), (XIII)(8)(b), (XIII)(8)(c), (XIII)(8)(d), (XIII)(8)(e), (XIII)(8)(f), (XIII)(9)(a), (XIII)(9)(b), (XIII)(9)(c), (XIII)(9)(d), (XIII)(9)(e), (XIII)(9)(f), (XIII)(9)(g), (XIII)(9)(h), (XIII)(9)(i), (XIII)(9)(j), and combinations thereof, and the types of LPS molecules.
[0483] In one embodiment, the composition comprises a mixture of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more modified LPS molecules selected from the following: formula (I)(1)(a), formula (I)(1)(b), formula (I)(1)(c), formula (I)(1)(d), formula (I)(1)(e), formula (I)(1)(f), formula (I)(2)(a), formula (I)(2)(b), formula (I)(2)(c), formula (I)(3)(a), formula (I)(3)(b), formula (I)(3)(c), and formula (I)(5). (a) Equation (I)(5)(b) Equation (I)(6)(a) Equation (I)(6)(b) Equation (I)(7)(a) Equation (I)(7)(b) Equation (I)(7)(c) Equation (I)(7)(d) Equation (I)(8)(a) Equation (I)(8)(b) Equation (I)(8)(c) Equation (I)(9)(a) Equation (I)(9)(b) Equation (I)(9)(c) Equation (I)(9)(d) Equation (I)(9)(e) Equation (I)(9)(f) Equation (II)(1)(a) Equation (II)(1)(b) Equation (II)(1)(c) Equation (II)(1)(d) Equation (II)(2)(a) Equation (II)(2)(b) Equation (II)(2)(c), Equation (II)(2)(d), Equation (III)(1)(a), Equation (III)(1)(b), Equation (III)(1)(c), Equation (III)(1)(d), Equation (IV)(1)(a), Equation (IV)(1)(b), Equation (IV)(1)(c), Equation (V)(1)(a), Equation (V)(1)(b), Equation (V)(1)(c), Equation (V)(1)(d), Equation (V)(1)(e), Equation (V)(1)(f), Equation (V)(1)(g), Equation (V)(1)(h), Equation (V)(1)(i), Equation (VI)(1)(a), Equation (VI)(1)(b), Equation (VI)(1)(c), Equation (VI)(1)(d), Equation (VI)(1)(e), Equation (VI)(1)(f), Equation (VI)(1)(g), Equation (VI)(1)(h), Equation (VI)(1)(i), Equation (VI)(1)(j), Equation (VI)(2)(a), Equation (VI)(2)(b), Equation (VI)(2)(c), Equation (VII)(1)(a), Equation (VII)(1)(b), Equation (VII)(1)(c), Equation (VIII)(1)(a), Equation (VIII)(1)(b), Equation (VIII)(1)(c), Equation (VIII)(1)(d), Equation (IX)(1)(a), Equation (IX)(1)(b), Equation (IX)(1)(c)Equation (IX)(1)(d), Equation (X)(1)(a), Equation (X)(1)(b), Equation (X)(1)(c), Equation (X)(1)(d), Equation (XI)(1)(a), Equation (XI)(1)(b), Equation (XI)(1)(c), Equation (XI)(1)(d), Equation (XII)(1), Equation (XIII)(2)(a), Equation (XIII)(2)(b), Equation (XIII)(3)(a), Equation (XIII)(3)(b), Equation (XIII)(4)(a), Equation (XIII)(4)(b), Equation (XIII)(5)(a), Equation (XIII)(5)(b), Equation (XIII)(5)(c), Equation (XIII)(5)(d), Equation (XIII)(6)(a), Equation (XIII)(6)(b), Equation (XIII)(6)(c), Equation (XIII)(6)(d), Equation (XIII)(6)(e), Equation (XII) Types of LPS molecules, including formulas (XIII)(6)(f), (XIII)(7)(a), (XIII)(7)(b), (XIII)(7)(c), (XIII)(7)(d), (XIII)(7)(e), (XIII)(7)(f), (XIII)(8)(a), (XIII)(8)(b), (XIII)(8)(c), (XIII)(8)(d), (XIII)(8)(e), (XIII)(8)(f), (XIII)(9)(a), (XIII)(9)(b), (XIII)(9)(c), (XIII)(9)(d), (XIII)(9)(e), (XIII)(9)(f), (XIII)(9)(g), (XIII)(9)(h), (XIII)(9)(i), (XIII)(9)(j), and combinations thereof.
[0484] In one embodiment, the composition comprises a mixture of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more modified LPS molecules selected from the following: formula (I)(1)(a), formula (I)(1)(b), formula (I)(1)(c), formula (I)(1)(d), formula (I)(1)(e), formula (I)(1)(f), formula (I)(2)(a), formula (I)(2)(b), formula (I)(2)(c), formula (I)(3)(a), formula (I)(3)(b), formula (I)(3)(c), formula (I)(5) (a) Equation (I) (5) (b) Equation (I) (6) (a) Equation (I) (6) (b) Equation (I) (7) (a) Equation (I) (7) (b) Equation (I) (7) (c) Equation (I) (7) (d) Equation (I) (8) (a) Equation (I) (8) (b) Equation (I) (8) (c) Equation (I) (9) (a) Equation (I) (9) (b) Equation (I) (9) (c) Equation (I) (9) (d) Equation (I) (9) (e) Equation (I) (9) (f) Equation (II) (2) (a) Equation (II) (2) (b) Equation (II) (2) (c) Equation (II) (2) (d) Equation (III) (1) (a) Equation (III) ( 1)(b), Equation (III)(1)(c), Equation (III)(1)(d), Equation (IV)(1)(a), Equation (IV)(1)(b), Equation (IV)(1)(c), Equation (V)(1)(a), Equation (V)(1)(b), Equation (V)(1)(c), Equation (V)(1)(d), Equation (V)(1)(e), Equation (V)(1)(f), Equation (V)(1)(g), Equation (V)(1)(h), Equation (V)(1)(i), Equation (VI)(1)(a), Equation (VI)(1)(b), Equation (VI)(1)(c), Equation (VI)(1)(d), Equation (VI)(1)(e), Equation (VI)(1)(f), Equation (VI)(1)(g) Equations (VI)(1)(h), (VI)(1)(i), (VI)(1)(j), (VI)(2)(a), (VI)(2)(b), (VI)(2)(c), (VII)(1)(a), (VII)(1)(b), (VII)(1)(c), (VIII)(1)(a), (VIII)(1)(b), (VIII)(1)(c), (VIII)(1)(d), (IX)(1)(a), (IX)(1)(b), (IX)(1)(c), (IX)(1)(d), (X)(1)(a), (X)(1)(b), (X)(1)(c)Equations (X)(1)(d), (XI)(1)(a), (XI)(1)(b), (XI)(1)(c), (XI)(1)(d), (XIII)(2)(a), (XIII)(2)(b), (XIII)(3)(a), (XIII)(3)(b), (XIII)(4)(a), (XIII)(4)(b), (XIII)(5)(a), (XIII)(5)(b), (XIII)(5)(c), (XIII)(5)(d), (XIII)(6)(a), (XIII)(6)(b), (XIII)(6)(c), (XIII)(6)(d), (XIII)(6)(e), (XIII)(6)(f), (XIII)(7)(a), (XII) Formulas (XIII)(7)(b), (XIII)(7)(c), (XIII)(7)(d), (XIII)(7)(e), (XIII)(7)(f), (XIII)(8)(a), (XIII)(8)(b), (XIII)(8)(c), (XIII)(8)(d), (XIII)(8)(e), (XIII)(8)(f), (XIII)(9)(a), (XIII)(9)(b), (XIII)(9)(c), (XIII)(9)(d), (XIII)(9)(e), (XIII)(9)(f), (XIII)(9)(g), (XIII)(9)(h), (XIII)(9)(i), (XIII)(9)(j), and combinations thereof, and the types of LPS molecules.
[0485] In one embodiment, the composition comprises a mixture selected from the following modified LPS molecule species: formula (I)(1)(a), formula (I)(1)(b), formula (I)(1)(c), formula (I)(1)(d), formula (I)(1)(e), formula (I)(1)(f), formula (I)(2)(a), formula (I)(2)(b), formula (I)(2)(c), formula (I)(3)(a), formula (I)(3)(b), formula (I)(3)(c), formula (II)(1)(a), formula (II)(1)(b), formula (II)(1)(c), formula (II)(1)(d) Equation (II)(2)(a), Equation (II)(2)(b), Equation (II)(2)(c), Equation (II)(2)(d), Equation (III)(1)(a), Equation (III)(1)(b), Equation (III)(1)(c), Equation (III)(1)(d), Equation (IV)(1)(a), Equation (IV)(1)(b), Equation (IV)(1)(c), Equation (V)(1)(a), Equation (V)(1)(b), Equation (V)(1)(c), Equation (V)(1)(d), Equation (V)(1)(e), Equation (V)(1)(f), Equation (V)(1)(g), Equation (V) (1)(h), Equation (V)(1)(i), Equation (VI)(1)(a), Equation (VI)(1)(b), Equation (VI)(1)(c), Equation (VI)(1)(d), Equation (VI)(1)(e), Equation (VI)(1)(f), Equation (VI)(1)(g), Equation (VI)(1)(h), Equation (VI)(1)(i), Equation (VI)(1)(j), Equation (VI)(2)(a), Equation (VI)(2)(b), Equation (VI)(2)(c), Equation (VII)(1)(a), Equation (VII)(1)(b), Equation (VII)(1)(c), Equation ( VIII)(1)(a), Formula (VIII)(1)(b), Formula (VIII)(1)(c), Formula (VIII)(1)(d), Formula (IX)(1)(a), Formula (IX)(1)(b), Formula (IX)(1)(c), Formula (IX)(1)(d), Formula (X)(1)(a), Formula (X)(1)(b), Formula (X)(1)(c), Formula (X)(1)(d), Formula (XI)(1)(a), Formula (XI)(1)(b), Formula (XI)(1)(c), Formula (XI)(1)(d), Formula (XII)(1), and the types of LPS molecules in combination thereof.
[0486] In one embodiment, the composition comprises a mixture selected from the following modified LPS molecule species: formula (I)(1)(a), formula (I)(1)(b), formula (I)(1)(c), formula (I)(1)(d), formula (I)(1)(e), formula (I)(1)(f), formula (I)(2)(a), formula (I)(2)(b), formula (I)(2)(c), formula (I)(3)(a), formula (I)(3)(b), formula (I)(3)(c), formula (II)(2)(a), formula (II)(2)(b), formula (II)(2)(a), formula (II)(2)(b), formula (II)(2)(a) c) Equation (II)(2)(d), Equation (III)(1)(a), Equation (III)(1)(b), Equation (III)(1)(c), Equation (III)(1)(d), Equation (IV)(1)(a), Equation (IV)(1)(b), Equation (IV)(1)(c), Equation (V)(1)(a), Equation (V)(1)(b), Equation (V)(1)(c), Equation (V)(1)(d), Equation (V)(1)(e), Equation (V)(1)(f), Equation (V)(1)(g), Equation (V)(1)(h), Equation (V)(1)(i) Equations (VI)(1)(a), (VI)(1)(b), (VI)(1)(c), (VI)(1)(d), (VI)(1)(e), (VI)(1)(f), (VI)(1)(g), (VI)(1)(h), (VI)(1)(i), (VI)(1)(j), (VI)(2)(a), (VI)(2)(b), (VI)(2)(c), (VII)(1)(a), (VII)(1)(b), (VII)(1)(c), (VIII) (1)(a), Formula (VIII)(1)(b), Formula (VIII)(1)(c), Formula (VIII)(1)(d), Formula (IX)(1)(a), Formula (IX)(1)(b), Formula (IX)(1)(c), Formula (IX)(1)(d), Formula (X)(1)(a), Formula (X)(1)(b), Formula (X)(1)(c), Formula (X)(1)(d), Formula (XI)(1)(a), Formula (XI)(1)(b), Formula (XI)(1)(c), Formula (XI)(1)(d), and combinations thereof of LPS molecules.
[0487] In one embodiment, the composition comprises a mixture of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more modified LPS molecules selected from the following: formula (I)(1)(a), formula (I)(1)(b), formula (I)(1)(c), formula (I)(1)(d), formula (I)(1)(e), formula (I)(1)(f), formula (I)(2)(a), formula (I)(2)(b), formula (I)(2)(c), formula (I)(3)(a), formula (I)(3)(b), formula (I)(1)(2)(c). (3)(c), Equation (II)(1)(a), Equation (II)(1)(b), Equation (II)(1)(c), Equation (II)(1)(d), Equation (II)(2)(a), Equation (II)(2)(b), Equation (II)(2)(c), Equation (II)(2)(d), Equation (III)(1)(a), Equation (III)(1)(b), Equation (III)(1)(c), Equation (III)(1)(d), Equation (IV)(1)(a), Equation (IV)(1)(b), Equation (IV)(1)(c), Equation (V)(1)(a), Equation (V)(1)(b), Equation (V)(1)(c), Equation (V)(1)(d) Equations (V)(1)(e), (V)(1)(f), (V)(1)(g), (V)(1)(h), (V)(1)(i), (VI)(1)(a), (VI)(1)(b), (VI)(1)(c), (VI)(1)(d), (VI)(1)(e), (VI)(1)(f), (VI)(1)(g), (VI)(1)(h), (VI)(1)(i), (VI)(1)(j), (VI)(2)(a), (VI)(2)(b), (VI)(2)(c), (VII)(1)(a), (VII)(1)() b) Formula (VII)(1)(c), Formula (VIII)(1)(a), Formula (VIII)(1)(b), Formula (VIII)(1)(c), Formula (VIII)(1)(d), Formula (IX)(1)(a), Formula (IX)(1)(b), Formula (IX)(1)(c), Formula (IX)(1)(d), Formula (X)(1)(a), Formula (X)(1)(b), Formula (X)(1)(c), Formula (X)(1)(d), Formula (XI)(1)(a), Formula (XI)(1)(b), Formula (XI)(1)(c), Formula (XI)(1)(d), Formula (XII)(1), and the types of LPS molecules in combination thereof.
[0488] In one embodiment, the composition comprises a mixture of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more modified LPS molecules selected from the following: formula (I)(1)(a), formula (I)(1)(b), formula (I)(1)(c), formula (I)(1)(d), formula (I)(1)(e), formula (I)(1)(f), formula (I)(2)(a), formula (I)(2)(b), formula (I)(2)(c), and formula (I)(3)(a). Equations (I)(3)(b), (I)(3)(c), (II)(2)(a), (II)(2)(b), (II)(2)(c), (II)(2)(d), (III)(1)(a), (III)(1)(b), (III)(1)(c), (III)(1)(d), (IV)(1)(a), (IV)(1)(b), (IV)(1)(c), (V)(1)(a), (V)(1)(b), (V)(1)(c), (V)(1)(d), (V)(1)(e), (V)(1) (f), Equation (V)(1)(g), Equation (V)(1)(h), Equation (V)(1)(i), Equation (VI)(1)(a), Equation (VI)(1)(b), Equation (VI)(1)(c), Equation (VI)(1)(d), Equation (VI)(1)(e), Equation (VI)(1)(f), Equation (VI)(1)(g), Equation (VI)(1)(h), Equation (VI)(1)(i), Equation (VI)(1)(j), Equation (VI)(2)(a), Equation (VI)(2)(b), Equation (VI)(2)(c), Equation (VII)(1)(a), Equation (VII)(1)(b), Equation (VII)(1)(c), Formula (VIII)(1)(a), Formula (VIII)(1)(b), Formula (VIII)(1)(c), Formula (VIII)(1)(d), Formula (IX)(1)(a), Formula (IX)(1)(b), Formula (IX)(1)(c), Formula (IX)(1)(d), Formula (X)(1)(a), Formula (X)(1)(b), Formula (X)(1)(c), Formula (X)(1)(d), Formula (XI)(1)(a), Formula (XI)(1)(b), Formula (XI)(1)(c), Formula (XI)(1)(d), and combinations thereof of LPS molecules.
[0489] In one embodiment, the composition comprises a mixture selected from the following modified LPS molecule species: formula (I)(1)(a), formula (I)(1)(b), formula (I)(1)(c), formula (I)(1)(d), formula (I)(1)(e), formula (I)(1)(f), formula (I)(2)(a), formula (I)(2)(b), formula (I)(2)(c), formula (I)(3)(a), formula (I)(3)(b), formula (I)(3)(c), formula (I)(5)(a), formula (I)( 5)(b), Formula (I)(6)(a), Formula (I)(6)(b), Formula (I)(7)(a), Formula (I)(7)(b), Formula (I)(7)(c), Formula (I)(7)(d), Formula (I)(8)(a), Formula (I)(8)(b), Formula (I)(8)(c), Formula (I)(9)(a), Formula (I)(9)(b), Formula (I)(9)(c), Formula (I)(9)(d), Formula (I)(9)(e), Formula (I)(9)(f), and the types of LPS molecules in combination thereof.
[0490] In one embodiment, the composition comprises a mixture of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29 modified LPS molecules selected from the following: (I)(1)(a), formula (I)(1)(b), formula (I)(1)(c), formula (I)(1)(d), formula (I)(1)(e), formula (I)(1)(f), formula (I)(2)(a), formula (I)(2)(b), formula (I)(2)(a), formula (I)(2)(b), formula (I)(2)(b). c) Formula (I)(3)(a), Formula (I)(3)(b), Formula (I)(3)(c), Formula (I)(5)(a), Formula (I)(5)(b), Formula (I)(6)(a), Formula (I)(6)(b), Formula (I)(7)(a), Formula (I)(7)(b), Formula (I)(7)(c), Formula (I)(7)(d), Formula (I)(8)(a), Formula (I)(8)(b), Formula (I)(8)(c), Formula (I)(9)(a), Formula (I)(9)(b), Formula (I)(9)(c), Formula (I)(9)(d), Formula (I)(9)(e), Formula (I)(9)(f), and the types of LPS molecules in combination thereof.
[0491] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (I)(1)(a), formula (I)(1)(b), formula (I)(1)(c), formula (I)(1)(d), formula (I)(1)(e), formula (I)(1)(f), formula (I)(2)(a), formula (I)(2)(b), formula (I)(2)(c), formula (I)(3)(a), formula (I)(3)(b), formula (I)(3)(c), and combinations thereof.
[0492] In one embodiment, the composition comprises at least two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve mixtures of modified LPS molecules selected from the following: formula (I)(1)(a), formula (I)(1)(b), formula (I)(1)(c), formula (I)(1)(d), formula (I)(1)(e), formula (I)(1)(f), formula (I)(2)(a), formula (I)(2)(b), formula (I)(2)(c), formula (I)(3)(a), formula (I)(3)(b), formula (I)(3)(c), and combinations thereof.
[0493] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (I)(1)(a), formula (I)(1)(b), formula (I)(1)(c), formula (I)(1)(d), formula (I)(1)(e), formula (I)(1)(f), and combinations thereof.
[0494] In one embodiment, the composition comprises at least two, three, four, five, or six modified LPS molecule species selected from the following formulas: formula (I)(1)(a), formula (I)(1)(b), formula (I)(1)(c), formula (I)(1)(d), formula (I)(1)(e), formula (I)(1)(f), and combinations thereof.
[0495] In one embodiment, the composition includes a mixture of modified LPS molecule types comprising or constituting at least one LPS molecule type of formula (I)(1)(a), at least one LPS molecule type of formula (I)(1)(b), at least one LPS molecule type of formula (I)(1)(c), at least one LPS molecule type of formula (I)(1)(d), at least one LPS molecule type of formula (I)(1)(e), and at least one LPS molecule type of formula (I)(1)(f).
[0496] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (I)(2)(a), formula (I)(2)(b), formula (I)(2)(c), and combinations thereof.
[0497] In one embodiment, the composition comprises at least two or three mixtures of modified LPS molecules selected from the following: formula (I)(2)(a), formula (I)(2)(b), formula (I)(2)(c), and combinations thereof.
[0498] In one embodiment, the composition includes a mixture of modified LPS molecule types comprising or constituting at least one LPS molecule type of formula (I)(2)(a), at least one LPS molecule type of formula (I)(2)(b), and at least one LPS molecule type of formula (I)(2)(c).
[0499] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: LPS molecules of formula (I)(3)(a), formula (I)(3)(b), formula (I)(3)(c), and combinations thereof.
[0500] In one embodiment, the composition comprises at least two or three mixtures of modified LPS molecules selected from the following: LPS molecules of formula (I)(3)(a), formula (I)(3)(b), formula (I)(2)(c), and combinations thereof.
[0501] In one embodiment, the composition includes a mixture of modified LPS molecule types comprising or constituting a mixture of at least one LPS molecule type of formula (I)(3)(a), at least one LPS molecule type of formula (I)(3)(b), and at least one LPS molecule type of formula (I)(3)(c).
[0502] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (I)(5)(a), formula (I)(5)(b), and combinations thereof.
[0503] In one embodiment, the composition comprises a mixture of two modified LPS molecules selected from the following: formula (I)(5)(a), formula (I)(5)(b), and combinations thereof.
[0504] In one embodiment, the composition comprises a mixture of modified LPS molecule types containing or constituting at least one LPS molecule type of formula (I)(5)(a) and at least one LPS molecule type of formula (I)(5)(b).
[0505] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (I)(6)(a), formula (I)(6)(b), and combinations thereof.
[0506] In one embodiment, the composition comprises a mixture of two modified LPS molecules selected from the following: formula (I)(6)(a), formula (I)(6)(b), and combinations thereof.
[0507] In one embodiment, the composition comprises a mixture of modified LPS molecule types containing or constituting at least one LPS molecule type of formula (I)(6)(a) and at least one LPS molecule type of formula (I)(6)(b).
[0508] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (I)(7)(a), formula (I)(7)(b), formula (I)(7)(c), formula (I)(7)(d), and combinations thereof.
[0509] In one embodiment, the composition comprises at least two, three, or four mixtures of modified LPS molecules selected from the following: formula (I)(7)(a), formula (I)(7)(b), formula (I)(7)(c), formula (I)(7)(d), and combinations thereof.
[0510] In one embodiment, the composition includes a mixture of modified LPS molecule types comprising or constituting at least one LPS molecule type of formula (I)(7)(a), a mixture of at least one LPS molecule type of formula (I)(7)(b), at least one LPS molecule type of formula (I)(7)(c), and at least one LPS molecule type of formula (I)(7)(d).
[0511] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (I)(8)(a), formula (I)(8)(b), formula (I)(8)(c), and combinations thereof.
[0512] In one embodiment, the composition comprises at least two or three mixtures of modified LPS molecules selected from the following: formula (I)(8)(a), formula (I)(8)(b), formula (I)(2)(c), and combinations thereof.
[0513] In one embodiment, the composition includes a mixture of modified LPS molecule types comprising or constituting at least one LPS molecule type of formula (I)(8)(a), at least one LPS molecule type of formula (I)(8)(b), and at least one LPS molecule type of formula (I)(8)(c).
[0514] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (I)(9)(a), formula (I)(9)(b), formula (I)(9)(c), formula (I)(9)(d), formula (I)(9)(e), formula (I)(9)(f), and combinations thereof.
[0515] In one embodiment, the composition comprises at least two, three, four, five, or six LPS molecules selected from the following modified LPS molecule types: formula (I)(9)(a), formula (I)(9)(b), formula (I)(9)(c), formula (I)(9)(d), formula (I)(9)(e), formula (I)(9)(f), and combinations thereof.
[0516] In one embodiment, the composition includes a mixture of modified LPS molecule types comprising or constituting at least one LPS molecule type of formula (I)(9)(a), at least one LPS molecule type of formula (I)(9)(b), at least one LPS molecule type of formula (I)(9)(c), at least one LPS molecule type of formula (I)(9)(d), at least one LPS molecule type of formula (I)(9)(e), and at least one LPS molecule type of formula (I)(9)(f).
[0517] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (II)(1)(a), formula (II)(1)(b), formula (II)(1)(c), formula (II)(1)(d), formula (II)(2)(a), formula (II)(2)(b), formula (II)(2)(c), formula (II)(2)(d), and combinations thereof.
[0518] In one embodiment, the composition comprises at least two, three, four, five, six, seven, or eight mixtures of modified LPS molecules selected from the following: formula (II)(1)(a), formula (II)(1)(b), formula (II)(1)(c), formula (II)(1)(d), formula (II)(2)(a), formula (II)(2)(b), formula (II)(2)(c), formula (II)(2)(d), and combinations thereof.
[0519] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (II)(1)(a), formula (II)(1)(b), formula (II)(1)(c), formula (II)(1)(d), and combinations thereof.
[0520] In one embodiment, the composition comprises at least two, three, or four mixtures of modified LPS molecules selected from the following: formula (II)(1)(a), formula (II)(1)(b), formula (II)(1)(c), formula (II)(1)(d), and combinations thereof.
[0521] In one embodiment, the composition comprises a mixture of modified LPS molecule types containing or constituting at least one LPS molecule type of formula (II)(1)(a), at least one LPS molecule type of formula (II)(1)(b), at least one LPS molecule type of formula (II)(1)(c), and at least one LPS molecule type of formula (II)(1)(d).
[0522] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (II)(2)(a), formula (II)(2)(b), formula (II)(2)(c), formula (II)(2)(d), and combinations thereof.
[0523] In one embodiment, the composition comprises at least two, three, or four mixtures of modified LPS molecules selected from the following: formula (II)(2)(a), formula (II)(2)(b), formula (II)(2)(c), formula (II)(2)(d), and combinations thereof.
[0524] In one embodiment, the composition comprises a mixture of modified LPS molecule types containing or constituting at least one LPS molecule type of formula (II)(2)(a), at least one LPS molecule type of formula (II)(2)(b), at least one LPS molecule type of formula (II)(2)(c), and at least one LPS molecule type of formula (II)(2)(d).
[0525] In one embodiment, the composition comprises a mixture of modified LPS molecular species of formula (XII)(1).
[0526] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (III)(1)(a), formula (III)(1)(b), formula (III)(1)(c), formula (III)(1)(d), and combinations thereof.
[0527] In one embodiment, the composition comprises at least two, three, or four mixtures of modified LPS molecules selected from the following: formula (III)(1)(a), formula (III)(1)(b), formula (III)(1)(c), formula (III)(1)(d), and combinations thereof.
[0528] In one embodiment, the composition comprises a mixture of modified LPS molecule types containing or constituting at least one LPS molecule type of formula (III)(1)(a), at least one LPS molecule type of formula (III)(1)(b), at least one LPS molecule type of formula (III)(1)(c), and at least one LPS molecule type of formula (III)(1)(d).
[0529] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (XII)(1), and combinations thereof.
[0530] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (IV)(1)(a), formula (IV)(1)(b), formula (IV)(1)(c), and combinations thereof.
[0531] In one embodiment, the composition comprises at least two or three mixtures of modified LPS molecules selected from the following: formula (IV)(1)(a), formula (IV)(1)(b), formula (IV)(1)(c), and combinations thereof.
[0532] In one embodiment, the composition includes a mixture of modified LPS molecule types comprising or constituting at least one LPS molecule type of formula (IV)(1)(a), at least one LPS molecule type of formula (IV)(1)(b), and at least one LPS molecule type of formula (IV)(1)(c).
[0533] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (V)(1)(a), formula (V)(1)(b), formula (V)(1)(c), formula (V)(1)(d), formula (V)(1)(e), formula (V)(1)(f), formula (V)(1)(g), formula (V)(1)(h), formula (V)(1)(i), and combinations thereof.
[0534] In one embodiment, the composition comprises at least two, three, four, five, six, seven, eight, or nine mixtures of modified LPS molecules selected from the following: formula (V)(1)(a), formula (V)(1)(b), formula (V)(1)(c), formula (V)(1)(d), formula (V)(1)(e), formula (V)(1)(f), formula (V)(1)(g), formula (V)(1)(h), formula (V)(1)(i), and combinations thereof.
[0535] In one embodiment, the composition comprises a mixture of modified LPS molecule types containing or constituting at least one LPS molecule type of formula (V)(1)(a), at least one LPS molecule type of formula (V)(1)(b), at least one LPS molecule type of formula (V)(1)(c), at least one LPS molecule type of formula (V)(1)(d), at least one LPS molecule type of formula (V)(1)(e), at least one LPS molecule type of formula (V)(1)(f), at least one LPS molecule type of formula (V)(1)(j), at least one LPS molecule type of formula (V)(1)(h), and at least one LPS molecule type of formula (V)(1)(i).
[0536] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (VI)(1)(a), formula (VI)(1)(b), formula (VI)(1)(c), formula (VI)(1)(d), formula (VI)(1)(e), formula (VI)(1)(f), formula (VI)(1)(g), formula (VI)(1)(h), formula (VI)(1)(i), formula (VI)(1)(j), formula (VI)(2)(a), formula (VI)(2)(b), formula (VI)(2)(c), and combinations thereof.
[0537] In one embodiment, the composition comprises at least two, three, four, five, six, seven, or eight mixtures of modified LPS molecules selected from the following: formula (VI)(1)(a), formula (VI)(1)(b), formula (VI)(1)(c), formula (VI)(1)(d), formula (VI)(1)(e), formula (VI)(1)(f), formula (VI)(1)(g), formula (VI)(1)(h), formula (VI)(1)(i), formula (VI)(1)(j), formula (VI)(2)(a), formula (VI)(2)(b), formula (VI)(2)(c), and combinations thereof.
[0538] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (VI)(1)(a), formula (VI)(1)(b), formula (VI)(1)(c), formula (VI)(1)(d), formula (VI)(1)(e), formula (VI)(1)(f), formula (VI)(1)(g), formula (VI)(1)(h), formula (VI)(1)(i), formula (VI)(1)(j), and combinations thereof.
[0539] In one embodiment, the composition comprises at least two, three, four, five, six, seven, eight, nine, or ten mixtures of modified LPS molecules selected from the following: formula (VI)(1)(a), formula (VI)(1)(b), formula (VI)(1)(c), formula (VI)(1)(d), formula (VI)(1)(e), formula (VI)(1)(f), formula (VI)(1)(g), formula (VI)(1)(h), formula (VI)(1)(i), formula (VI)(1)(j), and combinations thereof.
[0540] In one embodiment, the composition comprises a mixture of modified LPS molecule types comprising or consisting of at least one LPS molecule type of formula (VI)(1)(a), at least one LPS molecule type of formula (VI)(1)(b), at least one LPS molecule type of formula (VI)(1)(c), at least one LPS molecule type of formula (VI)(1)(d), at least one LPS molecule type of formula (VI)(1)(e), at least one LPS molecule type of formula (VI)(1)(f), at least one LPS molecule type of formula (VI)(1)(g), at least one LPS molecule type of formula (VI)(1)(h), at least one LPS molecule type of formula (VI)(1)(i), and at least one LPS molecule type of formula (VI)(1)(j).
[0541] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (VI)(2)(a), formula (VI)(2)(b), formula (VI)(2)(c), and combinations thereof.
[0542] In one embodiment, the composition comprises at least two or three mixtures of modified LPS molecules selected from the following: formula (VI)(2)(a), formula (VI)(2)(b), formula (VI)(2)(c), and combinations thereof.
[0543] In one embodiment, the modified LPS molecule species included in the composition comprises or constitute at least one LPS molecule species of formula (VI)(2)(a), at least one LPS molecule species of formula (VI)(2)(b), and at least one LPS molecule species of formula (VI)(2)(c).
[0544] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (VII)(1)(a), formula (VII)(1)(b), formula (VII)(1)(c), and combinations thereof.
[0545] In one embodiment, the composition comprises at least two or three mixtures of modified LPS molecules selected from the following: formula (VII)(1)(a), formula (VII)(1)(b), formula (VII)(2)(c), and combinations thereof.
[0546] In one embodiment, the composition includes a mixture of modified LPS molecule types comprising or constituting at least one LPS molecule type of formula (VII)(1)(a), at least one LPS molecule type of formula (VII)(1)(b), and at least one LPS molecule type of formula (VII)(1)(c).
[0547] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (VIII)(1)(a), formula (VIII)(1)(b), formula (VIII)(1)(c), formula (VIII)(1)(d), and combinations thereof.
[0548] In one embodiment, the composition comprises at least two, three, or four mixtures of modified LPS molecules selected from the following: formula (VIII)(1)(a), formula (VIII)(1)(b), formula (VIII)(1)(c), formula (VIII)(1)(d), and combinations thereof.
[0549] In one embodiment, the composition comprises a mixture of modified LPS molecule types containing or constituting at least one LPS molecule type of formula (VIII)(1)(a), at least one LPS molecule type of formula (VIII)(1)(b), at least one LPS molecule type of formula (VIII)(1)(c), and at least one LPS molecule type of formula (VIII)(1)(d).
[0550] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (IX)(1)(a), formula (IX)(1)(b), formula (IX)(1)(c), formula (IX)(1)(d), and combinations thereof.
[0551] In one embodiment, the composition comprises at least two, three, or four mixtures of modified LPS molecules selected from the following: formula (IX)(1)(a), formula (IX)(1)(b), formula (IX)(1)(c), formula (IX)(1)(d), and combinations thereof.
[0552] In one embodiment, the composition includes a mixture of modified LPS molecule types comprising or constituting at least one LPS molecule type of formula (IX)(1)(a), at least one LPS molecule type of formula (IX)(1)(b), at least one LPS molecule type of formula (IX)(1)(c), and at least one LPS molecule type of formula (IX)(1)(d).
[0553] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (X)(1)(a), formula (X)(1)(b), formula (X)(1)(c), formula (X)(1)(d), and combinations thereof.
[0554] In one embodiment, the composition comprises at least two, three, or four mixtures of modified LPS molecules selected from the following: formula (X)(1)(a), formula (X)(1)(b), formula (X)(1)(c), formula (X)(1)(d), and combinations thereof.
[0555] In one embodiment, the composition includes a mixture of modified LPS molecule types comprising or constituting at least one LPS molecule type of formula (X)(1)(a), at least one LPS molecule type of formula (X)(1)(b), at least one LPS molecule type of formula (X)(1)(c), and at least one LPS molecule type of formula (X)(1)(d).
[0556] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (XI)(1)(a), formula (XI)(1)(b), formula (XI)(1)(c), formula (XI)(1)(d), and combinations thereof.
[0557] In one embodiment, the composition comprises at least two, three, or four mixtures of modified LPS molecules selected from the following: formula (XI)(1)(a), formula (XI)(1)(b), formula (XI)(1)(c), formula (XI)(1)(d), and combinations thereof.
[0558] In one embodiment, the composition includes a mixture of modified LPS molecule types comprising or constituting at least one LPS molecule type of formula (XI)(1)(a), at least one LPS molecule type of formula (XI)(1)(b), at least one LPS molecule type of formula (XI)(1)(c), and at least one LPS molecule type of formula (XI)(1)(d).
[0559] In one embodiment, the composition comprises a mixture selected from the following modified LPS molecule species: formula (XIII)(2)(a), formula (XIII)(2)(b), formula (XIII)(3)(a), formula (XIII)(3)(b), formula (XIII)(4)(a), formula (XIII)(4)(b), formula (XIII)(5)(a), formula (XIII)(5)(b), formula (XIII)(5)(c), formula (XIII)(5)(d), formula (XIII)(6)(a), formula (XIII)(6)(b), formula (XIII)(6)(c), formula (XIII)(6)(d), formula (XIII)(6)(e), formula (XIII)(6)(f), formula (XIII)(7)(a), formula (XIII)(7)(b), formula ( XIII)(7)(c), Formula (XIII)(7)(d), Formula (XIII)(7)(e), Formula (XIII)(7)(f), Formula (XIII)(8)(a), Formula (XIII)(8)(b), Formula (XIII)(8)(c), Formula (XIII)(8)(d), Formula (XIII)(8)(e), Formula (XIII)(8)(f), Formula (XIII)(9)(a), Formula (XIII)(9)(b), Formula (XIII)(9)(c), Formula (XIII)(9)(d), Formula (XIII)(9)(e), Formula (XIII)(9)(f), Formula (XIII)(9)(g), Formula (XIII)(9)(h), Formula (XIII)(9)(i), Formula (XIII)(9)(j), and combinations thereof, as well as the types of LPS molecules.
[0560] In one embodiment, the composition comprises a mixture of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 35, 36, 37, or 38 modified LPS molecules selected from the following: (XIII)(2)(a), formula (XIII)(2)(b), formula (XIII)(3)(a), formula (XIII)(3)(b), formula (XIII)(4)(a), formula (XIII)(4)(b), formula (XIII) (5)(a), formula (XIII)(5)(b), formula (XIII)(5)(c), formula (XIII)(5)(d), formula (XIII)(6)(a), formula (XIII)(6)(b), formula (XIII)(6)(c), Formulas (XIII)(6)(d), (XIII)(6)(e), (XIII)(6)(f), (XIII)(7)(a), (XIII)(7)(b), (XIII)(7)(c), (XIII)(7)(d), (XIII)(7)(e), (XIII)(7)(f), (XIII)(8)(a), (XIII)(8)(b), (XIII)(8)(c), (XIII)(8)(d), (XIII)(8)(e), (XIII)(8)(f), (XIII)(9)(a), (XIII)(9)(b), (XIII)(9)(c), (XIII)(9)(d), (XIII)(9)(e), (XIII)(9)(f), (XIII)(9)(g), (XIII)(9)(h), (XIII)(9)(i), (XIII)(9)(j), and combinations thereof, and the types of LPS molecules.
[0561] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (XIII)(2)(a), formula (XIII)(2)(b), and combinations thereof.
[0562] In one embodiment, the composition comprises a mixture of two modified LPS molecules selected from the following: formula (XIII)(2)(a), formula (XIII)(2)(b), and combinations thereof.
[0563] In one embodiment, the composition comprises a mixture of modified LPS molecule types containing or constituting at least one LPS molecule type of formula (XIII)(2)(a) and at least one LPS molecule type of formula (XIII)(2)(b).
[0564] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (XIII)(3)(a), formula (XIII)(3)(b), and combinations thereof.
[0565] In one embodiment, the composition comprises a mixture of three modified LPS molecules selected from the following: formula (XIII)(3)(a), formula (XIII)(3)(b), and combinations thereof.
[0566] In one embodiment, the composition comprises a mixture of modified LPS molecule types containing or constituting at least one LPS molecule type of formula (XIII)(3)(a) and at least one LPS molecule type of formula (XIII)(3)(b).
[0567] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (XIII)(4)(a), formula (XIII)(4)(b), and combinations thereof.
[0568] In one embodiment, the composition comprises a mixture of four modified LPS molecules selected from the following: formula (XIII)(4)(a), formula (XIII)(4)(b), and combinations thereof.
[0569] In one embodiment, the composition comprises a mixture of modified LPS molecule species containing or constituting at least one LPS molecule species of formula (XIII)(4)(a) and at least one LPS molecule species of formula (XIII)(4)(b).
[0570] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (XIII)(5)(a), formula (XIII)(5)(b), formula (XIII)(5)(c), formula (XIII)(5)(d), and combinations thereof.
[0571] In one embodiment, the composition comprises a mixture of two modified LPS molecules selected from the following: formula (XIII)(5)(a), formula (XIII)(5)(b), formula (XIII)(5)(c), formula (XIII)(5)(d), and combinations thereof.
[0572] In one embodiment, the composition comprises a mixture of modified LPS molecule types containing or constituting at least one LPS molecule type of formula (XIII)(5)(a), at least one LPS molecule type of formula (XIII)(5)(b), at least one LPS molecule type of formula (XIII)(5)(c), and at least one LPS molecule type of formula (XIII)(5)(d).
[0573] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (XIII)(6)(a), formula (XIII)(6)(b), formula (XIII)(6)(c), formula (XIII)(6)(d), formula (XIII)(6)(e), formula (XIII)(6)(f), and combinations thereof.
[0574] In one embodiment, the composition comprises a mixture of two modified LPS molecules selected from the following: formula (XIII)(6)(a), formula (XIII)(6)(b), formula (XIII)(6)(c), formula (XIII)(6)(d), formula (XIII)(6)(e), formula (XIII)(6)(f), and combinations thereof.
[0575] In one embodiment, the composition includes a mixture of modified LPS molecule types comprising or constituting at least one LPS molecule type of formula (XIII)(6)(a), at least one LPS molecule type of formula (XIII)(6)(b), at least one LPS molecule type of formula (XIII)(6)(c), at least one LPS molecule type of formula (XIII)(6)(d), at least one LPS molecule type of formula (XIII)(6)(e), and at least one LPS molecule type of formula (XIII)(6)(f).
[0576] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (XIII)(7)(a), formula (XIII)(7)(b), formula (XIII)(7)(c), formula (XIII)(7)(d), formula (XIII)(7)(e), formula (XIII)(7)(f), and combinations thereof.
[0577] In one embodiment, the composition comprises a mixture of two modified LPS molecules selected from the following: formula (XIII)(7)(a), formula (XIII)(7)(b), formula (XIII)(7)(c), formula (XIII)(7)(d), formula (XIII)(7)(e), formula (XIII)(7)(f), and combinations thereof.
[0578] In one embodiment, the composition comprises a mixture of modified LPS molecule types containing or constituting at least one LPS molecule type of formula (XIII)(7)(a), at least one LPS molecule type of formula (XIII)(7)(b), at least one LPS molecule type of formula (XIII)(7)(c), at least one LPS molecule type of formula (XIII)(7)(d), at least one LPS molecule type of formula (XIII)(7)(e), and at least one LPS molecule type of formula (XIII)(7)(f).
[0579] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (XIII)(8)(a), formula (XIII)(8)(b), formula (XIII)(8)(c), formula (XIII)(8)(d), formula (XIII)(8)(e), formula (XIII)(8)(f), and combinations thereof.
[0580] In one embodiment, the composition comprises a mixture of two modified LPS molecules selected from the following: formula (XIII)(8)(a), formula (XIII)(8)(b), formula (XIII)(8)(c), formula (XIII)(8)(d), formula (XIII)(8)(e), formula (XIII)(8)(f), and combinations thereof.
[0581] In one embodiment, the composition comprises a mixture of modified LPS molecule types containing or constituting at least one LPS molecule type of formula (XIII)(8)(a), at least one LPS molecule type of formula (XIII)(8)(b), at least one LPS molecule type of formula (XIII)(8)(c), at least one LPS molecule type of formula (XIII)(8)(d), at least one LPS molecule type of formula (XIII)(8)(e), and at least one LPS molecule type of formula (XIII)(8)(f).
[0582] In one embodiment, the composition comprises a mixture of modified LPS molecules selected from the following: formula (XIII)(9)(a), formula (XIII)(9)(b), formula (XIII)(9)(c), formula (XIII)(9)(d), formula (XIII)(9)(e), formula (XIII)(9)(f), formula (XIII)(9)(g), formula (XIII)(9)(h), formula (XIII)(9)(i), formula (XIII)(9)(j), and combinations thereof.
[0583] In one embodiment, the composition comprises a mixture of two modified LPS molecules selected from the following: formula (XIII)(9)(a), formula (XIII)(9)(b), formula (XIII)(9)(c), formula (XIII)(9)(d), formula (XIII)(9)(e), formula (XIII)(9)(f), formula (XIII)(9)(g), formula (XIII)(9)(h), formula (XIII)(9)(i), formula (XIII)(9)(j), and combinations thereof.
[0584] In one embodiment, the composition comprises a mixture of modified LPS molecule types comprising or consisting of at least one LPS molecule type of formula (XIII)(9)(a), at least one LPS molecule type of formula (XIII)(9)(b), at least one LPS molecule type of formula (XIII)(9)(c), at least one LPS molecule type of formula (XIII)(9)(d), at least one LPS molecule type of formula (XIII)(9)(e), at least one LPS molecule type of formula (XIII)(9)(f), at least one LPS molecule type of formula (XIII)(9)(g), at least one LPS molecule type of formula (XIII)(9)(h), at least one LPS molecule type of formula (XIII)(9)(i), and at least one LPS molecule type of formula (XIII)(9)(j).
[0585] In one embodiment, at least one LPS molecule species is a naturally occurring LPS molecule species. In one embodiment, the naturally occurring LPS molecule species is non-toxic.
[0586] In one embodiment, the endotoxin activity of naturally occurring LPS molecules is less than 5000 endotoxin equivalents (EEU) / μg, preferably less than 4000 EEU / μg, 3000 EEU / μg, 2000 EEU / μg, 1500 EEU / μg, or 1000 EEU / μg; this can be assessed, for example, by a mononuclear cell activation assay (MAT) based on peripheral blood mononuclear cells (PBMCs) and IL-6 response.
[0587] Bacteria existed on Earth long before humans, thus humans co-evolved with bacteria, which are primarily found in the gut microbiome, as well as on the skin and all body surfaces. *E. coli* has long coexisted with humans, providing the host with vitamins and aiding digestion. Therefore, it is not surprising that the TLR4 LPS receptor, present on the surface of different human cells, can accurately recognize the structure of *E. coli* LPS molecules, much like a glove can recognize a hand. Thus, the differences between *E. coli* LPS molecules and typical (i.e., unmodified) *E. coli* LPS molecules include, for example, fewer or more fatty acid chains, and / or shorter and / or longer fatty acid chains. Differentiation can also occur at the phosphate level at the reduced C1 position and / or non-reduced C4' position of the lipid A domain, where they either lack a negative charge or substitute for the neutralization of the negative charge.
[0588] In this case, some LPS molecules that have undergone this differentiation will not be recognized by receptors like typical E. coli LPS molecules, and therefore will not induce cytokine release leading to high inflammation.
[0589] Naturally occurring non-toxic LPS molecules may include, but are not limited to, LPS molecules, among others:
[0590] i. At most one, for example, one or zero, unsubstituted phosphate groups are contained at the reduced C1 position and / or the non-reduced C4' position of the lipid A domain; and / or
[0591] ii. Compared to toxic LPS molecules, such as those from E. coli or Salmonella enterica, it contains fewer or more fatty acid chains—containing six fatty acid chains, four of which are primary fatty acid chains and two are secondary fatty acid chains; and / or
[0592] iii. Compared to toxic LPS molecules, such as those from E. coli or Salmonella enterica, it contains shorter and / or longer fatty acid chains—containing four primary 3-OH-C bonds. 11 Fatty acid chain, one secondary carbon 14 Fatty acid chain and a secondary C 12 Fatty acid chains.
[0593] In one embodiment, the non-toxic, naturally occurring LPS molecule species does not contain two secondary C atoms simultaneously present at the C2' and C3' positions of the lipid A domain. 12 and / or C 14 Fatty acid chains. In one embodiment, the non-toxic, naturally occurring LPS molecule species does not contain two secondary C atoms simultaneously present at the C2' and C3' positions of the lipid A domain. 12Fatty acid chains. In one embodiment, the non-toxic, naturally occurring LPS molecule species does not contain two secondary C atoms simultaneously present at the C2' and C3' positions of the lipid A domain. 14 Fatty acid chain. In one embodiment, the non-toxic, naturally occurring LPS molecule does not contain a secondary C12 bond located simultaneously at both the C2' and C3' positions of the lipid A domain. 12 Fatty acid chain and a secondary C 14 Fatty acid chains.
[0594] In one embodiment, the non-toxic, naturally occurring LPS molecule does not contain four primary 3-OH-C atoms simultaneously present at the C2' and C3 positions of the lipid A domain. 14 The fatty acid chain does not contain two secondary carbon atoms. 12 and / or C 14 Fatty acid chains. In one embodiment, the non-toxic, naturally occurring LPS molecule species does not contain four secondary 3-OH-C atoms simultaneously present at the C2' and C3' positions of the lipid A domain. 14 The fatty acid chain does not contain two secondary carbon atoms. 12 Fatty acid chains. In one embodiment, the non-toxic, naturally occurring LPS molecule does not contain four primary 3-OH-C bonds simultaneously present at the C2' and C3' positions of the lipid A domain. 14 The fatty acid chain does not contain two secondary carbon atoms. 14 Fatty acid chains. In one embodiment, the non-toxic, naturally occurring LPS molecule does not contain four primary 3-OH-C bonds simultaneously present at the C2' and C3 positions of the lipid A domain. 14 The fatty acid chain does not contain a secondary carbon. 14 A fatty acid chain and a C 12 Fatty acid chains.
[0595] In one embodiment, the non-toxic, naturally occurring LPS molecule species does not contain a phosphate group at the C1 position of the reduced end of its lipid A domain or a phosphate group at the C4' position of the non-reduced end of its lipid A domain, or neither.
[0596] In one embodiment, the non-toxic, naturally occurring LPS molecule contains a lipid A domain that contains a disaccharide, such as β-1,6-glucosamine [GlcN] disaccharide, β-1,6-diaminoglucosamine [DAG] disaccharide, or a β-1,6-disaccharide containing one GlcN residue and one DAG residue.
[0597] However, non-toxic, naturally occurring LPS molecules also include those whose lipid A domain contains only one sugar, such as glucosamine, glucosamine, or diaminohexose. These LPS molecules are also included in this invention.
[0598] Examples of non-toxic, naturally occurring LPS molecules include, but are not limited to, LPS molecules from the genus *Bordezoae* (e.g., LPS molecules from *Bordezoae pertussis*), LPS molecules from *Vibrio hygroscopicus* (e.g., LPS molecules from *Vibrio linearis*), LPS molecules from *Neisseria* (e.g., LPS molecules from *Neisseria meningitidis*), LPS molecules from *Vibrio cholerae* (e.g., LPS molecules from *Vibrio cholerae*), LPS molecules from *Helicobacter pylori* (e.g., LPS molecules from *Helicobacter pylori*), LPS molecules from the genus *Porphyromonas*, LPS molecules from *Leptospira* (e.g., *Leptospira renalis*), LPS molecules from *Flavobacterium meningosepticum* (e.g., *Flavobacterium meningosepticum*), LPS molecules from *Rhodopsinia*, LPS molecules from *Rhizobium*, LPS molecules from the genus *Bacteroides*, and LPS molecules from the genus *Prevotella*.
[0599] In one embodiment, the non-toxic LPS molecule species from Bordetella contains four or fewer C64 molecules. 14 A fatty acid chain and a C 10 Fatty acid chains.
[0600] In one embodiment, the non-toxic LPS molecule species from *Vibrio hygroscopicus* contains 2 C... 12 Fatty acid chains with 4 or fewer carbon atoms 10 Fatty acid chains.
[0601] In one embodiment, the non-toxic LPS molecule species from Neisseria contains 2 C... 14 Fatty acid chains and 4 Cs 12 Fatty acid chains.
[0602] In one implementation, the non-toxic LPS molecule species derived from Vibrio contains 3 Cs. 14 Fatty acid chains and 3 Cs 12 Fatty acid chains.
[0603] In one embodiment, the non-toxic LPS molecule species derived from Helicobacter pylori contains 1 C 16 Fatty acid chains and 3 Cs 18 Fatty acid chains.
[0604] Other examples of non-toxic, naturally occurring LPS molecules include, but are not limited to, those selected from, Figure 1The compounds of formulas (I)(0)(a) and (l)(0)(b) shown, such as Figure 5 Compounds of formula (II)(0) shown, such as Figure 34 The types of LPS molecules of compounds and combinations thereof of formula (XIII)(0)(a) and (XIII)(0)(b) are shown.
[0605] Other examples of non-toxic, naturally occurring LPS molecules include, but are not limited to, those selected from, Figure 1 The compounds of formulas (I)(0)(a) and (l)(0)(b) shown, such as Figure 5 The compounds of formula (II)(0) shown, and the types of LPS molecules in their combinations.
[0606] In one embodiment, the composition includes naturally occurring LPS molecules selected from formulas (I)(1)(a), (I)(1)(b), and combinations thereof.
[0607] In one embodiment, the composition comprises a mixture of at least two naturally occurring LPS molecules selected from the following: formula (I)(1)(a), formula (I)(1)(b), and combinations thereof.
[0608] In one embodiment, the composition comprises a mixture of naturally occurring LPS molecule species containing or constituting at least one LPS molecule species of formula (I)(1)(a) and at least one LPS molecule species of formula (I)(1)(b).
[0609] In one embodiment, the composition comprises naturally occurring LPS molecules of formula (II)(0).
[0610] In one embodiment, the composition according to the invention comprises at least one modified LPS molecule species as described above and at least one naturally occurring LPS molecule species as described above.
[0611] In one embodiment, the composition according to the invention comprises a mixture of modified LPS molecules as described above and naturally occurring LPS molecules.
[0612] In one embodiment, the composition according to the invention comprises LPS molecules that are monodisperse in an aqueous solution, preferably in water and / or PBS, which can be evaluated, for example, by DLS measurement; preferably, the DLS measurement is performed at a scattering angle Θ = 90°, an incident laser wavelength λ = 633 nm, and a temperature of 25°C.
[0613] As used herein, the term “monodisperse” in relation to LPS molecular species refers to molecules that are substantially homogeneous in size in aqueous solutions (e.g., in water and / or in PBS).
[0614] "Substantially uniform" means that LPS molecules have a narrow size distribution around the average size. In one embodiment, the size of LPS molecules in water and / or PBS shows a standard deviation of less than 20% relative to their average size, for example, less than 10%, or less than 5%.
[0615] In one embodiment, the composition according to the invention comprises LPS molecules formulated as liposomes. According to this embodiment, the liposomes may comprise, substantially consist of, or consist only of LPS molecules according to the invention.
[0616] As used herein, "liposome" refers to a vesicle comprising a lipid phase of an amphiphilic molecular bilayer, such as phospholipids or cholesterol, enclosing an internal aqueous phase. Liposomes can be monolayered (i.e., containing a single lipid bilayer) or multilayered (i.e., containing at least two or more concentric lipid bilayers).
[0617] Phospholipids are lipids containing phosphate groups. They consist of a polar, hydrophilic "head" and two aliphatic, hydrophobic "tails". Examples of phospholipids include, but are not limited to, phosphatidic acids and glycerol phosphates.
[0618] Liposomes can be prepared by various methods and approaches known in the art.
[0619] In one embodiment, in the sense of the invention, the LPS molecule species is formulated into liposomes in the form of (1) liposomes containing any suitable amphiphilic molecules and encapsulating the LPS molecule species according to the invention; or (2) liposomes consisting substantially or entirely of the LPS molecule species according to the invention.
[0620] In one embodiment, the composition according to the invention comprises an LPS molecule formulated as a liposome, and further comprises at least one additional therapeutic agent unconjugated or conjugated to the LPS molecule.
[0621] In one embodiment, the composition according to the invention comprises an LPS molecule species formulated as liposomes, and further comprises at least one additional therapeutic agent, encapsulated or not encapsulated in the liposomes.
[0622] Other suitable examples of therapeutic agents include, but are not limited to, chemotherapeutic agents, targeted therapies, cytotoxic agents, antibiotics, antiviral agents, cell cycle synchronizers, cell receptor ligands, immunomodulators, pro-apoptotic agents, anti-angiogenic agents, cytokines, growth factors, antibodies or their antigen-binding fragments, cell therapies, antigens, etc.
[0623] Detailed examples of these therapeutic agents have been described above as suitable agents conjugated at the Z, R1, and / or R2 positions on Formulas A and B. However, it will be readily understood by those skilled in the art that, according to the invention, these therapeutic agents may additionally or alternatively be provided not in combination with the compositions according to the invention.
[0624] In one embodiment, the additional therapeutic agent is a targeted therapeutic agent as defined above, preferably an anti-CD20 monoclonal antibody or its antigen-binding fragment. In one embodiment, the anti-CD20 monoclonal antibody is selected from teimozumab, oxotuzumab, octolithumab, oflambumab, rituximab, tosimomab, or its antigen-binding fragment; preferably, the anti-CD20 monoclonal antibody is rituximab or its antigen-binding fragment.
[0625] In one embodiment, the additional therapeutic agent is an immunostimulant as defined above, preferably an immune checkpoint inhibitor. In one embodiment, the immune checkpoint inhibitor is selected from or consists of the following inhibitors: CTLA4 inhibitors, PD-1 inhibitors, PD-L1 inhibitors, LAG-3 inhibitors, B7-H3 inhibitors, B7-H4 inhibitors, TIM3 inhibitors, A2AR inhibitors, GITR inhibitors, CD47 inhibitors, TNFR2 inhibitors, CD19 inhibitors, and / or IDO inhibitors. In one embodiment, the immune checkpoint inhibitor is selected from nivolumab, pembrolizumab, cimiprimab, pildizumab, AMP-224, AMP-514, MPDL3280A, MDX-1105, MEDI-4736, arelumab, ipilimumab, trimemumab, pildizumab, IMP321, MGA271, BMS-986016, lirelurumab, urerlurumab, PF-05082566, IPH2101, MEDI-6469, CP-870,893, mogliflozin, varimulumab, galiximumab, avinumab and galiximumab, AUNP12, IDO pathway inhibitor (Indoximod), NLG-919, and INCB024360. In one embodiment, the immune checkpoint inhibitor is a PD-1 inhibitor or a PD-L1 inhibitor. Examples of PD-1 inhibitors include, but are not limited to, nivolumab, pembrolizumab, cimiprimab, spartazine, camrelizumab, sintilimab, tislelizumab, toripalimab, AMP-224, and AMP-514. Examples of PD-L1 inhibitors include, but are not limited to, atezolizumab, acilimab, durvalumab, KN035, CK-301, AUNP12, CA-170, and BMS-986189.
[0626] In one embodiment, the composition according to the invention is a pharmaceutical composition and further comprises at least one pharmaceutically acceptable excipient.
[0627] As used herein, the term "pharmaceuticalally acceptable excipient" refers to a solid, semi-solid, or liquid component of a pharmaceutical composition or vaccine composition that is not an active ingredient and, when administered to animals, preferably to humans, will not produce harmful, allergic, or other adverse reactions. Most of these pharmaceutically acceptable excipients are described, for example, in Allen (Ed.), 2017. Ansel's pharmaceutical dosage forms and drug delivery systems (11...). th ed.). Philadelphia, PA: Wolters Kluwer; Remington, Allen & Adeboye (Eds.), 2013. Remington: The science and practice of pharmacy (22 nd ed.).London:Pharmaceutical Press; and Sheskey,Cook&Cable(Eds.),2017.Handbook ofpharmaceutical excipients(8 th (ed.). London: Pharmaceutical Press; each of which is incorporated herein by reference in its entirety.
[0628] Pharmaceutically acceptable excipients include, but are not limited to, water, saline, Ringer's solution, glucose solution, ethanol solution, glucose solution, sucrose solution, dextran solution, mannose solution, mannitol solution, sorbitol solution, polyethylene glycol (PEG) solution, phosphate solution, acetate solution, gelatin solution, and collagen solution. Solutions, vegetable oil solutions, etc. They may also include suitable preservatives, stabilizers, antioxidants, antimicrobial agents, and buffers, such as BHA, BHT, citric acid, ascorbic acid, tetracycline, etc.
[0629] Other examples of pharmaceutically acceptable excipients that can be used in the compositions of the present invention include, but are not limited to, ion exchangers, alum, such as aluminum phosphate or aluminum hydroxide, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffering substances, such as phosphates, glycine, sorbic acid, potassium sorbate, partial glycerol ester mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, silica gel, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and lanolin.
[0630] In addition, some pharmaceutically acceptable excipients may include surfactants (e.g., hydroxypropyl cellulose); suitable carriers, such as solvents and dispersion media containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils, such as peanut oil and sesame oil; isotonic agents, such as sugars or sodium chloride; film-forming agents, such as lecithin; absorption-retarding agents, such as aluminum monostearate and gelatin; preservatives, such as benzalkonium chloride, benzyl chloride, chlorobutanol, thimerosal, etc.; buffers, such as boric acid, sodium bicarbonate and potassium bicarbonate, sodium borate and potassium borate, sodium carbonate and potassium carbonate, sodium acetate, sodium hydrogen phosphate, etc.; and tension agents, such as dextran 40, dextran 70, glucose, glycerol, etc. Potassium chloride, propylene glycol, sodium chloride; antioxidants and stabilizers, such as sodium bisulfite, sodium metabisulfite, sodium thiosulfate, thiourea, etc.; nonionic wetting or clarifying agents, such as polysorbate 80, polysorbate 20, poloxamer 282, and tyloxacillin; viscosity modifiers, such as dextran 40, dextran 70, gelatin, glycerin, hydroxyethyl cellulose, hydroxymethyl cellulose, lanolin, methyl cellulose, petrolatum, polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, carboxymethyl cellulose, etc.
[0631] In one embodiment, the composition according to the invention is a vaccine composition.
[0632] As used herein, the term "vaccine composition" refers to a composition comprising at least one antigen or immunogen and optionally an adjuvant in a pharmaceutically acceptable excipient, and which may be used to induce an immune response in a subject upon administration.
[0633] As used herein, the term “antigen” or “immunogen” means any substance that induces a state of susceptibility and / or immune response after an incubation period (usually several days to several weeks in humans) and that reacts in vivo or in vitro with antibodies and / or immune cells of the sensitized subject in a demonstrably identifiable manner.
[0634] As used herein, the term "adjuvant" refers to a substance that, upon administration, enhances and / or increases the immune response of a subject to an antigen.
[0635] Examples of adjuvants include, but are not limited to, helper peptides, aluminum salts (e.g., aluminum hydroxide gel (also known as alum), aluminum phosphate, etc.), Freund's incomplete adjuvants, Freund's complete adjuvants, saponins, Merck adjuvant 65, Smith-Kline Beecham adjuvant AS-2, Aquilla adjuvant QS-21, and MPL. TM Immunostimulants, 3d-MPL, LEIF, calcium salts, iron salts, zinc salts, acylated tyrosine, acylated sugars, cationic-derived polysaccharides, anionic-derived polysaccharides, polyphosphazenes, biodegradable microspheres, monophosphorylated lipid A, muramyl tripeptide phosphatidylethanolamine, cytokines (e.g., interleukin-2, interleukin-12, interleukin-4, interleukin-7, etc.), CpG-containing oligonucleotides, etc.
[0636] In one embodiment, the vaccine composition according to the invention comprises at least one LPS molecule species as described above, serving as both a major antigen and a major adjuvant. In fact, the LPS molecule species containing a core oligosaccharide domain may optionally be replaced by an antigenic domain, such as an O-antigen domain and / or a capped antigen, representing antigenicity and immunogenicity against the bacterial type of the derived LPS molecule species.
[0637] In one embodiment, the vaccine composition according to the invention comprises at least one LPS molecule species as described above as a primary antigen, and at least one adjuvant that is not an LPS molecule species as described above—an LPS molecule species as a second adjuvant.
[0638] In one embodiment, the vaccine composition according to the invention comprises at least one LPS molecule species as described above as a primary adjuvant, and at least one antigen that is not an LPS molecule species as described above—the LPS molecule species as a secondary antigen. In this embodiment, the at least one antigen may be an antigen derived from the same bacterial type as the LPS molecule species to produce a binding antigen effect against said bacterial species. Alternatively, the at least one antigen may not be an antigen derived from the same bacterial species as the LPS molecule species (i.e., an antigen derived from another bacterial species or any other antigen, such as pathogen-associated antigens, autoantigens, allergen-associated antigens, neoantigens, or others).
[0639] In one embodiment, the vaccine composition is a subunit vaccine. In one embodiment, the vaccine composition is a protein vaccine. In one embodiment, the vaccine composition is a cell-based vaccine.
[0640] Suitable examples of antigens include, but are not limited to, pathogen-associated antigens (e.g., antigens of viruses, fungi, or bacteria, or immunogenic molecules derived from them), autoantigens (e.g., cellular antigens, including cells containing normal transplant antigens and / or tumor-associated antigens, RR-Rh antigens, and antigens that are characteristic or specific to a particular cell or tissue or body fluid), allergen-associated antigens (e.g., those associated with environmental allergens), including grass, pollen, mold, dust, insects, dander, venom, etc.; occupational allergens, including latex, dander, polyurethane, epoxy resins, etc.; foods, including shellfish, peanuts, eggs, dairy products, etc.; and drugs, including antibiotics, anesthetics, etc.), neoantigens, and vaccines.
[0641] Suitable examples of pathogen-associated antigens include, but are not limited to, those derived from vaccinia virus, fowlpox virus, turkey influenza virus, bovine leukemia virus, feline leukemia virus, avian influenza, avian pneumonia virus, canine parvovirus, equine influenza, FHV, Newcastle disease virus (NDV), avian / Pennsylvanic / 1 / 83 influenza virus, infectious bronchitis virus, dengue virus, measles virus, rubella virus, pseudorabies virus, Epstein-Barr virus, HIV, SIV, EHV, BHV, HCMV, Hantavirus, Clostridium tetani, mumps virus, measles virus, and type 1. Herpes simplex virus, herpes simplex virus type 2, human cytomegalovirus, hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis E virus, respiratory syncytial virus, human papillomavirus, influenza virus, Bordetella, Vibrio hygroscopicus, Salmonella, Neisseria, Treponema pallidum, Chlamydia, Plasmodium, Toxoplasma gondii, Cryptococcus, Streptococcus, Staphylococcus, Haemophilus influenzae, diphtheria, tetanus, Escherichia coli, Candida, Aspergillus, Actinomyces, Burkholderia, Moraxella, Pseudomonas, Vibrio, Entamoeba histolytica, Giardia lamblia, and Trypanosomiasis.
[0642] Suitable examples of autoantigens include, but are not limited to, lupus autoantigen, Smith, Ro, La, Ul-RNP, fibrin, nuclear antigen, histone, glycoprotein gp70, ribosomal protein, pyruvate dehydrogenase, dehydrolipoamide acetyltransferase (PCD-E2), hair follicle antigen, human tropomyosin isoform 5 (hTM5), proinsulin, insulin, IA2, GAD65, type II collagen, human cartilage gp39 (HCgp39), gp130-RAPS, dnaJp1, citrulline proteins and peptides (including citrulline type II collagen, citrulline vimentin, and citrulline fibrinogen), myelin basic protein, protein lipoprotein (PLP), myelin oligodendrocyte glycoprotein (MOG), thyroid stimulating factor receptor (TSH-R), acetylcholine receptor (AchR), prolysin, PLP, glucose-6-phosphate isomerase, thyroglobulin, various tRNA synthetases, protease-3, and myeloperoxidase, including fragments thereof.
[0643] Suitable examples of tumor-associated antigens include, but are not limited to, MART-1 / Melan-A, gplOO, dipeptidyl peptidase IV (DPPIV), adenosine deaminase-binding protein (ADAbp), cyclophilin b, colorectal-associated antigen (CRC)-C017-1A / GA733, carcinoembryonic antigen (CEA) and its immunogenic epitopes CAP-1 and CAP-2, etv6, amll, prostate-specific antigen (PSA) and its immunogenic epitopes PSA-1, PSA-2 and PSA-3, prostate-specific membrane antigen (PSMA), T-cell receptor / CD3-ζ chain, MAGE tumor antigen family (e.g., MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A7, MAGE-A8, MAGE-A9, MAGE-A10, MAGE-A11, M AGE-A12, MAGE-Xp2 (MAGE-B2), MAGE-Xp3 (MAGE-B3), MAGE-Xp4 (MAGE-B4), MAGE-C1, MAGE-C2, MAGE-C3, MAGE-C4, MAGE-C5), GAGE swelling Tumor antigen families (e.g., GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7, GAGE-8, GAGE-9), BAGE, RAGE, LAGE-1, NAG, GnT-V, MUM-1, CDK4, tyrosinase, p53, MUC family (e.g., MUC1, MUC16, etc.), HER2 / neu, p21ras, RCAS1, alpha-fetoprotein, epithelial cadherin, α-catenin, β-catenin and γ-catenin, p120ctn, gpl00.sup.Pmelll 7. PRAME, NY-ESO-1, cdc27, adenomatous polyposis protein (APC), cytosine, gap junction protein 37, Ig idiotype, p15, gp75, GM2 and GD2 gangliosides, Smad family cancer antigen brain glycogen phosphorylase, SSX-1, SSX-2 (HOM-MEL-40), SSX-1, SSX-4, SSX-5, SCP-1 and CT-7, and c-erbB-2 and viral antigens, such as HPV-16 nuclear HPV-18 E6 and E7 antigens and EBV-encoded nuclear antigen (EBNA)-1, including fragments thereof. Further examples of tumor-associated antigens are described, for example, Li et al., 2004. Cancer Immunol Immunother. 53(3):139-43; Novellino et al., 2005. Cancer Immunol Immunother. 54(3):187-20; the entire contents of which are incorporated herein by reference.
[0644] In one embodiment, the antigen may be conjugated to an LPS molecule species, for example, at the Z, R1, and / or R2 positions of a modified LPS molecule species of Formula A or Formula B as described above.
[0645] In one embodiment, the composition according to the invention is a pharmaceutical.
[0646] As used herein, the term “drug” should be understood to mean a variety of pharmacological materials intended to be administered or delivered to any of a variety of patients, whether human or otherwise, through a variety of delivery mechanisms.
[0647] In one embodiment, the composition, pharmaceutical composition, drug or vaccine composition according to the invention is formulated for application to a subject.
[0648] In one embodiment, the composition, pharmaceutical composition, drug or vaccine composition according to the invention is formulated for systemic or local administration to a subject.
[0649] In one embodiment, the composition, pharmaceutical composition, drug or vaccine composition according to the invention is formulated for administration by injection, oral administration, topical administration, nasal administration, oral administration, rectal administration, vaginal administration, tracheal administration, endoscopic administration, transmucosal administration, transdermal administration, or intratumoral administration.
[0650] In one embodiment, the composition, pharmaceutical composition, drug or vaccine composition according to the invention is formulated for administration by injection, preferably by systemic injection.
[0651] Examples of formulations suitable for injection include, but are not limited to, solutions such as sterile aqueous solutions, gels, dispersants, emulsions, suspensions, and suitable solid forms for addition to a liquid prior to use to prepare a solution or suspension, such as powders, liposomes, outer membrane vesicles (OMVs), etc.
[0652] Examples of systemic injection include, but are not limited to, intravenous (iv), subcutaneous (sq), intradermal (id), intramuscular (im), intra-arterial, extra-gastric, intra-nodal, intra-lymphatic, intraperitoneal (ip), intracranial, intracardiac, intralesional, intraprostatic, intravaginal, intrarectal, intrathecal, intranasal, intratumoral (it), intravesical, and perfusion.
[0653] In one embodiment, the composition, pharmaceutical composition, drug or vaccine composition according to the invention is sterile upon injection. Methods for obtaining sterile compositions include, but are not limited to, GMP synthesis (wherein GMP stands for "Good Manufacturing Practice").
[0654] The aseptic injectable form of the composition can be aqueous or oil-based. These suspensions can be formulated using suitable dispersants or wetting agents and suspending agents according to techniques known in the art. Aseptic injectable formulations can also be as sterile injectable solutions or suspensions placed in non-toxic, non-enteric-acceptable diluents or solvents. Acceptable carriers and solvents that can be used include water, Ringer's solution, and isotonic sodium chloride solution. Furthermore, sterile fixed oils are commonly used as solvents or suspension media. For this purpose, any mild fixed oil can be used, including synthetic monoglycerides or diglycerides. Fatty acids, such as oleic acid and its glycerol derivatives, can be used to prepare injectables, as can pharmaceutically acceptable natural oils, such as olive oil or castor oil, especially their polyoxyethylated forms. These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants, such as carboxymethyl cellulose or similar dispersants, which are commonly used to formulate pharmaceutically acceptable dosage forms, including emulsions and suspensions. Other commonly used surfactants, such as Tween, Span, biosurfactants, and other emulsifiers or bioavailability enhancers typically used to prepare pharmaceutically acceptable solid, liquid, or other dosage forms, may also be used for formulation purposes.
[0655] It should be understood that the present invention also considers other suitable routes of administration, and the final method of administration will be determined by the attending physician within the scope of reasonable medical judgment.
[0656] In one embodiment, the composition, pharmaceutical composition, drug or vaccine composition according to the invention is formulated together with at least one other therapeutic agent that is not conjugated to or conjugated to an LPS molecule class.
[0657] In one embodiment, the composition, pharmaceutical composition, drug or vaccine composition according to the invention will be administered to the recipient before, simultaneously with or after the administration of at least one other therapeutic agent.
[0658] Examples of suitable therapeutic agents include, but are not limited to, chemotherapeutic agents, targeted therapies, cytotoxic agents, antibiotics, antiviral agents, cell cycle synchronizers, cell receptor ligands, immunomodulators, pro-apoptotic agents, anti-angiogenic agents, cytokines, growth factors, antibodies or their antigen-binding fragments, cell therapies, antigens, etc.
[0659] Suitable examples of cell therapy include, but are not limited to, adoptive cell therapy, CAR-T cell therapy, allogeneic cell therapy, embryonic stem cell therapy, neural stem cell therapy, mesenchymal stem cell therapy, and hematopoietic stem cell transplantation.
[0660] Other detailed examples of these therapeutic agents have been described above as suitable agents conjugated at the Z, R1, and / or R2 positions on Formulas A and B. However, it will be readily understood by those skilled in the art that, according to the invention, these therapeutic agents may additionally or alternatively be provided not in combination with compositions, pharmaceutical compositions, drug or vaccine compositions according to the invention.
[0661] In one embodiment, the additional therapeutic agent is a targeted therapeutic agent as defined above, preferably an anti-CD20 monoclonal antibody or its antigen-binding fragment. In one embodiment, the anti-CD20 monoclonal antibody is selected from teimozumab, oxotuzumab, octolithumab, oflambumab, rituximab, tosimomab, or its antigen-binding fragment; preferably, the anti-CD20 monoclonal antibody is rituximab or its antigen-binding fragment.
[0662] In one embodiment, the additional therapeutic agent is an immunostimulant as defined above, preferably an immune checkpoint inhibitor. In one embodiment, the immune checkpoint inhibitor is selected from CTLA4 inhibitors, PD-1 inhibitors, PD-L1 inhibitors, LAG-3 inhibitors, B7-H3 inhibitors, B7-H4 inhibitors, TIM3 inhibitors, A2AR inhibitors, GITR inhibitors, CD47 inhibitors, TNFR2 inhibitors, CD19 inhibitors, and / or IDO inhibitors. In one embodiment, the immune checkpoint inhibitor is selected from or consists of the following inhibitors: nivolumab, pembrolizumab, cimipril, pildizumab, AMP-224, AMP-514, MPDL. 3280A, MDX-1105, MEDI-4736, arelumab, ipilimumab, trimemumab, pildizilzumab, IMP321, MGA271, BMS-986016, lirelurumab, urerlurumab, PF-05082566, IPH2101, MEDI-6469, CP-870,893, mogliflozin, varilurumab, galiximumab, avinumab and galiximumab, AUNP12, IDO pathway inhibitor (Indoximod), NLG-919, and INCB024360. In one embodiment, the immune checkpoint inhibitor is a PD-1 inhibitor or a PD-L1 inhibitor. Examples of PD-1 inhibitors include, but are not limited to, nivolumab, pembrolizumab, cimiprimab, spartazine, camrelizumab, sintilimab, tislelizumab, toripalimab, AMP-224, and AMP-514. Examples of PD-L1 inhibitors include, but are not limited to, atezolizumab, acilimab, durvalumab, KN035, CK-301, AUNP12, CA-170, and BMS-986189.
[0663] As will be further detailed below, the modified LPS molecule species according to the invention, as well as compositions, pharmaceutical compositions, drug or vaccine compositions, optionally formulated with at least one additional therapeutic agent unconjugated and / or conjugated to the LPS molecule species, can be used for a wide range of therapeutic, vaccine and immunostimulatory purposes.
[0664] This invention relates to modified LPS molecules, compositions, pharmaceutical compositions, or drug or vaccine compositions according to the invention, which are used as pharmaceuticals.
[0665] Specifically, the present invention relates to modified LPS molecule types, compositions, pharmaceutical compositions, pharmaceutical or vaccine compositions according to the present invention for the treatment and / or prevention of cancer, inflammatory diseases or infectious diseases, or for stimulating immune responses or for vaccinating subjects in need.
[0666] The present invention also relates to methods for treating and / or preventing cancer in subjects in need, including administering to said subjects a modified LPS molecule species, composition, pharmaceutical composition, drug or vaccine composition according to the present invention.
[0667] The present invention also relates to modified LPS molecule species, compositions, pharmaceutical compositions, drug or vaccine compositions according to the present invention for the treatment and / or prevention of cancer in subjects in need.
[0668] Examples of cancer include those listed in Chapter 2, Sections C00 to D48 of the 10th revision of the International Classification of Diseases and Related Health Problems (ICD).
[0669] Other examples of cancer include, but are not limited to, recurrent, metastatic, or multidrug-resistant cancers.
[0670] Other examples of cancer include, but are not limited to, adenofibroma, adenoma, idiopathic extramedullary metaplasia, AIDS-related malignancies, ameloblastoma, anal cancer, angiofollicular mediastinal lymph node hyperplasia, angiokeratoma, angiolymphoid hyperplasia with eosinophilia, hemangiomatosis, anhidrotic ectodermal dysplasia, anterior facial dysplasia, apocrine metaplasia, APUD tumor, asphyxiated thoracic dysplasia, astrocytoma (including, for example, cerebellar astrocytoma and brain astrocytoma), atrial-finger dysplasia, atypical melanocytic hyperplasia, atypical metaplasia, autologous metaplasia, basal cell hyperplasia, benign giant lymph node hyperplasia, cholangiocarcinoma (including, for example, extrahepatic cholangiocarcinoma), bladder cancer, and bone cancer. Cancer, brain tumors (including, for example, brainstem glioma, cerebellar astrocytoma, malignant glioma, supratentorial primitive neuroectodermal tumor, visual pathway and hypothalamic glioma, ependymoma, medulloblastoma, gestational trophoblastic tumor glioma, and paraganglioma), branchionia, female breast cancer, male breast cancer, bronchial adenoma / carcinoid, bronchopulmonary dysplasia, epithelial cell carcinoma growth, epithelial cell precancerous growth, epithelial cell metastatic growth, carcinoid heart disease, carcinoid tumors (including, for example, gastrointestinal carcinoid tumors), cancer (including, for example, unknown primary cancer, adrenocortical carcinoma, islet cell carcinoma, adenocarcinoma, adenocortical carcinoma, basal cell carcinoma, basal squamous cell carcinoma) Cellular carcinoma, bronchiolar carcinoma, Brown-Pearce carcinoma, cystadenocarcinoma, ductal carcinoma, liver cancer, Krebs carcinoma, papillary carcinoma, oat cell carcinoma, small cell lung cancer, non-small cell lung cancer, squamous cell carcinoma, transitional cell carcinoma, Walker carcinoma, Merkel cell carcinoma, and skin cancer), cementum tumor, cementum hyperplasia, cerebral dysplasia, cervical cancer, cervical dysplasia, chondroma, cholesteatoma, chondroblastoma, chondroectodermal dysplasia, chordoma, mammilloma, chondroma, clavicle-cranial dysplasia, colon cancer, colorectal cancer, locally metastatic colorectal cancer, congenital adrenal hyperplasia, congenital ectodermal dysplasia, congenital sebaceous gland hyperplasia, connective tissue metaplasia, craniocarpal metatarsal dysplasia Complete skull dysplasia, skull metaphysis dysplasia, craniopharyngioma, cylindrica, cystadenoma, cystic hyperplasia (including, for example, breast cystic hyperplasia), phyllodes cystosarcoma, dentin dysplasia, denture hyperplasia, diaphyseal dysplasia, ductal hyperplasia, dysgerminoma, epiphyseal hemilimb dysplasia, multiple epiphyseal dysplasia, punctate epiphyseal dysplasia, ectodermal dysplasia, Ehrlich tumor, enamel dysplasia, cerebral ocular dysplasia, endometrial cancer (including, for example, ependymoma and endometrial hyperplasia), ependymoma, epithelial carcinoma, epithelial dysplasia, epithelial metaplasia, esophageal cancer, Ewing's tumor family (including, for example, Ewing's sarcoma), extrahepatic bile duct cancer, ocular cancer (including,Examples include intraocular melanoma and retinoblastoma, facial and digital genital dysplasia, familial fibrous dysplasia of the jaw, familial white fold dysplasia, fibroma, myofibril dysplasia, fibromuscular hyperplasia, fibrous osteodysplasia, vigorous osteodysplasia, focal epithelial hyperplasia, gallbladder cancer, gangliomas, gastric cancer (including, for example, gastric cancer), gastrointestinal carcinoid tumors, digestive tract tumors, gastrointestinal tumors, Gaucher disease, germ cell tumors (including, for example, extracranial germ cell tumors, gonadal germ cell tumors, and malignant ovarian germ cell tumors), giant cell tumors, gingival hyperplasia, glioblastoma, glomus tumor, granulosa cell tumor, androgenetic adenomas, hamartomas, head and neck cancer, hemangioendothelioma, hemangioma, hemangiopericytoma, liver cancer. Cellular carcinoma, hepatocellular carcinoma, hereditary renal-retinal dysplasia, hyperhidrotic ectodermal dysplasia, histiocytoma, histiocytosis, hypergammaglobulinemia, hypohidrotic ectodermal dysplasia, hypopharyngeal carcinoma, inflammatory fibrosis, inflammatory papillary hyperplasia, colorectal cancer, intestinal metaplasia, intestinal polyps, intraocular melanoma, intravascular papillary endothelial hyperplasia, renal carcinoma, laryngeal carcinoma, leiomyoma, leukemia (including, for example, acute lymphoblastic leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, acute myeloid leukemia, acute hairy cell leukemia, acute B-cell leukemia, acute T-cell leukemia, acute HTLV leukemia, chronic lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic granulocytic leukemia, chronic myeloid ... Hairy cell leukemia, chronic B-cell leukemia, chronic T-cell leukemia, and chronic HTLV leukemia), stromal cell tumors, lip and oral cancers, lipomas, liver cancer, lung cancer (including, for example, small cell lung cancer and non-small cell lung cancer), lymphangiomyoma, lymphangioma, lymphoma (including, for example, AIDS-related lymphoma, central nervous system lymphoma, primary central nervous system lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, gestational Hodgkin lymphoma, gestational non-Hodgkin lymphoma, mast cell lymphoma, B-cell lymphoma, adenolymphoma, Burkitt lymphoma, cutaneous T-cell lymphoma, large cell lymphoma, and small cell lymphoma), lymphopenic thymic dysplasia, lymphoproliferative disorders, macroglobulinemia ( This includes, for example, Waldenström macroglobulinemia, malignant carcinoid syndrome, malignant mesothelioma, malignant thymoma, breast hypoplasia, mandibular dysplasia, medulloblastoma, meningioma, mesenchymal tumor, mesonephroma, mesothelioma (including, for example, malignant mesothelioma), metaphyseal dysplasia, metaplastic anemia, metaplastic ossification, metaplastic polyps, metastatic squamous neck carcinoma (including, for example, metastatic squamous neck carcinoma with occult primary), Montinyi malformation, mononuclear fibrodysplasia, mucosal epithelial dysplasia, multiple endocrine neoplasia syndrome, multiple epiphyseal dysplasia, multiple myeloma / plasma cell tumor, mycosis fungoides, myelodysplastic syndrome, myeloid metaplasia, myeloproliferative disorders, chronic myeloproliferative disorders, myoblastoma, fibroids,Myxoma, nasal and sinus carcinoma, nasopharyngeal carcinoma, prostate tumors, colon tumors, abdominal tumors, bone tumors, breast tumors, digestive system tumors, liver tumors, pancreatic tumors, peritoneal tumors, endocrine gland tumors (including, for example, adrenal tumors, parathyroid tumors, pituitary tumors, testicular tumors, ovarian tumors, thymic tumors, and thyroid tumors), eye tumors, head and neck tumors, nervous system tumors (including, for example, central nervous system tumors and peripheral nervous system tumors), lymphatic system tumors, pelvic tumors, skin tumors, soft tissue tumors, spleen tumors, thoracic tumors, urogenital tract tumors, schwannomas, neuroblastomas, neuroepithelial tumors, neurofibromas, neurofibromatosis, neuromas, prostatic nodular hyperplasia, nodular regenerative hyperplasia, eye Auricular dysplasia, oculomotor dysplasia, oculogenic dysplasia, odontogenic dysplasia, odontomas, oculomotor dysplasia, oropharyngeal carcinoma, osteomas, ovarian cancer (including, for example, ovarian epithelial carcinoma and low-potency ovarian tumors), pancreatic cancer (including, for example, islet cell pancreatic carcinoma and exocrine pancreatic carcinoma), papilloma, paraganglioma, non-pheochromocytic paraganglioma, paranasal sinus and nasal cavity carcinoma, paraproteinemia, parathyroid carcinoma, periapical periodontal cementum dysplasia, pheochromocytoma (including, for example, penile cancer), pineal and supratentorial primitive neuroectodermal tumors, pineal adenoma, pituitary adenoma, plasmacytoma / multiple myeloma, plasmacytoma, pleural pulmonary blastoma, multiple fibrous dysplasia, polyps, pregnancy cancer, precancerous diseases (including, for example, benign growth factor hyperplasia) Abnormal diseases, such as benign tumors, fibrocystic disease, hypertrophic tissue, intestinal polyps, colonic polyps, esophageal dysplasia, leukoplakia, keratosis, Bowen's disease, farmer's dermatitis, solar cheilitis and solar keratosis), primary hepatocellular carcinoma, primary liver cancer, primary myelometra, prostate cancer, pseudochondrodysplasia of the vertebral epiphysis, pseudoepithelial hyperplasia, purpura, rectal cancer, renal cancer (including, for example, renal cell carcinoma, renal pelvis carcinoma, ureteral carcinoma, transitional cell carcinoma of the renal pelvis and ureter), reticuloendothelial hyperplasia, retinal dysplasia, retinoblastoma, salivary gland cancer, sarcomas (including, for example, uterine sarcoma, soft tissue sarcoma, carcinosarcoma, chondrosarcoma, fibrosarcoma, angiosarcoma, Kaposi's sarcoma, leiomyosarcoma, lipoma, etc. Fat sarcoma, lymphangiosarcoma, myoma, myxosarcoma, rhabdomyosarcoma, sarcoidosis sarcoma, osteosarcoma, Ewing sarcoma, malignant fibrous histiocytoma of bone and clear cell sarcoma of tenosynovium), sclerosing hemangioma, secondary myeloid metaplasia, senile sebaceous hyperplasia, optic septum dysplasia, Sertoli cell tumor, Sezary syndrome, skin cancer (including, for example, melanoma skin cancer and non-melanoma skin cancer), small bowel cancer, vertebral epiphyseal dysplasia, squamous metaplasia (including, for example, amniotic squamous metaplasia), gastric cancer, supratentorial primitive neuroectodermal and pineal gland tumors, supratentorial primary neuroectodermal tumors, symptomatic myelomecosis, teratoma, testicular cancer, meningocytoma, thymoma (including, for example, malignant thymoma), thyroid cancer, trophoblastic tumors (including,Examples include gestational trophoblastic tumors, ureteral cancer, uterine cancer, vaginal cancer, radial ventricular dysplasia, verrucous hyperplasia, vulvar cancer, Waldenström macroglobulinemia, and nephroblastoma.
[0671] In one embodiment, the cancer is selected from osteosarcoma, colorectal cancer, lymphoma (e.g., B-cell lymphoma), chondrosarcoma, bladder cancer, and breast cancer.
[0672] In one implementation, the cancer is selected from osteosarcoma, chondrosarcoma, lymphoma (e.g., B-cell lymphoma), bladder cancer, and breast cancer.
[0673] In one implementation, the cancer is selected from osteosarcoma, colorectal cancer, and lymphoma (e.g., B-cell lymphoma).
[0674] In one implementation, treating cancer in a subject in need also includes administering at least one additional therapeutic agent as defined above to the subject before, simultaneously with, or after treatment.
[0675] In one embodiment, the additional therapeutic agent is a targeted therapeutic agent as defined above, preferably an anti-CD20 monoclonal antibody or its antigen-binding fragment. In one embodiment, the anti-CD20 monoclonal antibody is selected from teimozumab, oxotuzumab, octolithumab, oflambumab, rituximab, tosimobumab or its antigen-binding fragment; preferably, the anti-CD20 monoclonal antibody is rituximab.
[0676] In one embodiment, the additional therapeutic agent is an immunostimulant as defined above, preferably an immune checkpoint inhibitor. In one embodiment, the immune checkpoint inhibitor is selected from or consists of the following inhibitors: CTLA4 inhibitors, PD-1 inhibitors, PD-L1 inhibitors, LAG-3 inhibitors, B7-H3 inhibitors, B7-H4 inhibitors, TIM3 inhibitors, A2AR inhibitors, GITR inhibitors, CD47 inhibitors, TNFR2 inhibitors, CD19 inhibitors, and / or IDO inhibitors. In another embodiment, the immune checkpoint inhibitor is selected from or consists of the following inhibitors: nivolumab, pembrolizumab, cimipril, pildizumab, AMP-224, AMP-514. The following are listed: MPDL3280A, MDX-1105, MEDI-4736, arelumab, ipilimumab, trimemumab, pildizilzumab, IMP321, MGA271, BMS-986016, lirelurumab, urerizumab, PF-05082566, IPH2101, MEDI-6469, CP-870,893, mogliflozin, varilurumab, galiliximab, avinumab and galiliximab, AUNP12, IDO pathway inhibitor (Indoximod), NLG-919, and INCB024360. In one embodiment, the immune checkpoint inhibitor is a PD-1 inhibitor or a PD-L1 inhibitor. Examples of PD-1 inhibitors include, but are not limited to, nivolumab, pembrolizumab, cimiprimab, spartazine, camrelizumab, sintilimab, tislelizumab, toripalimab, AMP-224, and AMP-514. Examples of PD-L1 inhibitors include, but are not limited to, atezolizumab, acilimab, durvalumab, KN035, CK-301, AUNP12, CA-170, and BMS-986189.
[0677] The present invention also relates to methods for treating and / or preventing inflammatory diseases in subjects in need, including administering to said subjects a modified LPS molecule species, composition, pharmaceutical composition, drug or vaccine composition according to the present invention.
[0678] The present invention also relates to modified LPS molecule species, compositions, pharmaceutical compositions, drug or vaccine compositions according to the present invention for the treatment and / or prevention of inflammatory diseases in subjects in need.
[0679] As used herein, the term “inflammatory disease” is used to define any disease caused by or resulting from inflammation of the subject. The term may include, but is not limited to, (1) inflammatory and / or allergic diseases, (2) autoimmune diseases, (3) transplant rejection, and (4) other diseases requiring suppression of adverse inflammatory responses.
[0680] Examples of inflammatory conditions include, but are not limited to, abdominal aortic aneurysm (AAA), acne, acute disseminated encephalomyelitis, acute leukocyte-mediated lung injury, Addison's disease, adult respiratory distress syndrome, AIDS-related dementia, allergic asthma, allergic conjunctivitis, allergic contact dermatitis, allergic rhinitis, allergic sinusitis, allergy, allergy, alopecia areata, Alzheimer's disease, allergic reactions, angioedema, ankylosing spondylitis, antiphospholipid syndrome, asthma, atherosclerosis, atopic dermatitis, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, Behçet's syndrome, blepharitis, bronchitis, bullous pemphigoid, and chronic inflammatory diseases. Diseases, chronic obstructive pulmonary disease, cirrhosis, closed head injury, coagulative necrosis, celiac disease, collagenous colitis, conjunctivitis, contact dermatitis, coronary heart disease, necrotizing phlebitis, cystic fibrosis, dermatitis, dermatomyositis, polymyositis, type 1 diabetes, type 2 diabetes, distal proctitis, metastatic colitis, drug allergy, dry eye syndrome, eczema, encephalitis, endometriosis, endotoxic shock, epilepsy, erythema multiforme, erythema nodosum, fibrinoid necrosis, fibromyalgia, giant cell arteritis (also known as Horton's disease), glomerulonephritis, nephritis syndrome, gout, gouty arthritis, graft-versus-host disease (e.g., acute graft-versus-host disease, chronic transplantation). (e.g., host-resistant diseases), Graves' disease, Guillain-Barré syndrome, Hashimoto's disease, hay fever, hyperacute transplant rejection, hyperlipidemia, allergic lung disease, idiopathic thrombocytopenic purpura, indeterminate colitis, inflammatory bowel disease (IBD) (e.g., Crohn's disease, ulcerative colitis, colitis, pouchitis, ileitis, enteritis, etc.), inflammatory liver disease, insect bite dermatitis, insect bite allergy, interstitial cystitis, iritis, ischemic colitis, lichen planus, liquefactive necrosis, lupus, systemic lupus erythematosus, lymphocytic colitis, meningitis, metabolic syndrome, multiple sclerosis, multiple traumatic injury, myasthenia gravis, myocarditis, myositis, somnolence, nephritis, obesity. Osteoarthritis, osteoporosis, otitis media, pancreatitis, Parkinson's disease, pemphigus vulgaris, periodontitis and gingivitis, periodontitis, pernicious anemia, polymyalgia rheumatica, polymyositis, postmenopausal metabolic syndrome, primary biliary cirrhosis, psoriasis, psoriatic arthritis, radiation poisoning, radiation syndrome, relapsing polychondritis, retinitis, rheumatoid arthritis, rheumatoid spondylitis, rhinoceros conjunctivitis, sarcoidosis, scleroderma, septic shock, herpes zoster, sinusitis, Sjögren's syndrome, smooth muscle proliferation disorder, photodermatitis, spondyloarthritis, fatty degeneration, stroke, systemic lupus erythematosus, urticaria, uveitis, vaginitis, vasculitis, vitiligo, and Wegener's granulomatosis.
[0681] In one implementation, treating an inflammatory disease in a subject in need further includes administering at least one additional therapeutic agent as defined above to the subject before, simultaneously with, or after treatment.
[0682] The present invention also relates to methods for treating and / or preventing infectious diseases in subjects in need, including administering to said subjects a modified LPS molecule species, composition, pharmaceutical composition, drug or vaccine composition according to the present invention.
[0683] The present invention also relates to modified LPS molecule species, compositions, pharmaceutical compositions, drug or vaccine compositions according to the present invention for the treatment and / or prevention of infectious diseases in subjects in need.
[0684] As used herein, the term “infectious disease” is used to define any disease caused by the invasion of an infectious agent (or pathogen) into an object, their reproduction, and the response of the object’s tissues to these infectious agents and the toxins they produce. The term may include, but is not limited to, (1) bacterial infection, (2) viral infection, (3) fungal infection, and (4) parasitic infection.
[0685] Examples of infectious diseases include, but are not limited to, Acinetobacter infection, Actinomycosis, African sleeping sickness (also known as African trypanosomiasis), AIDS (Acquired Immunodeficiency Syndrome), Amoebiasis, Apoplasmosis, Angiostrongylus cantonensis infection, Anisakis infection, Anthrax, Cryptococcus hemolyticus infection, Argentine hemorrhagic fever, Ascariasis, Aspergillus infection, Astrovirus infection, Babesia infection, Bacillus cereus infection, Bacteroides meningitis, Bacteroides pneumonia, Bacteroides vaginosis, Bacteroides infection, Balanopsis infection, Bartonella infection, Ascaris infection, BK virus infection, Trichophyton meningitis, Blastomycosis, Bolivian hemorrhagic fever, Botulism, Brazilian hemorrhagic fever, Brucellosis, Black Death, Burkholderia infection, brucellosis, Calicivirus infection, Campylobacteriosis, Candidiasis, Capillary nematode infection, Carrion disease, Cat scratch disease, Cellulitis, and South American disease. Trypanosomiasis (also known as American trypanosomiasis), chancroid, chickenpox, chikungunya, chlamydia, Chlamydia pneumoniae infection, cholera, chromoblastomycosis, chytriditis, liver fluke infection, Clostridium difficile colitis, coccidioidomycosis, Colorado tick fever, common cold (also known as acute viral nasopharyngitis or acute rhinitis), Creutzfeldt-Jakob disease, Crimean-Congo hemorrhagic fever, cryptococcosis, cryptosporidiosis, cutaneous larval migration syndrome, cyclosporidiosis Diseases including: cysticercosis, cytomegalovirus infection, dengue fever, streptomyces infection, binucleate amoebiasis, diphtheria, sparganosis, dracunculiasis, Ebola hemorrhagic fever, echinococcosis, ehrlichiosis, pinworm infection, enterococcal infection, enterovirus infection, epidemic typhus, erythema infectiosum, erythema, fascioliasis, fascioliasis, fatal familial insomnia, filariasis, Clostridium perfringens poisoning, and free amoebic infection.Fusobacterium infection, gas gangrene, dystrophinosis, Gerstmann syndrome, Giardiasis, glanders, Gnathostoma spinigerum infection, gonorrhea, granuloma inguinale, group A streptococcal infection, group B streptococcal infection, Haemophilus influenzae infection, hand-foot-mouth disease, Hantavirus pulmonary syndrome, Central Plains virus disease, Helicobacter pylori infection, hemolytic uremic syndrome, hemorrhagic fever with renal syndrome, Hendra virus infection, hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E, herpes simplex, histoplasmosis, hookworm infection, human bocavirus infection, human elchioidosis, human granulocytic anaplasmosis, human metapneumovirus infection, human monocytic elchioidosis, human papillomavirus infection, human parainfluenza virus infection, membrane capsid Tapeworm infection, infant botulism, infectious mononucleosis, influenza, isosporidiosis, Kawasaki disease, keratitis, *Aureobasidium japonicum* infection, kuru, Lassa fever, Legionnaires' disease, leishmaniasis, leptospirosis, listeriosis, Lyme disease, lymphatic filariasis, lymphocytic choriomeningitis, malaria, Marburg hemorrhagic fever, measles, Middle East Respiratory Syndrome (MERS), melioidosis (also known as Whitmore's disease), meningitis, meningococcal infection, metaclonorchiasis, microsporidiosis, molluscum contagiosum, monkeypox, mumps, murine typhus, mycoplasma pneumonia, genital mycoplasma infection, mycoplasma pedis, myiasis, neonatal conjunctivitis, Nipah virus infection, nocardiasis, *Onchocerca foetida* Parasporidiosis (also known as river blindness), clonorchiasis, paracoccidioidomycosis (also known as South American blastomycosis), paragonimiasis, pasteurellosis, head lice, body lice, pubic lice, pelvic inflammatory disease, pertussis, plague, pneumococcal infection, Pneumocystis pneumonia, pneumonia, poliomyelitis, Prevotella infection, primary amoebic meningitis, progressive multifocal leukoencephalopathy, psittacosis, Q fever, rabies, relapsing fever, respiratory syncytial virus infection, rhinocystis infection, rhinovirus infection, rickettsia infection, rickettsial pox, Rift Valley fever, Rocky Mountain spotted fever, rotavirus infection, rubella, salmonellosis, scabies, scarlet fever, schistosomiasis, sepsis, severe acute respiratory syndrome (also known as SARS, including SARS-) CoV-2), Shigella infection, herpes zoster, smallpox, sporotrichosis, staphylococcal food poisoning, staphylococcal infection, strongyloidiasis, subacute sclerosing panencephalitis, syphilis, tapeworm infection, tetanus, facial tinea, alopecia areata, tinea capitis, tinea corporis, tinea cruris, tinea manuum, tinea pedis, onychomycosis, tinea versicolor, toxocariasis, toxoplasmosis, trachoma, trichinosis, trichomoniasis, whipworm infection, tuberculosis, tularemia, typhus, typhus, Ureaplasma urealyticum infection, valley fever, Venezuelan equine encephalitis, Venezuelan hemorrhagic fever, Vibrio vulnificus infection, Vibrio parahaemolyticus enteritis, viral pneumonia, West Nile fever, pseudotuberculosis Yersinia infection, Yersiniasis, yellow fever, zeaspora, Zika fever, and zygomycosis.
[0686] In one implementation, treating an infectious disease in a subject in need further includes administering at least one additional therapeutic agent as defined above to the subject before, simultaneously with, or after treatment.
[0687] The present invention also relates to a method for stimulating an immune response in a desired subject, the method comprising or constituting the administration of a modified LPS molecule species, composition, pharmaceutical composition, drug or vaccine composition according to the present invention to the subject.
[0688] The present invention also relates to modified LPS molecule species, compositions, pharmaceutical compositions, drug or vaccine compositions according to the present invention for stimulating an immune response in a subject in need.
[0689] The present invention also relates to the use of modified LPS molecules, compositions, pharmaceutical compositions, pharmaceutical or vaccine compositions according to the present invention as immunostimulants.
[0690] In one embodiment, stimulating an immune response in a desired subject further includes administering at least one additional therapeutic agent as defined above to the subject before, simultaneously with, or after the administration of the agent. In a preferred embodiment, the at least one additional therapeutic agent is an antigen as defined above.
[0691] In one implementation, when the antigen is an autoantigen (e.g., a cellular antigen, including cells containing normal transplant antigens and / or tumor-associated antigens, RR-Rh antigens, or antigens with specific cellular, tissue, or humoral characteristics or specificity), stimulating an immune response in the desired subject does not involve administering at least one additional antigen to the subject. Alternatively, when the antigen is an autoantigen, stimulating an immune response in the desired subject may include administering at least one additional antigen, which is the same autoantigen or another antigen, to the subject before, simultaneously with, or after the administration of the antigen.
[0692] The present invention also relates to a method of vaccinating a subject in need, the method comprising or constituting the administration of a modified LPS molecule, composition, pharmaceutical composition, drug or vaccine composition according to the present invention to the subject.
[0693] The present invention also relates to modified LPS molecule species, compositions, pharmaceutical compositions, pharmaceutical or vaccine compositions according to the present invention for use in vaccinating subjects in need.
[0694] In one embodiment, vaccinating a recipient further includes administering at least one additional therapeutic agent as defined above to the recipient. In a preferred embodiment, the at least one additional therapeutic agent is an antigen as defined above.
[0695] In one implementation, when the antibody is an autoantigen (e.g., a cellular antigen, including cells containing normal transplant antigens and / or tumor-associated antigens, RR-Rh antigens, or antigens with specific cellular, tissue, or humoral characteristics or specificity, including neoantigens), vaccinating the recipient does not involve administering at least one additional antigen to the recipient. Alternatively, when the antigen is an autoantigen, vaccinating the recipient may include administering at least one additional antigen, which is the same autoantigen or another antigen, before, simultaneously with, or after the vaccination.
[0696] It is readily understood that the therapeutic, vaccine, and immunostimulatory purposes disclosed above are applicable to subjects in need, animals, but not humans. Therefore, the modified LPS molecule species according to the invention, as well as compositions, pharmaceutical compositions, drug or vaccine compositions, optionally formulated with at least one additional therapeutic agent unconjugated and / or conjugated to the LPS molecule species, can be used for a wide range of therapeutic, vaccine, and immunostimulatory purposes in the veterinary field.
[0697] As explained above, those skilled in the art will readily recognize that LPS molecules should be purified to varying degrees of purity depending on their intended use, and it is conceivable that, in cases of veterinary administration, LPS molecules may be less purified, or even unpurified. In such cases, naturally occurring LPS molecules and / or modified LPS molecules can be prepared directly from bacterial precipitates, culture concentrates, culture supernatants, enriched membrane fractions, and / or outer membrane vesicle (OMV) fractions, with little or no purification steps.
[0698] In one embodiment, the composition for veterinary application comprising at least one LPS molecule may be the same as described above; or alternatively may comprise a mixture of modified LPS molecules selected from LPS molecules of formula (XII)(1) or combinations thereof.
[0699] In one implementation, the object is an animal. Examples of animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, insects, and mollusks.
[0700] In one implementation, the desired objects are non-human animals, including but not limited to farm animals or animals of agricultural value (e.g., cattle, dairy cows, bison, pigs, sheep, goats, horses, donkeys, alpacas, llamas, deer, elk, moose, ostriches, emus, ducks, geese, chickens, partridges, quails, pheasants, mink, salmon, cod, catfish, herring, trout, bass, halibut, sharks, tuna, octopuses, lobsters, crayfish, snails, clams, oysters, etc.), companion animals (e.g., dogs, cats, rabbits, rodents, fish, snakes, etc.), and non-human primates (e.g., apes including chimpanzees, gorillas, and orangutans; small apes including gibbons; Old World monkeys; New World monkeys; and primitive monkeys including tarsiers, lemurs, and slow lorises).
[0701] In one implementation plan, the target of the need is people.
[0702] In one implementation, the recipients of the need are adults (e.g., individuals over 18 years of age in human years or individuals who have already achieved reproductive capacity). In another implementation, the recipients of the need are children (e.g., individuals under 18 years of age in human years or individuals who have not yet achieved reproductive capacity).
[0703] In one implementation, the target group is male. In another implementation, the target group is female.
[0704] In one implementation, the recipient is diagnosed with cancer, an inflammatory disease, and / or an infectious disease. In another implementation, the recipient is at risk of developing cancer, an inflammatory disease, and / or an infectious disease.
[0705] This invention relates to a complete kit, comprising:
[0706] i. Modified LPS molecule types, compositions, pharmaceutical compositions, pharmaceutical or vaccine compositions according to the present invention;
[0707] and
[0708] ii. Other treatments.
[0709] The term "kit kit," also known as "packaging," "commercial packaging," or "pharmaceutical packaging," should include physical entities of physically separated components intended for individual storage and / or use, but functionally related to each other. Specifically, the term "kit kit" includes physical entities of physically separated components (e.g., on the one hand, modified LPS molecule species, compositions, pharmaceutical compositions, drug or vaccine compositions according to the invention; and on the other hand, additional therapeutic agents) to be used or administered separately in any order at given time intervals, typically but not necessarily from hours to days, weeks, or more than weeks; or simultaneously, as a temporary formulation or individually, in any order, at time intervals of seconds or minutes.
[0710] Other suitable therapeutic agents include, but are not limited to, chemotherapeutic agents, targeted therapies, cytotoxic agents, antibiotics, antiviral agents, cell cycle synchronizers, cell receptor ligands, immunomodulators, pro-apoptotic agents, anti-angiogenic agents, cytokines, growth factors, antibodies or their antigen-binding fragments, cell therapies, antigens, etc.
[0711] Detailed examples of these additional therapeutic agents have been described above as suitable agents conjugated at the Z, R1, and / or R2 positions on Formulas A and B. However, it will be readily understood by those skilled in the art that, according to the invention, these additional therapeutic agents may be provided separately or alternatively from the kit according to the invention.
[0712] In one embodiment, the additional therapeutic agent is a targeted therapeutic agent as defined above, preferably an anti-CD20 monoclonal antibody or its antigen-binding fragment. In one embodiment, the anti-CD20 monoclonal antibody is selected from teimozumab, oxotuzumab, octolithumab, oflambumab, rituximab, tosimobumab or its antigen-binding fragment; preferably, the anti-CD20 monoclonal antibody is rituximab.
[0713] In one embodiment, the additional therapeutic agent is an immunostimulant as defined above, preferably an immune checkpoint inhibitor. In one embodiment, the immune checkpoint inhibitor is selected from CTLA4 inhibitors, PD-1 inhibitors, PD-L1 inhibitors, LAG-3 inhibitors, B7-H3 inhibitors, B7-H4 inhibitors, TIM3 inhibitors, A2AR inhibitors, GITR inhibitors, CD47 inhibitors, TNFR2 inhibitors, CD19 inhibitors, and / or IDO inhibitors. In one embodiment, the immune checkpoint inhibitor is selected from nivolumab, pembrolizumab, cimiprimab, pildizumab, AMP-224, AMP-514, MPDL3280A, MDX-1105, MEDI-4736, arelumab, ipilimumab, trimemumab, pildizumab, IMP321, MGA271, BMS-986016, lirelurumab, urerlurumab, PF-05082566, IPH2101, MEDI-6469, CP-870,893, mogliflozin, varimulumab, galiximumab, avinumab and galiximumab, AUNP12, IDO pathway inhibitor (Indoximod), NLG-919, and INCB024360. In one embodiment, the immune checkpoint inhibitor is a PD-1 inhibitor or a PD-L1 inhibitor. Examples of PD-1 inhibitors include, but are not limited to, nivolumab, pembrolizumab, cimiprimab, spartazine, camrelizumab, sintilimab, tislelizumab, toripalimab, AMP-224, and AMP-514. Examples of PD-L1 inhibitors include, but are not limited to, atezolizumab, acilimab, durvalumab, KN035, CK-301, AUNP12, CA-170, and BMS-986189.
[0714] In one implementation, the additional therapeutic agent is an antigen, as described above.
[0715] This article discloses a modified lipopolysaccharide (LPS) molecule species, wherein the LPS molecule species is:
[0716] - There are no phosphate groups at the reduced end C1 position and / or the non-reduced end C4 position of the lipid A domain; and
[0717] - The lipid A domain is replaced by a hydrophilic portion at the non-reducing C6' position, provided that the hydrophilic portion is not a hydroxyl group; preferably, the lipid A domain is replaced by a monosaccharide, oligosaccharide, or polysaccharide portion at the non-reducing C6' position.
[0718] In one embodiment, the modified LPS molecule species has the general formula B:
[0719]
[0720] in
[0721] -X and Y are independent of each other as –O– or –NH–;
[0722] -R1 is a hydroxyl group (–OH), which may optionally be substituted, provided that if substituted, the substitution is not by a phosphate group (–OPO3H2).
[0723] Composition; and R2 is a phosphate group (–OPO3H2) or a hydroxyl group (–OH), optionally substituted; or
[0724] -R1 is a phosphate group (-OPO3H2) or a hydroxyl group (-OH); optionally substituted; R2 is a hydroxyl group (-OH), optionally substituted.
[0725] The condition is that, if substituted, the substituent is not composed of a phosphate group (–OPO3H2);
[0726] -R3 is a monosaccharide, oligosaccharide, or polysaccharide moiety; optionally substituted, preferably R3 is optionally substituted with an antigenic domain.
[0727] The core oligosaccharide, preferably an O-antigen domain and / or a capped antigen;
[0728] -R4 and R6 are fatty acid residues that are independent of each other; optionally, they are substituted; and
[0729] -R5 and R7 are hydrogen or fatty acid residues that are independent of each other; they may be substituted.
[0730] In one embodiment, the modified LPS molecule is selected from formulas (I)(1)(a), (I)(1)(b), (I)(1)(c), (I)(1)(d), (I)(1)(e), (I)(1)(f), (I)(2)(a), (I)(2)(b), (I)(2)(c), (I)(3)(a), (I)(3)(b), (I)(3)(c), (II)(2)(a), (II)(2)(b), (II)(2)(c), and (II)(2)(b). d) Equation (III)(1)(a), Equation (III)(1)(b), Equation (III)(1)(c), Equation (III)(1)(d), Equation (IV)(1)(a), Equation (IV)(1)(b), Equation (IV)(1)(c), Equation (V)(1)(a), Equation (V)(1)(b), Equation (V)(1)(c), Equation (V)(1)(d), Equation (V)(1)(e), Equation (V)(1)(f), Equation (V)(1)(g), Equation (V)(1)(h), Equation (V)(1)(i), Equation (VI)(1)(a) Equations (VI)(1)(b), (VI)(1)(c), (VI)(1)(d), (VI)(1)(e), (VI)(1)(f), (VI)(1)(g), (VI)(1)(h), (VI)(1)(i), (VI)(1)(j), (VI)(2)(a), (VI)(2)(b), (VI)(2)(c), (VII)(1)(a), (VII)(1)(b), (VII)(1)(c), (VIII)(1)(a), (VI) Formulas (II)(1)(b), (VIII)(1)(c), (VIII)(1)(d), (IX)(1)(a), (IX)(1)(b), (IX)(1)(c), (IX)(1)(d), (X)(1)(a), (X)(1)(b), (X)(1)(c), (X)(1)(d), (XI)(1)(a), (XI)(1)(b), (XI)(1)(c), (XI)(1)(d), (XII)(1), and combinations thereof, and the types of LPS molecules, such as Figures 2 to 4 As shown in 7 to 17 and 27, the R at the C6' position is a monosaccharide, oligosaccharide, or polysaccharide portion containing a core oligosaccharide domain and an optional antigen domain, preferably an O-antigen domain and / or a capped antigen.
[0731] This document also discloses modified LPS molecule species enrichment clusters, wherein the LPS molecule species enrichment clusters contain at least 10% of the modified LPS molecule species according to the invention; preferably at least 50% of the modified LPS molecule species according to the invention.
[0732] In one embodiment, the modified LPS molecule-rich aggregate forms particles in an aqueous solution having an average size of less than about 200 nm in diameter, preferably less than about 150 nm, as can be evaluated by dynamic light scattering (DLS) at 25 °C.
[0733] This document also discloses compositions comprising at least one modified LPS molecule species according to the present invention; or LPS molecule species enriched aggregates according to the present invention.
[0734] In one embodiment, the composition comprises:
[0735] - A mixture of at least two or fewer modified LPS molecules: formula (I)(1)(a), formula (I)(1)(b), formula (I)(1)(c), formula (I)(1)(d), formula (I)(1)(e) and formula (I)(1)(f); preferably a mixture of six modified LPS molecules;
[0736] or
[0737] - A mixture of at least two or more modified LPS molecules: formula (I)(2)(a), formula (I)(2)(b), and formula (I)(2)(c); preferably a mixture of three modified LPS molecules; or
[0738] - A mixture of at least two or more modified LPS molecules: formula (I)(3)(a), formula (I)(3)(b), and formula (I)(3)(c); preferably a mixture of three modified LPS molecules; or
[0739] - A mixture of at least two or fewer modified LPS molecules: formula (II)(2)(a), formula (II)(2)(b), formula (II)(2)(c), formula (II)(2)(d); preferably a mixture of four modified LPS molecules; or
[0740] - A mixture of at least two or fewer modified LPS molecules: formula (III)(1)(a), formula (III)(1)(b), formula (III)(1)(c), formula (III)(1)(d); preferably a mixture of four modified LPS molecules; or
[0741] - A mixture of at least two or more modified LPS molecules: formula (IV)(1)(a), formula (IV)(1)(b), and formula (IV)(1)(c); preferably a mixture of three modified LPS molecules; or
[0742] - A mixture of at least two or more modified LPS molecule species: formula (V)(1)(a), formula (V)(1)(b), formula (V)(1)(c), formula (V)(1)(d), formula (V)(1)(e), formula (V)(1)(f), formula (V)(1)(g), formula (V)(1)(h), formula (V)(1)(i);
[0743] Preferably, it is a mixture of nine modified LPS molecules; or
[0744] - A mixture of at least two or fewer modified LPS molecules: formula (VI)(1)(a), formula (VI)(1)(b), formula (VI)(1)(c), formula (VI)(1)(d), formula (VI)(1)(e), formula (VI)(1)(f), formula (VI)(1)(g), formula (VI)(1)(h), formula (VI)(1)(i), formula (VI)(1)(j); preferably a mixture of ten modified LPS molecules; or
[0745] - A mixture of at least two or more modified LPS molecules: formula (VI)(2)(a), formula (VI)(2)(b), and formula (VI)(2)(c); preferably a mixture of three modified LPS molecules; or
[0746] - A mixture of at least two or fewer modified LPS molecules: formula (VII)(1)(a), formula (VII)(1)(b), and formula (VII)(1)(c); preferably a mixture of three modified LPS molecules; or
[0747] - A mixture of at least two or fewer modified LPS molecules: formula (VIII)(1)(a), formula (VIII)(1)(b), formula (VIII)(1)(c), formula (VIII)(1)(d); preferably a mixture of four modified LPS molecules; or
[0748] - A mixture of at least two or fewer modified LPS molecules: formula (IX)(1)(a), formula (IX)(1)(b), formula (IX)(1)(c), formula (IX)(1)(d); preferably a mixture of four modified LPS molecules; or
[0749] - A mixture of at least two or fewer modified LPS molecules: formula (X)(1)(a), formula (X)(1)(b), formula (X)(1)(c), formula (X)(1)(d); preferably a mixture of four modified LPS molecules; or
[0750] - A mixture of at least two or fewer modified LPS molecules: formula (XI)(1)(a), formula (XI)(1)(b), formula (XI)(1)(c), formula (XI)(1)(d); preferably a mixture of four modified LPS molecules; or
[0751] - A mixture of modified LPS molecules of formula (XII)(1).
[0752] In one embodiment, the composition is a pharmaceutical composition or a vaccine composition, and further comprises at least one pharmaceutically acceptable excipient.
[0753] This article also discloses naturally occurring, non-toxic LPS molecules and / or modified LPS molecules, or compositions containing them:
[0754] - Used for the treatment and / or prevention of cancer in individuals who require it.
[0755] - Used for the treatment and / or prevention of inflammatory diseases in individuals who require it.
[0756] - Used for the treatment of and / or infectious diseases in those who need it.
[0757] - Used to stimulate an immune response in subjects in need, and / or
[0758] - Used to vaccinate those in need.
[0759] The naturally occurring non-toxic LPS molecules and / or modified LPS molecules, or compositions comprising them, are selected from:
[0760] - Modified LPS molecules according to the present invention; modified LPS molecule-rich aggregates according to the present invention; or compositions according to the present invention; or
[0761] -Does not contain two secondary Cs 12 and / or C 14 The LPS molecule type of the fatty acid chain; and / or the reduced end C1 position of its lipid A domain and the non-reduced end C4' position of its lipid A domain are not composed of phosphate groups.
[0762] In one embodiment, the LPS molecule species or composition is selected from:
[0763] - Selected from the following LPS molecule types: formula (I)(0)(a), formula (I)(0)(b), formula (II)(0), formula (II)(1)(a), formula (II)(1)(b), formula (II)(1)(c), and formula (II)(1)(d), such as Figures 1 to 6 As shown;
[0764] A mixture of LPS molecular species of formula (I)(0)(a) and formula (I)(0)(b), such as Figure 1 As shown;
[0765] -A mixture of at least two types of LPS molecules of formula (II)(0), such as Figure 5 As shown;
[0766] - A mixture of at least two types of LPS molecules of formula (II)(1)(a), (II)(1)(b), (II)(1)(c), and (II)(1)(d).
[0767] like Figure 6 As shown;
[0768] -The composition according to the invention comprises a mixture of the following modified LPS molecule types: formula (I)(1)(a), formula (I)(1)(b), formula (I)(1)(c), formula (I)(1)(d), formula (I)(1)(e) and formula (I)(1)(f);
[0769] - The composition according to the invention comprises a mixture of the following modified LPS molecule types: formula (I)(2)(a), formula (I)(2)(b) and formula (I)(2)(c); or
[0770] - The composition according to the invention comprises a mixture of the following modified LPS molecule types: formula (VI)(1)(a), formula (VI)(1)(b), formula (VI)(1)(c), formula (VI)(1)(d), formula (VI)(1)(e), formula (VI)(1)(f), formula (VI)(1)(g), formula (VI)(1)(h), formula (VI)(1)(i) and formula (VI)(1)(j).
[0771] In one embodiment, the treatment and / or prevention of cancer, inflammatory diseases, or infectious diseases further includes administering at least one additional therapeutic agent to the subject, preferably selected from chemotherapeutic agents, targeted therapeutic agents, cytotoxic agents, antibiotics, antiviral agents, cell cycle synchronizers, cell receptor ligands, immunomodulators, pro-apoptotic agents, anti-angiogenic agents, cytokines, growth factors, antibodies or antigen-binding fragments thereof, cell therapies, and antigens.
[0772] In one embodiment, at least one additional therapeutic agent is a targeted therapeutic agent, preferably an anti-CD20 antibody or its antigen-binding fragment.
[0773] In one embodiment, at least one additional therapeutic agent is an immunostimulant, preferably an immune checkpoint inhibitor, more preferably selected from CTLA4 inhibitors, PD-1 inhibitors, PD-L1 inhibitors, LAG-3 inhibitors, B7-H3 inhibitors, B7-H4 inhibitors, TIM3 inhibitors, A2AR inhibitors, GITR inhibitors, CD47 inhibitors, TNFR2 inhibitors, CD19 inhibitors, and IDO inhibitors; more preferably, at least one additional therapeutic agent is a PD-1 inhibitor or a D-L1 inhibitor.
[0774] In one embodiment, vaccinating a subject in need further includes administering at least one antigen to the subject, preferably selected from pathogen-associated antigens, autoantigens, allergen-associated antigens, and neoantigens.
[0775] In one embodiment, the desired object is an animal other than a human, and the naturally occurring non-toxic LPS molecules and / or modified LPS molecules or compositions comprising them are selected from, Figure 27 The types of LPS molecules shown in formula (XII)(1).
[0776] This article also discloses a complete kit, including:
[0777] - Modified LPS molecules according to the present invention; LPS molecule-rich clusters according to the present invention; compositions according to the present invention; or those not containing two secondary Cs. 12 and / or C 14 Fatty acid chains and / or in their lipid A
[0778] The reduced C1 position of the domain and the non-reduced C4' position of its lipid A domain are not composed of phosphate groups.
[0779] Types of modified LPS molecules; and
[0780] - Other therapeutic agents are preferably selected from chemotherapeutic agents, targeted therapies, cytotoxic agents, antibiotics, antiviral agents, cell cycle synchronizers, cell receptor ligands, immunomodulators, pro-apoptotic agents, anti-angiogenic agents, cytokines, growth factors, antibodies or their antigen-binding fragments, cell therapies, and antigens.
[0781] Brief description of the attached figures
[0782] Figure 1The structures of two naturally occurring LPS molecule species, “LPS B2 0.0”, from *Bordecia pertussis*, are shown in formulas (I)(0)(a) and (I)(0)(b). The disaccharide of the lipid A domain is substituted with R at the non-reducing C6' position, where R is a monosaccharide, oligosaccharide, or polysaccharide moiety, including a core oligosaccharide domain and optionally an antigenic domain, such as an O-antigen domain and / or a capped antigen.
[0783] Figure 2 The structures of six chemically modified LPS molecules, “LPS B2 0.1”, from formulas (I)(1)(a) to (I)(1)(f), derived from Bordetella pertussis are shown. The disaccharide of the lipid A domain is substituted with R at the non-reducing C6' position, where R is a monosaccharide, oligosaccharide, or polysaccharide moiety, including a core oligosaccharide domain and optionally an antigenic domain, such as an O-antigen domain and / or a capped antigen.
[0784] Figure 3 The structures of three chemically modified LPS molecule species, “LPS B2 1.1”, from formulas (I)(2)(a) to (I)(2)(c), derived from *Bordecia pertussis* are shown. The disaccharide of the lipid A domain is substituted with R at the non-reducing C6' position, where R is a monosaccharide, oligosaccharide, or polysaccharide moiety, including a core oligosaccharide domain and optionally an antigenic domain, such as an O-antigen domain and / or a capped antigen.
[0785] Figure 4 The structures of three chemically modified LPS molecules, “LPS B2 1.2”, from formulas (I)(3)(a) to (I)(3)(c), derived from *Bordecia pertussis* are shown. The disaccharide of the lipid A domain is substituted with R at the non-reducing C6' position, where R is a monosaccharide, oligosaccharide, or polysaccharide moiety, including a core oligosaccharide domain and optionally an antigenic domain, such as an O-antigen domain and / or a capped antigen.
[0786] Figure 5 The structure of a naturally occurring LPS molecule species “LPS W10.0” from *Vibrio filamentosa*, formula (II)(0), is shown. The disaccharide of the lipid A domain is substituted with R at the non-reducing C6' position, where R is a monosaccharide, oligosaccharide, or polysaccharide moiety, including a core oligosaccharide domain and optional antigenic domains, such as an O-antigen domain and / or a capping antigen. The presence or absence of phosphorylated ethanolamine (PEA) residues at the reducing C1 position and the non-reducing C4' position of the lipid A domain, as shown in parentheses, are also noted.
[0787] Figure 6The structures of four chemically modified LPS molecule species, “LPS W1 1.0”, from formulas (II)(1)(a) to (II)(1)(d), derived from *Vibrio filamentosa* are shown. The disaccharide of the lipid A domain is substituted with R at the non-reducing C6' position, where R is a monosaccharide, oligosaccharide, or polysaccharide moiety, including a core oligosaccharide domain and optional antigenic domains, such as an O-antigen domain and / or a capped antigen.
[0788] Figure 7 The structures of four chemically modified LPS molecule species, “LPS B1 1.2”, from formulas (II)(2)(a) to (II)(2)(d), derived from *Vibrio filamentosa* are shown. The disaccharide of the lipid A domain is substituted with R at the non-reducing C6' position, where R is a monosaccharide, oligosaccharide, or polysaccharide moiety, including a core oligosaccharide domain and optional antigenic domains, such as an O-antigen domain and / or a capped antigen.
[0789] Figure 8 The structures of four chemically modified LPS molecules, “LPS SM1 1.2”, derived from the enteric Salmonella Minnesota R595 serotype, are shown in formulas (III)(1)(a) to (III)(1)(d). The disaccharide of the lipid A domain is substituted with R at the non-reducing C6' position, where R is a monosaccharide, oligosaccharide, or polysaccharide moiety, including a core oligosaccharide domain and optionally an antigenic domain, such as an O-antigen domain and / or a capped antigen. The phosphate group shown in parentheses at the non-reducing C4' position of the lipid A domain is present or absent.
[0790] Figure 9 The structures of three chemically modified LPS molecules of formulas (IV)(1)(a) to (IV)(1)(c) are shown: “LPS ST1 1.2” from the enteric Salmonella Typhimurium Ra serotype, “LPS E2 1.2” from Escherichia coli K12, or “LPS V1 1.2” from Vibrio fischeri (all three share the same lipid A domain). The disaccharide of the lipid A domain is substituted with R at the non-reducing C6' position, where R is a monosaccharide, oligosaccharide, or polysaccharide moiety, including a core oligosaccharide domain and an optional antigenic domain, such as an O-antigen domain and / or a capped antigen.
[0791] Figure 10 The structures of nine chemically modified LPS molecule species “LPS E1 0.1” from Escherichia coli J5, represented by formulas (V)(1)(a) to (V)(1)(i), are shown. The disaccharide of the lipid A domain is substituted with R at the non-reducing C6' position, where R is a monosaccharide, oligosaccharide, or polysaccharide moiety, including a core oligosaccharide domain and optional antigenic domains, such as an O-antigen domain and / or a capped antigen.
[0792] Figure 11 The structures of ten chemically modified LPS molecule species “LPS A1 0.1” from Formulas (VI)(1)(a) to (VI)(1)(j) from *Actinomyces pleuropneumoniae* are shown. The disaccharide of the lipid A domain is substituted with R at the non-reducing C6' position, where R is a monosaccharide, oligosaccharide, or polysaccharide moiety, including a core oligosaccharide domain and optional antigenic domains, such as an O-antigen domain and / or a capped antigen.
[0793] Figure 12 The structures of three chemically modified LPS molecule species, “LPS A1 1.2”, from Formula (VI)(2)(a) to (VI)(2)(c), derived from *Actinomyces pleuropneumoniae* are shown. The disaccharide of the lipid A domain is substituted with R at the non-reducing C6' position, where R is a monosaccharide, oligosaccharide, or polysaccharide moiety, including a core oligosaccharide domain and optionally an antigenic domain, such as an O-antigen domain and / or a capped antigen.
[0794] Figure 13 The structures of three chemically modified LPS molecule species, “LPS K1 1.2”, from *Burkholderia melioides*, of formulas (VII)(1)(a) to (VII)(1)(c) are shown. The disaccharide of the lipid A domain is substituted with R at the non-reducing C6' position, where R is a monosaccharide, oligosaccharide, or polysaccharide moiety, including a core oligosaccharide domain and optionally an antigenic domain, such as an O-antigen domain and / or a capped antigen. The phosphate group shown at the non-reducing C4' position of the lipid A domain may or may not be present.
[0795] Figure 14 The structures of four chemically modified LPS molecule species, “LPS M1 1.2”, from Formula (VIII)(1)(a) to (VIII)(1)(d), derived from Moraxella catarrhalis are shown. The disaccharide of the lipid A domain is substituted with R at the non-reducing C6' position, where R is a monosaccharide, oligosaccharide, or polysaccharide moiety, including a core oligosaccharide domain and optional antigenic domains, such as an O-antigen domain and / or a capped antigen.
[0796] Figure 15 The structures of four chemically modified LPS molecule specie...
Claims
1. A modified lipopolysaccharide (LPS) molecular species enriched population comprising at least 80% of modified LPS molecular species, wherein the modified LPS molecular species: - has no phosphate group at the C1 position of the reducing end of its lipid A domain; and - The C6' position of the non-reducing end of its lipid A domain is substituted with a monosaccharide, oligosaccharide or polysaccharide group.
2. The modified LPS molecular species enriched population according to claim 1, wherein the modified LPS molecular species has the general formula A: in -Y is –O– or –NH–; -R2 is a phosphate group (-OPO3H2) or a hydroxyl group (-OH); the group is unsubstituted or substituted by an ethanolamine group (-OCH2-CH2-NH2), a phosphoethanolamine group (-OPO3H-CH2-CH2-NH2), a diphosphoethanolamine group (-OPO3H2-PO3H-CH2-CH2-NH2), a 4-amino-4-deoxy-L-arabinose (LArap4N) residue, a glucosamine residue, a galactosamine residue, an alkyl group, an aminoalkyl group, an aryl group, a carboxyalkyl group, a cycloalkyl group, an ether group, a polyether group, a halogenated alkyl group, a heteroaryl group or a nitrooxyalkyl group; - R3 is a monosaccharide, oligosaccharide or polysaccharide group; or R3 is a core oligosaccharide which is unsubstituted or substituted with an antigenic domain; - R6 is a fatty acid residue; - R7 is hydrogen or a fatty acid residue; -Z is a hydroxyl group (-OH), which is unsubstituted or substituted with an ethanolamine group (-OCH2-CH2-NH2), a phosphoethanolamine group (-OPO3H-CH2-CH2-NH2), a diphosphoethanolamine group (-OPO3H2-PO3H-CH2-CH2-NH2), a 4-amino-4-deoxy-L-arabinose (LArap4N) residue, a glucosamine residue, a galactosamine residue, an alkyl group, an aminoalkyl group, an aryl group, a carboxyalkyl group, a cycloalkyl group, an ether group, a polyether group, a haloalkyl group, a heteroaryl group, a nitrooxyalkyl group, or a therapeutic agent, or Z is in -X is –O– or –NH–; -R1 is a hydroxyl group (-OH), which is unsubstituted or substituted by an ethanolamine group (-OCH2-CH2-NH2), a phosphoethanolamine group (-OPO3H-CH2-CH2-NH2), a diphosphoethanolamine group (-OPO3H2-PO3H-CH2-CH2-NH2), a 4-amino-4-deoxy-L-arabinose (LArap4N) residue, a glucosamine residue, a galactosamine residue, an alkyl group, an aminoalkyl group, an aryl group, a carboxyalkyl group, a cycloalkyl group, substituted with an ether group, a polyether group, a haloalkyl group, a heteroaryl group, a nitroxyalkyl group, or a therapeutic agent; - R4 is a fatty acid residue; and -R5 is hydrogen or a fatty acid residue.
3. The modified LPS molecular species enriched population according to claim 1, wherein the modified LPS molecular species has the general formula B: in -X and Y are independently -O- or -NH-; -R1 is a hydroxyl group (-OH), which is unsubstituted or substituted with an ethanolamine group (-OCH2-CH2-NH2), a phosphoethanolamine group (-OPO3H-CH2-CH2-NH2), a diphosphoethanolamine group (-OPO3H2-PO3H-CH2-CH2-NH2), a 4-amino-4-deoxy-L-arabinose (LArap4N) residue, a glucosamine residue, a galactosamine residue, an alkyl group, an aminoalkyl group, an aryl group, a carboxyalkyl group, a cycloalkyl group, an ether group, a polyether group, a haloalkyl group, a heteroaryl group, a nitrooxyalkyl group, or a therapeutic agent; and R2 is a phosphate group (–OPO3H2) or a hydroxyl group (–OH), which is unsubstituted or substituted by an ethanolamine group (–OCH2-CH2-NH2), a phosphoethanolamine group (–OPO3H-CH2-CH2-NH2), a diphosphoethanolamine group (–OPO3H2-PO3H-CH2-CH2-NH2), a 4-amino-4-deoxy-L-arabinose (LArap4N) residue, a glucosamine residue, a galactosamine residue, an alkyl group, an aminoalkyl group, an aryl group, a carboxyalkyl group, a cycloalkyl group, an ether group, a polyether group, a haloalkyl group, a heteroaryl group or a nitrooxyalkyl group; - R3 is a monosaccharide, oligosaccharide or polysaccharide group; or R3 is a core oligosaccharide which is unsubstituted or substituted with an antigenic domain; - R4 and R6 are independently a fatty acid residue; and - R5 and R7 are independently hydrogen or a fatty acid residue.
4. The modified LPS molecular species enriched population according to claim 1, wherein the modified LPS molecular species is selected from the group consisting of LPS molecular species having the following formula: wherein R at the C6' position is a monosaccharide, oligosaccharide or polysaccharide group comprising the core oligosaccharide domain and the antigenic domain; and wherein X at the C1 position is an ethyl moiety.
5. The enriched population of modified LPS molecular species according to claim 1, wherein the modified LPS molecular species forms particles having an average size of less than about 200 nm in diameter in aqueous solution as can be assessed by dynamic light scattering (DLS) at 25°C.
6. A composition comprising the enriched population of modified LPS molecular species according to claim 1.
7. The composition according to claim 6, wherein the composition comprises: i. an enriched population comprising a mixture of at least two modified LPS molecular species having formula (I)(l)(a), formula (I)(l)(b), formula (I)(l)(c), formula (I)(l)(d), formula (I)(l)(e) and formula (I)(l)(f); or ii. an enriched population comprising a mixture of at least two modified LPS molecular species having formula (I)(2)(a), formula (I)(2)(b) and formula (I)(2)(c); or iii. an enriched population comprising a mixture of at least two modified LPS molecular species having formula (I)(3)(a), formula (I)(3)(b) and formula (I)(3)(c); or iv. an enriched population comprising a mixture of at least two modified LPS molecular species having formula (I)(5)(a) and formula (I)(5)(b); or v. an enriched population comprising a mixture of at least two modified LPS molecular species having formula (I)(6)(a) and formula (I)(6)(b); or vi. an enriched population comprising a mixture of at least two modified LPS molecular species having formula (I)(7)(a), formula (I)(7)(b), formula (I)(7)(c) and (I)(7)(d); or vii. An enriched population comprising a mixture of at least two modified LPS molecular species having formula (I)(8)(a), formula (I)(8)(b) and formula (I)(8)(c); or viii. an enriched population comprising a mixture of at least two modified LPS molecular species having formula (I)(9)(a), formula (I)(9)(b), formula (I)(9)(c), formula (I)(9)(d), formula (I)(9)(e) and formula (I)(9)(f); or ix. An enriched population comprising a mixture of at least two modified LPS molecular species having formula (II) (2) (a), formula (II) (2) (b), formula (II) (2) (c), formula (II) (2) (d); or x. An enriched population comprising a mixture of at least two modified LPS molecular species having formula (III) (1) (a), formula (III) (1) (b), formula (III) (1) (c), or formula (III) (1) (d); or xi. an enriched population comprising a mixture of at least two modified LPS molecular species having formula (IV)(1)(a), formula (IV)(1)(b), formula (IV)(1)(c); or xii. An enriched population comprising a mixture of at least two modified LPS molecule species having formula (V)(1)(a), formula (V)(1)(b), formula (V)(1)(c), formula (V)(1)(d), formula (V)(1)(e), formula (V)(1)(f), formula (V)(1)(g), formula (V)(1)(h), formula (V)(1)(i); or xiii. An enriched population comprising a mixture of at least two modified LPS molecular species having formula (VI)(1)(a), formula (VI)(1)(b), formula (VI)(1)(c), formula (VI)(1)(d), formula (VI)(1)(e), formula (VI)(1)(f), formula (VI)(1)(g), formula (VI)(1)(h), formula (VI)(1)(i), or formula (VI)(1)(j); or xiv. An enriched population comprising a mixture of at least two modified LPS molecular species having formula (VI)(2)(a), formula (VI)(2)(b), formula (VI)(2)(c); or xv. An enriched population comprising a mixture of at least two modified LPS molecular species having formula (VII)(1)(a), formula (VII)(1)(b), formula (VII)(1)(c); or xvi. An enriched population comprising a mixture of at least two modified LPS molecular species having formula (VIII)(1)(a), formula (VIII)(1)(b), formula (VIII)(1)(c), formula (VIII)(1)(d); or xvii. An enriched population comprising a mixture of at least two modified LPS molecular species having formula (IX) (1) (a), formula (IX) (1) (b), formula (IX) (1) (c), formula (IX) (1) (d); or xviii. An enriched population comprising a mixture of at least two modified LPS molecular species having formula (X)(1)(a), formula (X)(1)(b), formula (X)(1)(c), or formula (X)(1)(d); or xix. An enriched population comprising a mixture of at least two modified LPS molecular species having formula (XI)(1)(a), formula (XI)(1)(b), formula (XI)(1)(c), or formula (XI)(1)(d); or xx. an enriched population comprising a mixture of at least two modified LPS molecular species having formula (XIII)(2)(a) and formula (XIII)(2)(b); or xxi. An enriched population comprising a mixture of at least two modified LPS molecular species having formula (XIII)(3)(a) and formula (XIII)(3)(b); or xxii. An enriched population comprising a mixture of at least two modified LPS molecular species having formula (XIII)(4)(a) and formula (XIII)(4)(b); or xxiii. An enriched population comprising a mixture of at least two modified LPS molecular species having formula (XIII)(5)(a), formula (XIII)(5)(b), formula (XIII)(5)(c) and formula (XIII)(5)(d); or xxiv. An enriched population comprising a mixture of at least two modified LPS molecular species having formula (XIII)(6)(a), formula (XIII)(6)(b), formula (XIII)(6)(c), formula (XIII)(6)(d), formula (XIII)(6)(e) and formula (XIII)(6)(f); or xxv. An enriched population comprising a mixture of at least two modified LPS molecular species having formula (XIII)(7)(a), formula (XIII)(7)(b), formula (XIII)(7)(c), formula (XIII)(7)(d), formula (XIII)(7)(e) and formula (XIII)(7)(f); or xxvi. An enriched population comprising a mixture of at least two modified LPS molecular species having formula (XIII)(8)(a), formula (XIII)(8)(b), formula (XIII)(8)(c), formula (XIII)(8)(d), formula (XIII)(8)(e) and formula (XIII)(8)(f); or xxvii. An enriched population comprising a mixture of at least two modified LPS molecular species having formula (XIII)(9)(a), formula (XIII)(9)(b), formula (XIII)(9)(c), formula (XIII)(9)(d), formula (XIII)(9)(e), formula (XIII)(9)(f), formula (XIII)(9)(g), formula (XIII)(9)(h), formula (XIII)(9)(i) and formula (XIII)(9)(j).
8. The composition according to claim 6, which is a pharmaceutical composition or a vaccine composition, and further comprises at least one pharmaceutically acceptable excipient.
9. Use of a naturally occurring non-toxic LPS molecule species and / or a modified LPS molecule species enriched population or a composition comprising the same in the preparation of a medicament for treating and / or preventing cancer, inflammatory diseases or infectious diseases in a subject in need thereof, wherein the naturally occurring non-toxic LPS molecule species and / or a modified LPS molecule species enriched population or a composition comprising the same is selected from: - a modified LPS molecular species enriched population according to claim 1; or a composition according to claim 6; or -Do not contain two secondary Cs simultaneously at the C2' and C3' positions of the lipid A domain 12 and / or C14 A naturally occurring, non-toxic species of LPS molecules with fatty acid chains.
10. Use of naturally occurring non-toxic LPS molecular species and / or modified LPS molecular species enriched populations or compositions comprising the same in the preparation of a medicament for stimulating an immune response in a subject in need thereof, Wherein the naturally occurring non-toxic LPS molecule species and / or the enriched population of modified LPS molecule species, or the composition comprising the same, is selected from the group consisting of: - a modified LPS molecular species enriched population according to claim 1; or a composition according to claim 6; or -Do not contain two secondary Cs simultaneously at the C2' and C3' positions of the lipid A domain 12 and / or C 14 A naturally occurring, non-toxic species of LPS molecules with fatty acid chains.
11. Use of naturally occurring non-toxic LPS molecular species and / or modified LPS molecular species enriched populations or compositions comprising the same in the preparation of a medicament for vaccinating a subject in need thereof, Wherein the naturally occurring non-toxic LPS molecule species and / or the enriched population of modified LPS molecule species, or the composition comprising the same, is selected from the group consisting of: - a modified LPS molecular species enriched population according to claim 1; or a composition according to claim 6; or -Do not contain two secondary Cs simultaneously at the C2' and C3' positions of the lipid A domain 12 and / or C 14 A naturally occurring, non-toxic species of LPS molecules with fatty acid chains.
12. The use of claim 11 for preparing a medicament, wherein the LPS molecule species or composition is selected from: - an LPS molecule species selected from the group consisting of LPS molecule species having the formula: - a mixture of LPS molecular species having formula (I)(0)(a) and formula (I)(0)(b); - a mixture of at least two LPS molecular species having formula (II) (0); - a mixture of at least two LPS molecular species having formula (II) (1) (a), formula (II) (1) (b), formula (II) (1) (c), formula (II) (1) (d); - A composition according to claim 7, comprising a mixture of modified LPS molecular species having formula (I)(1)(a), formula (I)(1)(b), formula (I)(1)(c), formula (I)(1)(d), formula (I)(1)(e) and formula (I)(1)(f); - A composition according to claim 7, comprising a mixture of modified LPS molecular species having formula (I)(2)(a), formula (I)(2)(b) and formula (I)(2)(c); - A composition according to claim 7, comprising a mixture of modified LPS molecular species having formula (VI)(1)(a), formula (VI)(1)(b), formula (VI)(1)(c), formula (VI)(1)(d), formula (VI)(1)(e), formula (VI)(1)(f), formula (VI)(1)(g), formula (VI)(1)(h), formula (VI)(1)(i) and formula (VI)(1)(j); or - A composition according to claim 7, comprising a mixture of modified LPS molecular species having formula (I)(8)(a), formula (I)(8)(b) and formula (I)(8)(c).
13. The use of claim 9 for preparing a medicament, wherein the treatment and / or prevention of cancer, inflammatory diseases or infectious diseases further comprises administering to the subject at least one additional therapeutic agent.
14. Use for the preparation of a medicament according to claim 13, wherein at least one additional therapeutic agent is a targeted therapeutic agent.
15. The use for preparing a medicament according to claim 14, wherein the targeted therapeutic agent is an anti-CD20 antibody or an antigen-binding fragment thereof.
16. Use according to claim 13 for the preparation of a medicament, wherein at least one additional therapeutic agent is an immunostimulant.
17. The use for preparing a medicament according to claim 16, wherein the immunostimulant is an immune checkpoint inhibitor, and wherein the immune checkpoint inhibitor is a PD-1 inhibitor.
18. The use for preparing a medicament according to claim 10, wherein an immune response is stimulated in a subject in need thereof and at least one antigen is administered to the subject.
19. The use of any one of claims 9 to 18 for preparing a medicament, wherein the subject in need is an animal other than a human, and the naturally occurring non-toxic LPS molecule species and / or the modified LPS molecule species are selected from the group consisting of of LPS molecules.
20. A kit comprising: - The modified LPS molecular species enriched population according to claim 1; The composition according to claim 6; or does not contain two secondary Cs at the C2' and C3' positions of the lipid A domain. 12 and / or C 14 fatty acid chain of the LPS molecule; and - Additional therapeutic agents.
